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Medicinal plants have been important sources of novel therapeutics 
since time immemorial. Current antiplatelet and anticoagulant drugs used to 
treat cardiovascular diseases have numerous adverse effects. The objectives of 
this study are to investigate the potential antiplatelet and anticoagulant effects 
of a local medicinal plant, Ardisia elliptica Thunberg and to isolate and 
identify the active compound(s) responsible for the actives. 
Ardisia elliptica is a local medicinal plant used in Malay traditional 
medicine for the treatment of pain in the region of the heart, parturition 
complications, fever, diarrhoea and liver poisoning. We hypothesised that A. 
elliptica possesses bioactive components that have antiplatelet and/or 
anticoagulant properties. 
A 70% v/v methanol extract was obtained from the leaves of the plant 
and fractionated. HPLC and GC-MS were used for the analysis of the extract 
and fractions. Platelet aggregation assay was performed on the extract and 
fractions using a platelet aggregometer. Effects on plasma coagulation were 
studied by measuring the prothrombin time and activated partial 
thromboplastin time. The plant extract was found to have both antiplatelet and 
anticoagulant activities. From the most active fraction, β-amyrin was 
successfully isolated and purified by preparative and semi-preparative HPLC. 
α –amyrin co-eluted with another compound and was not successfully 
purified. The IC50 values for inhibition of collagen-induced platelet 
aggregation inhibition were 21.3 and 10.5 µM for α- and β-amyrin 
respectively. These values indicated that α- and β-amyrin are three and six 
times more active respectively than aspirin (IC50 value= 62.7 µM). Hence, α- 
 xii
and β-amyrin are some of the active components in A. elliptica contributing to 
its antiplatelet activity. However α- and β-amyrin did not exhibit anticoagulant 
activity in the plasma coagulant assays, suggesting that other compounds are 
responsible for the anticoagulant activity in extracts of A. elliptica. 
As the conventional process of repeated fractionation is a tedious 
process for the discovery of bioactive components, a platform method for drug 
discovery from plant extracts using multivariate data analysis (MVDA) was 
developed. The MVDA method independently predicted that α- and β-amyrin 
were active components in the plant extract for antiplatelet activity. The 
developed MVDA method is a more time-efficient and cost effective method 
than the conventional bioassay guided fractionation method. 
The 70% v/v methanol extract and β-amyrin were subsequently studied 
in rats for their effects on tail bleeding, platelet aggregation and plasma 
coagulation. The extract and β-amyrin administered to rats orally were shown 
to prolong the tail bleeding times and inhibited platelet aggregation 
significantly. However anticoagulant activity was not observed at these 
dosages in vivo. 
The pharmacokinetic profile of β-amyrin was then studied in rats. It 
was found that β-amyrin had a very long terminal elimination half-life (t1/2λz = 
10.2 ± 3.0 h) and slow clearance (Cl = 2.04 ± 0.24 ml min−1 kg−1). The 
absolute oral bioavailability of β-amyrin in the crude plant extract was found 
to be generally low although slightly higher than that in the suspension of the 
pure form (3.83% vs 0.86%). 
In conclusion, the results presented in this thesis provide some 
scientific evidence for the traditional uses of A. elliptica. Further work is 
warranted to develop the lead compounds into useful therapeutics. 
 xiii
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methanol extract; ●-- ethanol extract; ●--water extract; ●-- 




Figure 4.8  Percent inhibition of platelet aggregation by different A. 
elliptica extracts (0.2 mg ml-1) and fractions (0.2 mg ml-1), β-
amyrin (10 µg ml-1) and aspirin (10 µg ml-1) compared to 
control; n = 6 except for β-amyrin and aspirin where n = 3; * 
p < 0.001 
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Figure 4.9  Effects of A. elliptica extracts (0.2 mg ml-1), fractions (0.2 
mg ml-1) and heparin (1 µg ml-1 and 5 µg ml-1) on PT 




Figure 4.10  Effects of A. elliptica extracts (0.2 mg ml-1), fractions 
derived from the 70% v/v methanol extract (0.2 mg ml-1) and 
heparin (1 µg ml-1 and 5 µg ml-1) on aPTT compared to 
control; n = 6 except heparin where n = 3; * p < 0.001 
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Figure 5.1 Ex vivo comparison of percentage inhibition of collagen-
induced platelet aggregation after treatment with different 
test samples in SD rats. Error bars represent standard 
deviation and experiments on each animal were done in 
triplicates. Doses of test samples indicated in brackets; n 
denotes the actual number of rats being analysed for each 
test sample. * p < 0.05 compared to aspirin 
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Figure 5.2  Ex vivo comparison of (A) PT and (B) APTT after treatment 
with different test samples in SD rats. Error bars represent 
standard deviation and experiments on each animal were 
done in triplicates. Doses of test samples indicated in 




Figure 5.3  GC-MS chromatograms of (A) a pre-dosing plasma sample 
(B) a blank plasma sample spiked with 1 μg ml-1 
methyltestosterone (peak 1; 5.944 min) and 100 ng ml-1 each 
of β-amyrin (peak 2; 15.854 min) and α-amyrin (peak 3; 
17.193 min) (C) methyltestosterone (peak 1; 5.937 min), β-
amyrin (peak 2; 15.836 min) and α-amyrin (peak 3; 17.170 
min) in a plasma sample taken from a rat 5 h after being 
dosed with 300 mg kg-1 of the plant extract. 
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Figure 5.4 (A) Plasma concentration versus time profiles of amyrins in 
rats after receiving:  a single intravenous administration of 1 
mg kg-1 β-amyrin standard (■) (n = 3); a single oral dose of 
β-amyrin standard at 3 mg kg-1 (▲) (n = 3); a single oral 
dose of 300 mg kg-1 plant extract equivalent of 3 mg kg-1 of 
β-amyrin (▼) and 1.9 mg kg-1 of α-amyrin (♦) (n = 4). (B) 
Plasma concentration versus time profiles of amyrins for the 
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1.1 Cardiovascular diseases and limitations of current treatments 
Cardiovascular diseases such as coronary heart disease and stroke are the top 
killer of people globally, and by 2030 almost 23.6 million people are projected to die 
from cardiovascular diseases (WHO, 2010).  
Patients of cardiovascular disease usually have myocardial infarction due to 
coronary artery thrombosis. Myocardial infarction is generally caused by platelets 
adhering onto the subendothelial matrix of the artery after it has been damaged by a 
ruptured artherosclerotheic plague. The aggregation of platelet at the site induces the 
formation of a prothrombotic surface which then induces a clot to form and 
subsequently vascular blockage (Michelson, 2010). Patients with cardiovascular 
diseases related to thromboembolism are usually treated with antiplatelets or 
anticoagulants like aspirin and warfarin to decrease the risk of recurrences of heart 
attack and stroke. Despite the efficacy of current drugs used in the treatment of such 
diseases, drugs like aspirin and warfarin are associated with numerous adverse effects, 
which will be elaborated later. 
 
1.1.1 Antiplatelet drugs 
Antiplatelet drugs used clinically are broadly classified into four classes: 
cyclooxygenase (COX) inhibitors, adenosine diphosphate (ADP) receptor antagonists, 
glycoprotein (GP) IIb/IIIa antagonists, and phosphodiesterase inhibitors (Michelson, 
2010).  
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1.1.1.1 Cyclooxygenase inhibitors 
There are two forms of COX: COX-1 and COX-2. COX-1 is constitutively 
expressed in the endoplasmic reticular membrane of all cells, such as gastric, vascular 
cell, kidney and platelets (Morita et al., 1995). It thus has varying roles such as 
maintenance of renal blood flow, gastric mucosal protection and platelet activation, 
though the generation of different prostaglandins (Smith, 1992). COX-2 exists in 
microvascular endothelial cells, which generates prostaglandin I2 (McAdam et al., 
1999) that has functions like decreasing platelet aggregation, vasodilation and 
inhibition of gastric acid secretion (Michelson, 2007). Aspirin is an example of drugs 
under the class of cyclooxygenase inhibitors. It works by inhibiting the catalytic 
activity of cyclooxygenase-1 (COX-1), thereby preventing the conversion of 
arachidonic acid into prostaglandin H2, and eventually thromboxane A2 (TXA2) (Loll 
et al., 1995). When TXA2 is not generated, platelets are prevented from activation via 
the thromboxane receptor. Because aspirin deactivates both COX-1 and COX-2, 
gastric mucosal erosion is a common adverse effect in patients taking the drug. 
Aspirin administration is associated with predisposition to Helicobacter pylori 
infections (Patrono et al., 2001).  In addition, aspirin administration is also associated 
with Reye’s syndrome, making it difficult for usage in susceptible individuals 
especially children and teenagers less than 18 years old (Glasgow, 2006).  
 
1.1.1.2 ADP receptor antagonists 
The second class of antiplatelet drugs are the ADP receptor antagonists. ADP 
activates platelet aggregation by increasing the concentration of free cytoplasmic 
calcium via the Gq-coupled P2Y1 receptor and the inhibition of the Gi-coupled P2Y12 
receptor, which inhibits adenylyl cyclase. Both the receptors need to be activated 
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before platelets can aggregate (Michelson, 2007). When the P2Y1 receptor is 
activated, platelets undergo shape change and as well as a rapid reversible shape 
change. When the P2Y12 receptor is activated, platelets aggregate in a slow, sustained, 
progressive fashion that is not preceded by shape change (Michelson, 2010). 
Currently only P2Y12 receptor antagonist are studied clinically. Examples include 
ticlopidine, clopidogrel and prasugrel (Michelson, 2010). Ticlopidine is an 
irreversible antagonist of the P2Y12 receptor. It has adverse effects like bleeding, 
gastrointestinal toxicity (heartburn, indigestion, nausea and vomiting), rash, 
neutropaenia and rare cases of thrombotic thrombocytopaenic purpura (Michelson, 
2007; Michelson, 2008). Because of its numerous adverse effects, ticlopidine has been 
largely replaced by clopidogrel. Clopidogrel has a better adverse effect profile 
compared to ticlopidine as it does not show gastrointestinal toxicity (Matetzky et al., 
2004; Sabatine et al., 2005; Michelson, 2007; Snoep et al., 2007; Michelson, 2010). 
However clopidogrel has a slow onset of action and shows interindividual variability 
where poor inhibition of platelet response was seen in some patients (Matetzky et al., 
2004; Sabatine et al., 2005; Snoep et al., 2007).  Prasugrel is another antagonist of the 
P2Y12 receptor being introduced and it does not show the adverse effects exhibited by 
both ticlopidine and clopidogrel (Michelson, 2010). Prasugrel is also more potent than 
clopidogrel (Payne et al., 2007; Wiviott et al., 2007; Michelson et al., 2009), but 
according to  Wiviott et al. (2007), the TRITON-TIMI 38 (Trial to assess 
Improvement in Therapeutic outcomes by optimizing platelet inhibition with 
prasugrel–Thrombolysis In myocardial Infarction 38), a Phase III trial on patients 
with acute coronary syndromes, patients with prasugrel has more haemorrhagic 
adverse effects. There were more patients in the prasugrel group than clopidogrel 
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group experiencing major bleeding and the rate of life-threatening bleeding was also 
higher. 
1.1.1.3 GP IIb/IIIa antagonists 
The third class of antiplatelet drugs are the GPIIb/IIIa antagonists. There are 
three FDA approved GPIIb/IIIa antagonists, which includes abxicimab, eptifibatide 
and tirofiban (Michelson, 2010). These drugs target the final pathway of platelet 
aggregation, where fibrinogen, or under conditions of high shear stress, von 
willibrand factor (VWF), binds to GPIIb/IIIa (Michelson, 2010). All the three drugs 
require intravenous administration, and show adverse effects like bleeding and 
thrombocytopaenia (Michelson, 2007; Michelson, 2010). Numerous clinical trials 
have been conducted on the use of GPIIb/IIIa antagonists (Table 1.1). 
These clinical trials show varying results. While many of the trials showed a 
positive effect, there were also some trials which showed disappointing results. For 
example in GUSTO-IV, there was no significant reduction in the number of acute 













Table 1.1 Clinical trials conducted on the use of GPIIb/IIIa antagonists. 
Clinical trial Reference 
CAPTURE (C7E3 Anti-Platelet Therapy in Unstable 
Refractory Angina)  
Simoons et al., 1997 
EPIC (Evaluation of c7E3 for Prevention of Ischemic 
Complications) 
Califf et al., 1994 
EPILOG (Evaluation of PTCA to Improve Long- Term 
Outcome with Abciximab GPIIb-IIIa Blockade) 
Topol et al., 1997 
EPISTENT (Evaluation of Platelet Inhibition in Stenting) Lincoff et al., 1999 
ESPRIT (Enhanced Suppression of the Platelet IIb- IIIa 
Receptor with Integrilin Therapy)  
Tcheng et al., 2000 
GUSTO-IV (Global Use of Strategies to Open Occluded 
Coronary Arteries-IV)  
Simoons et al., 2001 
IMPACT II (Integrilin to Minimize Platelet Aggregation and 
Coronary Thrombosis II)2  
Tcheng et al., 1997 
PRISM (Platelet Receptor Inhibition in Ischemic Syndrome 
Management)  
Bazzino et al., 1998 
PRISM-Plus (Platelet Receptor Inhibition in Ischemic 
Syndrome Management in Patients Limited by Unstable 
Angina)  
Bazzino et al., 1998 
PURSUIT (Platelet IIb-IIIa in Unstable Angina: Receptor 
Suppression Using Integrilin Therapy)  
Harrington et al., 
1998 
RESTORE (Randomized Efficacy Study of Tirofobanvfor 
Outcomes and Restenosis)  
Hanrath et al., 1997 
TARGET (Do Tirofoban and ReoPro Give Similar Efficacy 
Trial)  





1.1.1.4 Phosphodiesterase inhibitors 
The fourth class of drugs belong to the family of phosphodiesterase (PDE) 
inhibitors. The majority of the PDEs found in platelets are PDE3 and PDE5, which 
utilises mainly cyclic AMP (cAMP) and cyclic GMP (cGMP) as substrates 
respectively (Hasalam et al., 1999). Phosphodiesterase inhibitors work by different 
pathways, including the inhibition of cyclic nucleotide phosphodiesterase and 
adenosine uptake blockage. This results in the increase in cAMP and cGMP levels in 
the platelet, which inhibits signal transduction leading to platelet aggregation 
(Michelson, 2007). Two examples of the phosphodiesterase inhibitors are 
dipyridamole and cilostazol. Dipyridamole inhibits cGMP PDE5 in the platelets while 
cilostazol is selective for cAMP PDE3. Dipyridamole was reported to cause headache, 
dizziness, hypotension, flushing, gastrointestinal toxicity (nausea, vomiting, diarrhoea 
and abdominal pain) and rash (Sacco et al., 2008; Michelson, 2010). Cilostazol was 
reported to cause bleeding, headache, diarrhoea, palpitations, dizziness, rash and 
pancytopaenia (Lee et al., 2007; Michelson, 2010). The adverse effects of cilostazol 
led to approximately 15% of patients to discontinue use of the drug (Lee et al., 2007). 
 
1.1.2 Anticoagulation drugs 
 The process of blood coagulation is complex. Briefly, there are three stages of 
plasma coagulation: initiation, propagation and fibrin formation (Rang et al., 2003; 
Weitz and Bates, 2005). The initiation step can occur by two pathways, the intrinsic 
pathway and the extrinsic pathway (Figure 1.1). The coagulation cascade starts with 
the formation of tissue factor (TF)/ factor VIIa (FVIIIa) complex at the site of tissue 
injury via the extrinsic pathway. The intrinsic pathway is initiated by the interaction 
of factor XII, high molecular weight kininogen (HMWK) and prekallikrein to form 
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XIIa.  XIIa in turn converts XI to XIa which activates IX to IXa.  In the extrinsic 
pathway, factor X is also converted to Xa via factor VIIa, tissue factor, and cofactors 
like calcium and phospholipids. Propagation of the coagulation cascade occurs at this 
step, where factor X is activated. The activated factor X then converts prothrombin to 
thrombin. The final stage, fibrin formation occurs when fibrinogen is converted to 
fibrin by thrombin (Rang et al., 2003; Weitz and Bates, 2005). When screening for 
haemostasis, tests including prothrombin time (PT) and activated partial 
thromboplastin time (aPTT) are commonly used. PT is a reflection of the extrinsic and 
final common pathways of the plasma coagulation cascade, while aPTT reflects the 
intrinsic and final common pathways (Kamal et al., 2007). 
  
 
Figure 1.1 The coagulation cascade shown in conjunction with the participation of 
the tissue factor pathway inhibitor (TFPI).  (PL, negatively charged phospholipids; 
TF, tissue factor; HMWK, high molecular weight kininogen.) 
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Warfarin had been the most common oral anticoagulant drug used for over 60 
years since its introduction in the 1940s (Ahrens et al., 2010). Warfarin prevents 
coagulation by inhibiting the γ-carboxylation of the vitamin K dependent coagulation 
factors II, VII, IX and X, by inhibiting the vitamin K epoxide reductase complex 
subunit 1 (VKORC1) (Whitlon et al., 1978). Despite the efficacy of warfarin, patients 
taking the drug are at risk of serious or fatal bleeding. Warfarin also has an 
unpredictable pharmacokinetic profile, which is dependent on genetic variability 
(Ahrens et al., 2010). Genetic factors influencing warfarin’s pharmacokinetic profiles 
include polymorphisms in the VKORC1 and CYP2C9 genes (Rettie and Tai, 2006). 
CYP2C9 is a major hepatic enzyme required for metabolic clearance of warfarin. 
Therefore mutations in the CYP2C9 gene will lead to decreased clearance of the drug, 
causing a prolonged half-life and over anticoagulation. A polymorphism in the 
VKORC1 gene also puts patients at risk of overdosage. Individuals with the 
VKORC1*2 polymorphism requires less warfarin than those with the wildtype gene. 
This puts patients at risk of overdosage leading to excessive bleeding (Ahrens et al., 
2010). Non-genetic factors causing problems associated with varying drug responses 
in different patients include body mass index, age and drug history. Another widely 
used anticoagulant, heparin is generally safe to use. However heparin has to be 
injected, which limits its use to not more than two weeks (Melnikova, 2009). Like 
warfarin, adverse effects of heparin therapy include haemorrhage and heparin-induced 
thrombocytopenia (HIT type II), which occurs in 3% of patients (Melnikova, 2009). 
HIT can cause thrombosis, leading to limb gangrene or death (Rang et al., 2003; 
Thong and Kam, 2005). 
 9
In view of the short comings of the currently used antiplatelet and 
anticoagulation drugs, development of better drugs with fewer adverse effects is 
necessary.  
 
1.2 Medicinal plants 
 
Herbal medicines have been used since antiquity. There are currently three 
major types of herbalism being practiced: Asian, European and indigenous herbalism. 
Among Asian herbalism, the most famous would include those from China (as part of 
Traditional Chinese Medicine or TCM) and India (also known as Aryuveda). TCM 
and Aryuveda have been practiced for thousands of years, and their remedies usually 
comprise of mixtures of plant and/or animal parts. The combination of different 
components acts in such a way that one component will work in complementary with 
another, and enhance the therapeutic effects of the mixture (Elvin-Lewis, 2001). 
European herbalism has its origins from Mediterranean civilisations. It was believed 
in the Middle Ages that the shape and colour of the plant would imply what it is 
useful for.  This was stated in the Doctrine of Signatures, a philosophy which helped 
decide how plants were selected for treatment of diseases, for example, a heart-shaped 
leaf and yellow plant parts would be good for treating heart and hepatitis conditions 
respectively. Compounds from these plants were eventually being isolated or 
synthesised for usage. Indigenous herbalism is very diverse and practiced among 
cultures that are still intact. The different types of herbalism vary among regions, are 
usually based on anecdotal information and have widely accepted efficacy and safety. 
 Although traditional medicines had been used for centuries, the use of herbal 
medicines for treatment of illnesses was slowly phased out. Allopathic practitioners 
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viewed herbal medicine as not potentially useful or even harmful as many herbal 
concoctions did not have proof of safety and efficacy. As such, western medicine 
became the mainstream healthcare system in most parts of the world. However, there 
had been a revival of the “back to nature” belief among people. Many practitioners 
believed that ‘primary active ingredients in herbs are synergized by secondary 
compounds, and secondary compounds mitigate the adverse effects caused by primary 
active ingredients’ (McPartland and Pruitt, 1999). In addition to that, a revival of 
interest in the traditional screening of drugs from plants has been observed following 
success stories of discovery of blockbuster drugs from natural sources. Examples are 
such as paclitaxel (Taxol®) from the Pacific Yew tree, huperzine from Huperzia 
serrata and the more recent Tamiflu®, whose active compound was synthesised from 
shikimic acid isolated from a Chinese herb Illicium anisatum or star anise.  
 
1.2.1 Natural products in drug discovery  
While the impact of natural products on drug discovery is apparent, 
pharmacognosy is not favoured by the pharmaceutical industries. This is because 
making use of synthetic chemical libraries and combinatorial synthesis is deemed to 
be more convenient, faster and simpler. Although such techniques are preferred, some 
combinatorial libraries have very low hit rates or even no hits at all (Koehn and 
Carter, 2005). A review of the drugs introduced since 1994 showed that 
approximately 50% of the drugs are either natural product or natural product-derived 
compounds (Newman and Cragg, 2007). Examples of these are anticancer drugs 
vincristine and vinblastine from the Madagascar periwinkle (Catharanthus roseus) 
introduced during the 1960s, and an antibacterial drug daptomycin (derived from a 
bacterium, Streptomyces roseosporus) introduced in 2003. In addition, of the 1184 
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new chemical entities (NCEs) analysed between years 1981 to 2006, only 30% was 
made by totally synthetic routes (Newman and Cragg, 2007). The other NCEs are 
natural products or related to natural products, derived biologically, modified from 
natural products, or having pharmacophores from natural compounds. These statistics 
show that many NCEs are derived naturally. This is so because being secondary 
metabolites from natural sources, they could have exhibited more characteristics that 
resemble other existing drugs when compared to totally synthetic compounds (Koehn 
and Carter, 2005). Thus they are easier to use as lead compounds for modification into 
drugs. 
Research is actively ongoing for natural products for treatment of different 
diseases. For example, lipoic acid which is naturally occurring in both plants and 
animals, is being studied as a treatment for Alzheimer’s disease (Bonda et al., 2010). 
For cancer treatment, natural products such as polyphenol from green tea (Araujo et 
al., 2011; Chen et al., 2011; Siddiqui et al., 2011) and curcumin from turmeric (Sato 
et al., 211; Sharma et al., 2011) are popularly studied. A search on the database Web 
of Science using the keywords “natural product*” generated over 100,000 hits from 
years 1991 to 2010. It can be seen from Figure 1.2 that the number of papers 
published has increased steadily from 2 in 1991 to over 9600 in 2010. From the 
current situation, natural products will definitely continue to be an important source of 






















Figure 1.2 Number of publication hits generated by Web of Science using 
keywords “natural product*” from 1991 to 2010. 
 
1.2.2 Antiplatelet and anticoagulant compounds from medicinal plants 
Medicinal plants are a rich source of antiplatelet and anticoagulant 
compounds. The commonly used antiplatelet, aspirin (acetylsalicylic acid) for 
example, had its origins from salicin obtained from the willow plant (Salix spp.). 
Willow leaves were used to treat pain since the times of ancient Assyrians and 
Egyptians (Levesque and Lafont, 2000).  Similarly, the anticoagulant drug warfarin 
(3-phenyacetyl ethyl, 4-hydroxycoumarin) had its origins from a medicinal plant, the 
sweet clover. The effect of sweet clover was first observed in cattle suffering form 
haemorrhage when the plant was used as cattle-feed (Mueller and Scheidt, 1994). 
Chua and Koh (2006) had reviewed 55 medicinal plants and 136 phyto-constituents 
with antiplatelet and anticoagulant activities (Chua and Koh, 2006). 
From garlic, an antiplatelet compound, methyl allyl trisulfide, had been 
isolated and was found to inhibit platelet aggregation induced by arachidonic acid, 
collagen, thrombin, ADP, PAF and U46619 (Lim et al., 1999). Kaempferol 3-O-β-
glucopyranoside and kaempferol 3-O-β-neohesperidoside extracted from the wild 
garlic Allium ursinum also inhibited platelet aggregation induced by collagen 
(Carotenuto et al., 1996). Other anti-platelet compounds have been discovered from 
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well-known plants such as Ginkgo biloba (Diamond et al., 2000) and green tea (Son et 
al., 2004).  
Anticoagulant compounds were also isolated from numerous medicinal plants. 
Quercetin 3-acetyl-7,3´,4´-trisulphate and quercetin 3,7,3´,4´-tetrasulphate isolated 
from Flaveria bidentis exhibit anticoagulant activity at a concentration of 1 mM 
(Guglielmone et al., 2002), prolonging PT and aPTT. Quercetin 3,7,3´,4´-tetrasulphate 
was found to inhibit platelet aggregation induced by thromboxane B2 formation due to 
collagen or arachidonic acid (Guglielmone et al., 2005). 
Reports of active compounds from medicinal plants with antiplatelet or 
anticoagulant activities from the year 2006 onwards are listed in Table 1.2. 
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Table 1.2 List of reports of active compounds from medicinal plants with antiplatelet or anticoagulant activities 
 Plant Mechanism Reference 
Antiplatelet compounds    





Inhibit thrombin-induced aggregation Thisoda et al., 
2006 






Inhibit AA, U46619 and epinephrine-induced 
platelet aggregation 





Inhibit AA and U46619-induced aggregation Kim et al., 2010 
Coumarin, cinnamaldehyde, 









Inhibit collagen, ADP and thrombin-induced 
aggregation 
Tsuchiya et al., 
2008 




Harmane, harmine Perganum harmala Inhibit collagen-induced aggregation Im et al., 2009 
Hydroxychavicol Piper betel Inhibit AA and collagen-induced aggregation; 
inhibit TXB2 and COX-1 and COX-2 




Inhibit collagen, U46619 and thrombin-induced 
aggregation 
Jeng et al., 2007 
Taxinine, taxinine A, taxinine B, 
2-deacetoxytaxinine B, taxacin, 
taxchinin B, taxol 
Taxus cuspidata Inhibit AA and U46619-induced aggregation Kim and Yun-
Choi, 2010 
    
Anticoagulation compounds    
    
7-hydroxycoumarin Aegle marmelos, 
Citrus aurantium 
Prolong PT, clotting time and bleeding time Ramesh and 
Pugalendi, 2007 
Polyphenolic-polysaccharide. 
Carbohydrate consists of 
rhamnose (3.5%), arabinose 
(21.1 %), xylose (0.8 %), 
mannose (0.9 %), glucose (21.0 
%), galactose (22.8 %). 
Arnica motana Prolong PT and aPTT in vitro Pawlaczyk et al., 
2009 
Polyphenolic-polysaccharide. 
Carbohydrate consists of 
rhamnose (4.2%), arabinose 
(28.6%), xylose (2.4%), 
mannose (0.6%), glucose 
(8.0%), galactose (23.5%). 




Carbohydrate consists of 
rhamnose (5.5%), arabinose 
(13.6%), xylose (4.2%), 
mannose (0.9%), glucose 
(4.2%), galactose (15.7%). 
Filipendula ulmaria Prolong PT and aPTT in vitro Pawlaczyk et al., 
2009 
Polyphenolic-polysaccharide. 
Carbohydrate consists of 
rhamnose (1.0%), arabinose 
(6.8%), xylose (1.4%), mannose 
(0.9%), glucose (8.0%), 
galactose (19.3%). 
Fragaria vesca Prolong PT and APTT in vitro Pawlaczyk et al., 
2009 
Acidic glycoconjugate (MW 
~12.500) consisting of 
carbohydrates (30%), 
phenolics (1 g contained 
1.2mMof gallic acid equivalent) 
and proteins (0.8%). 
Carbohydrates predominated by 
uronic acids (~66%), galactose 
(~12%), rhamnose 
(~10%) and arabinose (~9%) 
residues 
Lythrum salicaria Prolong PT and aPTT in vitro. Procoagulation 
seen in vivo. 




Carbohydrate consists of 
rhamnose (2.4%), arabinose 
(9.8%), xylose (1.1%), mannose 
(2.9%), glucose (25.8%), 
galactose (16.1%). 
 
Rubus plicatus Prolong PT and aPTT in vitro Pawlaczyk et al., 
2009 
Polyphenolic-polysaccharide. 
Carbohydrate consists of 
rhamnose (6.0%), arabinose 
(17.2%), xylose (1.6%), 
mannose (1.6%), glucose 
(17.8%), galactose (30.8%). 
Solidago virgaurea Prolong PT and APTT in vitro Pawlaczyk et al., 
2009 
AA- arachidonic acid; U46619-thromboxane A2 mimic; ADP-adenosine diphosphate; TXB2-thromboxane B2; PT- prothrombin 
time; aPTT-activated partial thromboplastin time. 
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1.2.3 Ardisia elliptica  
1.2.3.1 The genus Ardisia  
Ardisia is a genus in the family of Myrsinaceae. Approximately 400 to 
500 species of Ardisia exists in the tropical regions of East and Southeast Asia, 
Americas, Australia and the Pacific Islands (Chen and Pipoly, 1996; eFloras, 
2010; Kobayashi and de Mejia, 2005). In this project, a traditional Malay herb, 
Ardisia elliptica Thunberg (A. elliptica), is chosen for the investigation of its 
antiplatelet and anticoagulant activities. Figure 1.3 shows the photograph of the 
trees, leaves, flowers and fruits of A. elliptica. There are many taxonomic 
confusions in this genus and correct identification of the plants are difficult 
(Kobayashi and de Mejia, 2005). For example, A. crenata is considered to be a 
synonym to A. crispa by some authorities (Duke and Ayensu, 1985). Perry (1980) 
and Burkill (1966) considered the two names to be synonymous, but according to 
eFloras (2010), they are separate species. In addition, taxonomical information on 
A. elliptica is confusing, leading to problems in plant identification. Burkill 
(1966) had written on A. littoralis, but this name had been recognised as a 
synonym of A. elliptica by different authors (Perry, 1980; HMRC and IMR, 
2002). While Burkill (1966) stated that A. humilis is probably an older name of A. 
elliptica, Perry (1980) considered them separate but others agreed with Burkill 
(HMRC and IMR, 2002). In addition, a review by Kobayashi and de Mejia (2005) 
accepted A. solanacea and A. squamulosa as synonyms of A. elliptica. eFloras 




     
      
Figure 1.3 Photographs of A) trees B) flowers C) unripe fruits (Pink) D) ripe 
fruits (dark purple) of A. elliptica. 
 
1.2.3.2 Description of Ardisia elliptica 
 A. elliptica is a tropical evergreen subshrub that is native to China, 
Malaysia, Singapore and Sri Lanka (Chong et al., 2009; Koop, 2004; NParks, 
2006). Various common names include Shoebutton ardisia or Sea-shore ardisia in 
English and Cham in Thai (HMRC and IMR, 2002; NParks, 2006). In Malay, A. 
elliptica is known by different names such as mata pelanduk or mata ayam 




( 方紫金牛东 ) or chun bu lao (春不老) (Yen, 2005; eFloras, 2010). A. elliptica 
reaches maturity between two to four years. The trees are usually one to five 
meters in height with a single stem and perpendicular branches attached (Figure 
1.3A) (Koop, 2004). A. elliptica belongs to the family of Myrsinaceae which 
consists of about 30 genera and 1000 species (Carr, 2005). Its leaves are typical of 
the Myrsinaceae family, being simple, glandular and alternate. Young leaves are 
often reddish while mature leaves are oval, fleshy, leathery in texture and can 
grow up to 20 cm in length (FLEPPC, 2010). The flowers of A. elliptica are 
auxillary and grow in inflorescences on the branches. The flowers are star shaped 
and about 13 mm in width, with the five petals forming a sympetalous corolla 
(Figure 1.3B) (Carr, 2005). Fruits of A. elliptica are drupes. They are round and 
not more than 2.5 cm in width, turning from red to black when ripe (Figure 1.3C 
and D) (Carr, 2005; FLEPPC, 2010). The seeds are spherical and approximately 5 
mm in width. A. elliptica starts flowering during April and fruits by September.  
Fruiting continues until March (Koop, 2004). 
According to eFloras (2010), A. elliptica can be differentiated from closely 
related species (A. garrettii, A. solanacea and A. filiformis) by its marginate 
petiole, flowers in umbels, rugose basal sepals and a revolute leaf blade margin. 
 
1.2.3.3 Traditional uses of Ardisia 
 Several Ardisia species are used as ornamental plants, food or medicines.  
Out of the 400 to 500 species of Ardisia however, it is not known how many of 
the species were known to be medicinal due to the limited information available. 
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A review had been written on species of Ardisia known to be medicinal, including 
the phytochemical constituents isolated from the plants (Kobayashi and de Mejia, 
2005). Plants in the Ardisia species are well known for some biological 
compounds such as bergenin and ardisin. Some examples of Ardisia species used 
in traditional medicine include A. cornudetata, A. crenata, A. crispa, A. crassa, A. 
demissa and A. lanceolata. A. cornudetata is used in folk medicine in the south 
eastern regions of China as an anti-inflammatory/analgesic medicine, antidote for 
snake bites and to improve general blood circulation (Tian et al., 1987).  
The roots of A. crenata (朱砂根) is used in Traditional Chinese Medicine 
as an anodyne, detoxicant, febrifuge, for backaches, diphtheria, dog and snake 
bites, sore throat, toothache, traumatic injuries, pain in the thighs. The wine 
extract of the roots are used on broken bones, bruises or sprains (Duke and 
Ayensu, 1985). The roots of A. crispa are used by the Chinese for fever, sore 
throat, antidotal and diuretic. The plant is crushed and used for treatment of scurf. 
The juice is put in ears to treat ear aches. The plant is also used for broken bones, 
sprains, cough and other pulmonary diseases (Burkill, 1966; Duke and Ayensu, 
1985). It was also stated that the sap of the plant is used in the Malay Peninsular 
for scurvy and an infusion of the root is used as an anti-pyretic, a bechic, 
antidysenteric and antidiarrheic (Perry, 1980).  
A. crassa roots are used in central and southern parts of the Malay 
Peninsular for rheumatism (Burkill, 1966). A. demissa (synonym: A. 
odontophylla) is also used by the Malays for treatment of rheumatism and 
stomach ache (Burkill, 1966; HMRC and IMR, 2002). A. lanceolata is taken as an 
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entire plant and used during confinement and for wound healing (Burkill, 1966; 
HMRC and IMR, 2002). 
 Unlike A. crenata, a well known herb in TCM, there is comparatively very 
little information on the traditional uses of A. elliptica which is used by the 
Malays. According to Burkill (1966), the leaves and roots of A. elliptica is used 
traditionally in the Malay Peninsular as a herb. Usually, the leaves are boiled and 
the extract is drunk to treat pain in the region of the heart (chest pains), parturition 
complications, fever, diarrhoea and liver poisoning (Burkill, 1966; HMRC and 
IMR, 2002). The roots can be used to substitute the leaves. Young shoots of the 
plant are eaten as food (Burkill, 1966). 
 
1.2.3.4 Scientific findings of Ardisia elliptica 
A. elliptica has been studied scientifically for different biological activities 
which are summarised in Table 1.3. 
 
Table 1.3 List of biological activities studied scientifically for A. elliptica. 
Bioactivity  Reference 
Antiproliferative  Moongkarndi et al., 2004 
 
Antibacterial  Phadungkit and Luanratana, 2006 
 
Antiplatelet  Ching et al., 2010; Jalil et al., 2004 
 
Antiviral *  Kobayashi and de Mejia, 2005; 
Chiang et al., 2003 
 
Induce apoptosis  Yen, 2005 
 




Ethanolic extracts of A. elliptica fruits were found to have antiproliferative 
activity on human breast adenocarcinoma (SKBR3) cell line with an IC50 of 103 
μg ml-1 (Moongkarndi et al., 2004). A. elliptica was also reported to inhibit lung 
cancer cells (H661 cell line) by inducing apoptosis via up-regulation of TNFR, 
FADD, TRADD, Fas and caspase-3 gene expressions (Yen, 2005). In addition, 
the ethanolic extract of the fruits was found to be anti-salmonella. Three 
compounds, syringic acid, isorhamnetin and quercetin were isolated from the 
extract and were found to inhibit S. enteritidis, S. weltevreden, S. typhimurium 
and S. blockley with minimal inhibitory concentrations between 15.6 and 125.0 μg 
ml-1 (Phadungkit and Luanratana, 2006). The methanol extract of A. elliptica 
leaves was found to be a potent platelet-activating factor antagonist. The 
compound responsible for the activity was reported to be 5-(Z-Heptadec-4’-
enyl)resorcinol, with an IC50 of 7.08 x 10-6 M (Jalil et al., 2004). A review by 
Kobayashi and de Mejia (2005) reported that A.elliptica has antibacterial and 
antiviral properties (Kobayashi and de Mejia, 2005). However, as mentioned 
before, original reports of the studies reported the plant as A. solanacea (Khan et 
al., 1991) and A. sqamulosa (Chiang et al., 2003) respectively. According to 
eFloras (2010), Ardisia solanacea is considered as a separate specie. Thus further 
identification of the plant is necessary.  
 
1.2.3.5 Chemical constituents of Ardisia elliptica 
Currently there are 10 phytochemical constituents that have been reported 
in A. elliptica. They are α-amyrin, β-amyrin, bauerenol, bergenin, isorhamnetin, 
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quercetin, rapanone, syringic acid, 5-(Z-heptadec-4’-enyl)resorcinol and 5-
pentadecylresorcinol. These phytochemical constituents and the plant parts they 
are isolated from are listed in Table 1.4. 
 





Plant part Extract Reference 







Ahmad et al., 
1977; Chow et al., 
1991 
 
bauerenol Leaves Benzene Ahmad et al., 
1977 
 
bergenin Whole plant Methanol Liu et al., 1993 
 













Diethyl ether Chow et al., 1991 
 










Jalil et al., 2004 
5-pentadecylresorcinol Leaves Methanol 
 
Jalil et al., 2004 
 
 
1.2.3.6 Biological activities of amyrins 
The triterpenes, α- and β- amyrin are found in A. elliptica, and are of 
special interest in this work. The structures of α- and β- amyrin are shown in 
Figure 1.4. The compounds α- and β- amyrins are found naturally occurring in a 
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wide variety of plants. α- and β- amyrin belong to a class of compounds, the 



























Figure 1.4 Chemical structures of (A) α-amyrin (B) β-amyrin. 
 
There is much potential for α- and β- amyrins to be used as lead compounds. 
As seen in Table 1.2, α- and β- amyrins show a wide range of biological activities. 
In additional to that, the amyrins show weak cytotoxic activities. For example, α-
amyrin showed anti-protozoal activity but is low in cytotoxicity against myoblast 
(L-6) cells (Mwangi et al., 2010). The amyrins are also only weakly cytotoxic 
against other cell lines such as A549, HL-60, SK-OV-3 and A2780 cell lines 
(Chaturvedula et al., 2004; Chung et al., 2009; Thao et al., 2010). The toxicities of 
a mixture of α- and β- amyrin had been studied (Oliveira, 2005). The α- and β- 
amyrin mixture showed low toxicity as a dose of up to 3 g kg-1 (p.o.) and 2 g kg-1 
(i.p.) failed to cause any mortality in mice. 
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An α- and β-amyrin mixture showed a weak acetylcholinesterase 
inhibition (13.4%) at 1 mM (Gurovic et al., 2010). 
 
Analgesic / Antinociceptive  
Writhing and formalin tests conducted in mice showed inhibition of 
writhing when a α- and β-amyrin mixture was dosed at 10 and 50 mg kg-1, i.p. 
(Aragao et al., 2007).  A triterpene mixture of α- -amyrin (43.7%), β-amyrin 
(24.9%) and baurenol (31.4%) administered i.p 100 mg kg-1 to mice, exhibited 
51% analgesic activity when tested using the acetic acid-induced writhing test 
(Villasenor et al., 2004). 
Rats pretreated with α- and β-amyrin mixture (10, 30 and 100 mg kg-1, 
i.p.) significantly inhibited the face-rubbing response when the animals were 
treated with formalin or capsaicin. It was shown that the treatment reduced 
orofacial pain in part, through a peripheral opioid mechanism (Pinto et al., 2008). 
Mice dosed with α- and β-amyrin mixture (30 and 100 mg kg-1, p.o.) 
showed significant reduction in visceral pain-related behaviours and NK1 
immunoreactivity. It was suggested that the mechanisms involve blocking either 
Substance P release or its receptor function, and also partly by opening K-ATP(+) 
channels (Lima-Junior et al., 2007). 
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Mice treated with α- and β-amyrin mixture (3 to 100 mg kg-1, p.o.) 
significantly suppressed the nociceptive behaviours induced by either subplantar 
or intracolonic application of capsaicin. The treatment did not alter the 
pentobarbital sleeping time, nor the ambulation or motor coordination in open-
field and rota-rod tests, respectively. This indicated the absence of sedative or 
motor abnormality that could account for its antinociception. It was suggested the 
analgesia inducing effect of the triterpene mixture, could involve the vanilloid 
receptor (TRPV1) and an opioid mechanism (Oliveira et al., 2005). 
Intraperitoneal treatment with α- and β-amyrin mixture reduced the 
nociception caused by 8-bromo-cAMP (8-Br-cAMP) and by 12-O-
tetradecanoylphorbol-13-acetate (TPA) or the hyperalgesia caused by glutamate. 
However unlike morphine, the treatment did not induce analgesia in thermal 
models of pain. The antinociception caused by the mixture of compounds seemed 
to involve mechanisms independent of opioid, alpha-adrenergic, serotoninergic 
and nitrergic system mediation. It was suggested that the mechanisms involved 
the inhibition of protein kinase A- and protein kinase C-sensitive pathways (Otuki 
et al., 2005). 
 
Antiarthritic 
α-amyrin was tested on models of destructive arthritic processes and was 
found to  inhibit rat osteosarcoma cell growth with an IC50 of 14 µM (Kweifiookai 







A α- and β-amyrin mixture was found to have Minimal Inhibitory 
Concentrations (MICs) of 80, 80 and 90 µg ml-1 against the gram positive 
bacteria, Bacillus sphaericus, B. subtilis and Staphylococcus aureus respectively. 
The mixture was also found to have MICs of 90 and 50 µg ml-1 against the gram 
negative bacteria, Escherichia coli and Pseudomonas  syringae respectively 
(Mallavadhani et al., 2004). 
α-amyrin (1 mg) showed antibacterial activity against Escherichia coli, 
Staphylococcus aureus, Klebsiella pneumoniae and Bacillus thuringiensis with 
activity index (Inhibition area of test sample / Inhibition area of standard, 1 mg 
gentamycin) of 0.5, 0.44, 0.43 and 0.39 respectively (Singh and Singh, 2003). 
β-amyrin exhibited strong antibacterial activity against Salmonella 
typhimurium with a minimum bactericidal concentration (MBC) value of 300 μg 
ml–1 and with a MIC value of 95 μg ml–1. β-amyrin had moderate activities 
against Escherichia coli and Pseudomonas aeruginosa with MIC values of 97 μg 
ml–1 (Hichri et al., 2003). 
β-amyrin (1 mg) showed antibacterial activity against Escherichia coli, 
Staphylococcus aureus and Klebsiella pneumoniae with activity index (Inhibition 
area of test sample / Inhibition area of standard, 1mg gentamycin) of 0.64, 0.40 
and 0.35 respectively (Jain et al., 2003). 
 
Anti-colitis  
A α- and β-amyrin mixture given intraperitoneally at 3 mg kg-1 improved 
tissue damage scores and abolished polymorphonuclear cell infiltration in mice 
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with trinitrobenzene sulphonic acid (TNBS)-induced colitis. The inhibition of 
TNBS-induced colitis was related to the local suppression of inflammatory 
cytokines and COX-2 levels. The mechanism was suggested to occur via 
inhibition of NF-kappa B and CREB-signalling pathways (Vitor et al., 2009). 
 
Antidepressant  
Mice dosed with 10 and 25 mg kg-1 of α- and β-amyrin mixture after 
intraperitoneal or oral administrations showed sedative effects. When dosed at 2.5 
and 5.0 mg kg-1, a decrease in the immobility time was observed in the forced 
swimming test (Aragao et al., 2006). 
 
Anti-diarrhoeal 
A triterpene mixture of α- -amyrin (43.7%), β-amyrin (24.9%) and 
baurenol (31.4%) given orally resulted in a 29 and 55 % antidiarrhoeal activity at 
dosages of 100 and 250 mg kg-1 (p.o.) of mouse, respectively in a charcoal tracing 
test (Villasenor et al., 2004). 
 
Antifungal 
A α- and β-amyrin mixture showed MICs of 30, 125, 125, 250 and 60 µg 
ml-1 against Candida krusei, C. albicans, C. glabrata, C. tropicalis and C. 
parapsilosis respectively (Johann et al., 2007). 
A triterpene mixture of α- -amyrin (43.7%), β-amyrin (24.9%) and 
baurenol (31.4%) showed an antimicrobial index (diameter of clearing zone − 
diameter of well)/diameter of well) of 0.3, 0.6 and 0.8 against Staphylococcus 
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aureus, Candida albicans and Trichophyton mentagrophytes the using the agar 
cup method (Villasenor et al., 2004). 
α-amyrin (1 mg) showed antifungal activity against Aspergillus niger, 
Rhizoctonia phaseoli and Penicillium chrysogenum with activity index (Inhibition 
area of test sample / Inhibition area of standard, 1mg mycostatin) of 0.72, 0.5 and 
0.83 respectively (Singh and Singh, 2003). 
β-amyrin (1 mg) showed antifungal activity against Aspergillus niger, 
Aspergillus flavus and Penicillium chrysogenum with activity index (Inhibition 
area of test sample / Inhibition area of standard, 1mg mycostatin) of 0.9, 0.58 and 
0.9 respectively (Jain et al., 2003). 
 
Antihyperglycemic 
α-amyrin, given orally, was found to lower the blood glucose levels by 
13.9 and 8.12% at 5 and 24 h, respectively, in sucrose challenged streptozotocin 
induced diabetic rat (STZ-S) model at the dose of 100 mg kg-1 body weight. 
However the p-chlorobenzoic acid and nicotinic acid derivatives of α-amyrin 
showed more potent antihyperglycemic activity (Narender et al., 2009). 
 
Anti-inflammatory  
A α- and β-amyrin mixture (25 and 50 mg kg-1, i.p.) was able to reverse 
the edema of the paw of mice induced by carrageenan. The mixture was also able 
to prevent dextran-induced paw edema (Aragao et al., 2007). 
A single oral dose of α- and β-amyrin (10, 30 and 100 mg kg-1) given to 
rats reduced the L-arginine-induced increase in pancreatic wet weight/body 
weight ratio, and decreased serum levels of amylase and lipase, and TNF-alpha 
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and IL-6. Pancreatic myeloperoxidase activity, lipid peroxidation and 
nitrate/nitrite were also lowered (Melo et al., 2010).  
A triterpene mixture of α- -amyrin (43.7%), β-amyrin (24.9%) and 
baurenol (31.4%) administered i.p 100 mg kg-1 to mice, exhibited 20% anti-
inflammatory activity when tested using the carrageenan-induced mouse paw 
edema test (Villasenor et al., 2004). 
α-amyrin, applied topically on the ears of mice, was found to reduce 12-O-
tetradecanoylphorbol-13-acetate- (TPA) induced inflammation in mice with an 
IC50 of 0.2 mg per ear (Akihisa et al., 1996). 
Topical application of α-amyrin (0.1–1 mg/ear) in mice dose-dependently 
inhibited TPA -induced increase of prostaglandin E2 levels. It was found that α-
amyrin dose-dependently inhibited TPA-induced COX-2 expression in the mouse 
skin. Results also showed that treatment with α-amyrin prevented IκBα 
degradation, p65/RelA phosphorylation and NF-κB activation, and inhibited the 
activation of extracellular signal-regulated protein kinase (ERK), p38 mitogen-
activated protein kinase (MAPK) and protein kinase C (PKC)α (Medeiros et al., 
2007). 
α-amyrin was shown to inhibit platelet activating factor (PAF) receptor 
binding to 3H-PAF in rabbit platelets with IC50 values of 20.0 µM (Mazura et al., 
2007). 
α-amyrin and β-amyrin were individually found to inhibit TPA-induced 
inflammatory ear edema in mice with an IC50 of 0.50 and 0.83 µM per ear 
respectively (Yasukawa et al., 2010).  
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In another study, β-amyrin, applied topically on the ear of mice, was found 




β-amyrin (2.92 mM) showed 62.6%  protection against in vitro low 
density lipoprotein (LDL) oxidation in a copper-induced LDL oxidation test 
(Andrikopoulos et al., 2003). 
 
Antiplatelet 
A α- and β-amyrin mixture was found to inhibit aggregation of human 
platelets induced by adenosine 5'- diphosphate (ADP), collagen and arachidonic 
acid in vitro. The IC50 values for the inhibitory effect were 90.0, 117.9 and 181.4 
µM for collagen, ADP and arachidonic acid respectively (Aragao et al., 2007). 
 
Antiprotozoal  
α-amyrin was shown to exhibit anti-plasmodial activity against the 
parasitic protozoa, Plasmodium falciparum (K1 strain, chloroquine resistance) 
with an IC50 of 0.96 µg ml-1. α-amyrin also showed low to moderate activity 
against Trypanosoma brucei rhodesiense, Trypanosoma cruzi and Leishmania 
donovani with IC50 value of 11.21 µg ml-1, >30 µg ml-1 and 7.90 µg ml-1 
respectively. At the same time, α-amyrin was shown to have low cytotoxicity 
against myoblast (L-6) cells (IC50 > 90 µg ml-1), which makes it a good potential 
anti-protozoal drug (Mwangi et al., 2010). 
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In another study, α-amyrin and β -amyrin were shown to exhibit anti-
plasmodial activity against a chloroquine-sensitive strain of P. falciparum (D10) 
with an IC50 value of 50.3 and 89.9 µM  respectively (Chung et al., 2009). 
 
Antipruritic 
Mice fed orally with α- and β-amyrin (50, 100 and 200 mg kg-1) showed 
significantly inhibited scratching induced by dextran T40 and compound 48/80. 
The results suggested that the antipruritic effect was related to a stabilizing action 
on mast cell membrane (Oliveira et al., 2004). 
 
Antithrombin 
α-amyrin (0.5 mg ml-1) and β-amyrin (0.5 mg ml-1)  showed a 39% and 
78% antithrombin activity in vitro in a chromogenic assay respectively (Medeiros 
et al., 2002). 
 
Antitubercular  
A mixture of lupeol, α- and β-amyrin showed a MIC of 31.5 µg ml-1 
against Mycobacterium tuberculosis. Pure β-amyrin was shown to exhibit a MIC 
of 312.25 µg ml-1 against M. tuberculosis (Higuchi et al., 2008). 
 
Anxiolytic  
Mice dosed with 10, 25 and 50 mg kg-1 of α- and β-amyrin mixture after 
intraperitoneal or oral administrations showed decreased the number of crossings, 





α –amyrin showed cytostatic activity against cultured Hep-2 and Mc Coy 




α -amyrin exhibited weak cytotoxic activity against SK-OV-3 cancer cell 
lines with an IC50 value of 32.3 µM (Chung et al., 2009) and weak cytotoxic 
activity against A2780 ovarian cancer cell line with an IC50 value of 20.6 µg ml-1  
(Chaturvedula et al., 2004). 
β-amyrin exhibited weak cytotoxic activity against A549 and HL-60 cell 
lines with IC50 values of 46.2 and 38.6 µM, respectively (Thao et al., 2010). 
β-amyrin exhibited cytotoxic activity against SK-OV-3 cancer cell lines 
with an IC50 value of 12.4 µM (Chung et al., 2009). 
 
Gastroprotective  
Mice pretreated orally with α- and β-amyrin (50 and 100 mg kg-1) showed 
a lower intensity of ethanol-associated gastric mucosal damage (Oliveira et al., 
2004). 
Rats treated with α- and β-amyrin (100 mg kg-1) orally showed 50% of 
gastroprotection in the animals with acute gastric ulcers induced by absolute 









α –amyrin was found to inhibit soybean lipoxygenase with an IC50 of 15.0 
µM (Gutierrez-Lugo et al., 2004). 
β-amyrin (55.6 µg ml-1) reduced the calcium-ionophore (A23187)-induced 
synthesis of 5-lipoxygenase products by human neutrophils, 5-HETE by 58%,  6-
trans-leukotriene B4 by 56% and 6-trans-12-epileukotriene B4 by 58%. 5-HETE is 
proinflammatory and the results helped to account for the anti-inflammatory 
activities of β-amyrin (Kweifio-Okai and Macrides, 1992). 
 
Liver-protective  
Mice pretreatment with α- and β-amyrin (50 and 100 mg kg-1, i.p before 
acetaminophen) reduced the acetaminophen-induced acute increase in serum 
alanine aminotransferase  and aspartate aminotransferase  activities, replenished 
the depleted hepatic glutathione and also reduced histopathological alterations 
(Oliveira et al., 2005). 
 
Serine protease inhibitor 
α –amyrin was found to be a competitive inhibitor of bovine trypsin and 
chymotrypsin with Ki values of 29 µM and18 µM respectively. The IC50 values 
are 41 µM and 23 µM for trypsin and chymotrypsin respectively (Rajic et al., 
2000). 
 
Inhibit binding to human endothelin 1 ETA receptor 
β-amyrin (100 µM) was found to inhibit 49% of [3H]-BQ-123 from 
binding to the Endothelin receptor type A (ETA) receptor. β-amyrin was found to 
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be specific for ETA as the same concentration of compound could only inhibit 2% 
of  [3H]-angiotensin II from binding to the angiotensin II AT1 receptor (Caballero-
George et al., 2004). 
 
Tables 1.5 to 1.7 list the activities of the amyrins from literature, together with 
the plants which the amyrins were found. The tables are categorised by the purity 
of the amyrins studied: mixture of α- and β-amyrin in Table 1.5; α-amyrin in 




























Villasenor et al., 2004; Aragao et al., 2007; 
Oliveira et al., 2005; Otuki et al., 2005; Lima-







Mallavadhani et al., 2004 
Anti- colitis  
 
Protium kleinii Vitor et al., 2009 
Antidepressant  
 











Villasenor et al., 2004; Aragao et al., 2007; 
















Protium heptaphyllum Aragao et al., 2007 
Antitubercular  
 
Byrsonima fagifolia Higuchi et al., 2008 
Anxiolytic  
 









Protium heptaphyllum Oliveira et al., 2005 
Antipruritic 
 
Protium heptaphyllum Oliveira et al., 2004 
 
















Trichodesma amplexicaule Singh and Singh, 2003 






Chrysanthemum morifolium, Matricaria 
matricarioides, Calendula officinalis, Cosmos 
bipinnatus, Helianthus annuus, Helianthus. 
debilis, Arctium lappa, Carthamus tinctorius, 
Cirsium nipponicum, Cirsium tanakae, Cynara 
cardanculus, Silybum marianum, Taraxacumo 




Akihisa et al., 1996; Mazura et al., 2007; 













Hedera helix Medeiros et al., 2002 
Cytostatic activity 
 













Anadenanthera colubrina Gutierrez-Lugo et al., 2004 
 
Serine protease inhibitor N.A. Rajic et al., 2000 
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Arnebia hispidissima Jain et al., 2003 
Anti-inflammatory  
 
Chrysanthemum morifolium, Matricaria 
matricarioides, Calendula officinalis, Cosmos 
bipinnatus, Helianthus annuus, Helianthus. 
debilis, Arctium lappa, Carthamus tinctorius, 
Cirsium nipponicum, Cirsium tanakae, Cynara 
cardanculus, Silybum marianum, Taraxacumo 














Pistacia lentiscus Andrikopoulos et al., 2003 




Hedera helix Medeiros et al., 2002 
Antitubercular 
 









Chung et al., 2009; Thao et al., 2010 
 
Inhibit binding to human 
endothelin 1 ETA receptor 
 
N.A. Caballero-George et al., 2004 
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1.3 Applications of metabolomics in drug discovery 
Traditionally in drug discovery, a target is usually first chosen and the 
drug is then designed to interact with the specific target(s). This is a process of 
rational drug design. Advances in technology now allow for fast and automated 
processes such as High Throughput Screening (HTS), rapid DNA sequencing, cell 
assays and microarrays etc. These processes are critiqued as replacing rational 
scientific reasoning with numbers (Drews, 2000). It is difficult to determine 
whether the traditional or the newer rapid methods work better as the statistics are 
unclear. Some industries agreed that HTS has resulted in more drug hits, but on 
the other hand others showed that HTS did not contribute much to the new drug 
leads (Drews, 2000). In any case, it is generally agreed that there is a need for 
more haste in drug discovery to satisfy the demand of more potent drugs, 
changing diseases like influenza and cancer, as well as cheaper and improved 
drugs with lesser adverse effects. As discussed earlier, natural products form a 
large and important source for new drugs. In the case of natural product 
discovery, the process could be neither fast (using techniques like random 
screening, bioassay-guided fractionation etc.) nor rational (natural products 
discovered by serendipity, for example penicillin). Although HTS does help to 
increase the rate of screening, the process is still deemed to be non-rational. To 
solve the problem, metabolomic studies seemed a probable solution as it entails 
rapid screening and rational prediction of probable bioactive compounds from 
complex mixtures, thereby increasing the chances of a hit. 
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Metabolomics has been described as the analyses and interpretation of 
metabolite levels in a biological sample by target analysis, profiling, footprinting 
or fingerprinting (Fiehn, 2002). Metabolomics analysis is performed using 
techniques of chemoinformatics, bioinformatics, and multivariate data analysis 
(MVDA). Current applications of metabolomics include discovery of biomarkers 
of various diseases such as coronary heart disease (Brindle et al., 2002), Lesch-
Nyhan syndrome (Ohdoi et al., 2003) and cancer (Odunsi et al., 2005), 
investigation of genotype-phenotype relationships, and optimising cell culture, 
metabolic engineering cell cultures etc (Oldiges et al., 2007).  
In addition to the study of metabolites in animal and human models, 
metabolomics has also been developed for natural product research (Rochfort, 
2005). As pointed out by Shyur and Yang, 2008, metabolomics is especially 
useful for studying the plant metabolome as metabolites are much more complex 
in plants than in the mammalian system. Also, the numerous compounds 
produced by plants are influenced by the external environmental factors such as 
temperature, physical stress, predators and drought as well as internal factors 
including different phases of their life cycle (Wang et al., 2005). Moreover, 
decomposition of phytoconstituents can occur after harvesting of the plant parts, 
during extraction and preparation of the drug. A research by Wang et al. (2005) 
showed how the concentrations of ginkgolides and bilobalides can differ when 
Ginkgo leaves were harvested at sunrise and sunset. As such, metabolomic 
techniques can aid in optimising the harvesting of the medicinal plants and the 
growth conditions so that the amount of bioactive components in the plant is 
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maximised. The metabolomic approach can also be used for quality control so 
that only medicinal plants with appropriate amounts or mixtures of active 
components are used. Examples of studies using the metabolomic approach to 
help identify bioactive components in medicinal plants will be elaborated later. 
 
1.3.1 Metabolomics for quality control of medicinal plants 
 As mentioned above, metabolomics is often performed using multivariate 
data analysis (MVDA). As the name implies, MVDA is a technique that allows 
for the analysis of data sets with large number of variables. For example by using 
MVDA, Nuclear Magnetic Resonance (NMR) spectrums of crude plant extracts 
can be visualised, interpreted and compared with those of relatively similar 
extracts (Heinrich, 2008). NMR-spectroscopy and Principal component analysis 
(PCA) of Tanacetum parthenium was able to help distinguish between batches of 
14 commercially obtained samples based on their metabolic profile (Bailey et al., 
2002). Rasmussen et al. went a step further to use 1H-NMR-spectroscopy to 
differentiate between various preparations according to their global composition, 
and also between batches from the same supplier (Rasmussen et al., 2006). Other 
than NMR, it was shown that by using Ultra-high performance liquid 
chromatography/time-of-flight mass spectrometry on Panax notoginseng, and 
analysing the metabolites by MVDA, the duration of steaming of the herb can be 
deduced (Toh et al., 2010). These examples show the potential of metabolomics 
for quality control. As traditional medicine becomes more popularised and 
prominent in the world, it is important to characterise the medicinal plants used 
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and to be able to check for adulteration of the products. However more work 
needs to be done in order to use metabolomic techniques for routine and large 
scale testing. 
 
1.3.2 Metabolomics and analysis of pharmacological effects 
 A major aspect of drug discovery is concerned with the elucidation of the 
drug’s pharmacological effects. In order to do so, extensive mechanistic studies 
need to be performed. It had been shown that by using metabolomics, the 
pharmacological effect of medicinal plant extracts can be linked to its chemical 
profile. Wang et al. (2010) attempted to elucidate the mechanism by which a 
medicinal plant, Sophora flavescens up-regulates CYP3A. S. flavescens is used 
traditionally to treat of viral hepatitis, cancer, viral myocarditis, gastrointestinal 
haemorrhage and skin diseases. In the study, Principal-component analysis (PCA) 
and Orthogonal projection to latent structures-discriminant analysis (OPLS-DA) 
were used to analyse the chemical constituents of the plant. The chemical 
constituents were further analysed for their effects on the pregnane X receptor 
(PXR) activation and CYP3A regulation. Analysis showed that it was a single 
chemical, N-methylcytisine that was responsible for activating PXR (Wang et al., 
2010). 
 In the field of cancer therapy research, the mode of action of a plant 
extract obtained from Anoectochilus formosanus was compared to a single 
compound drug in MCF-7 cells (Yang et al., 2004). Metabolomic and 
transcriptomic analyses showed similar gene expression regulating profiles, 
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indicating a similar mode of action between the extract and the drug. By this 
technique, fewer possibilities with regards to the mechanism of action need to be 
considered, enabling more focus in research. 
 
1.3.3 Using metabolomics for drug discovery from medicinal plants 
  Discovery of active compounds from plant extracts is difficult due to a 
number of reasons. First, plant extracts comprise of a complex mixture of 
compounds which can be difficult to isolate, especially if they are in small 
quantities. In many cases, herbal medicines are taken as a concoction of different 
plants, thus increasing the difficulty of pinpointing the active component. 
Conventional methods of discovering bioactive components from medicinal 
plants involve bioassay-guided fractionation which involves repeated 
fractionation and bioassays. For very complex mixtures, isolating a single 
compound can be tedious and not cost efficient. Second, there are many examples 
where two or more of the compounds in the extract act together in synergism in 
order for the activity to be exhibited. Individually, their activity is not as strong as 
that in a mixture. When this is the case, bioassay-guided fractionation would not 
be useful for identifying the active component. An example of synergism can be 
illustrated from an Ayurvedic formulation, ‘Trikatu’. This preparation is used 
routinely for many diseases as a part of a multidrug formulation. Trikatu consists 
of a mixture of black pepper (Piper nigrum), long pepper (Piper longum) and 
ginger (Zingiber officinalis). It was found that the alkaloid, piperine found in 
pepper was a bioavailability enhancer. It was reported that blood levels of 
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rifampicin, phenytoin, pentobarbitone, theophylline and propanolol were 
increased when the drugs were taken together with piperine. When long pepper 
was taken together with vasaka leaves (Adhatoda vesica) for treatment of asthma, 
the bioavailability of vasicine (or peganine) from the leaves was enhanced (Johri 
and Zutshi, 1992). On top of synergism, there are other reasons that compounds 
should not be isolated from the plant extract. Plant extracts may contain unstable 
constituents, for example in Valeriana spp., Allium sativum, Zingiber officinalis 
and Humulus lupulus, which are “protected” from decomposition by antioxidants 
in the whole plant material (Williamson, 2001). Williamson further advised 
against isolation of the compounds when the active constituents are not 
completely identified, and also when the extracts have a range of activities 
(Williamson, 2001).  
 Another concern in natural product discovery is whether different plant 
parts can be used to replace parts used in existing remedies. The reason for the 
need to consider a replacement could be due to reasons such as ease of harvesting 
or for conservation purposes. For example, Vismia guineensis is an endangered 
shrub found in West Africa, and its roots are used in decoctions for various skin 
diseases such as dermatitis, leprosy, syphilis, herpes, scabies and eczemas. As 
harvesting of the root is destructive for the plant, a study was conducted to 
determine the feasibility of using the leaves of the plant instead. In the earlier 
days of metabolomics, the study involved the comparison of the chemical 
compositions of the root and leaves by HPLC-UV/PAD and HPLC-MS. The 
molecular weights and characteristic fragments of the chemicals were compared 
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with Electron Impact (EI) or HPLC-MS literature data, which allowed partial 
identification of the major peaks in the chromatograms. The results showed that 
only a minority of the constituents of the two organs were similar, which implied 
that the roots cannot be replaced by the leaves (Politi et al., 2004). 
 Successful reports on using metabolomics or MVDA for discovering 
bioactive compounds from medicinal plants are being reviewed. It has been 
hypothesised that by screening plant extracts with different composition, it would 
be “possible to calculate which compounds or group of compounds are associated 
with the highest bioactivity” using MVDA (Wang et al., 2005). Research on 
Quantitative composition-activity relationship (QCAR) has been conducted on 
herbal medicine using various algorithms and showed positive results (Cheng et 
al., 2006; Wang et al., 2006; Wang et al., 2008; Chau et al., 2009; Froufe et al., 
2009). Using chemoinformatic techniques on QCAR, Cheng et al. demonstrated 
the suitability of the technique to discover active components from the mixed 
extracts of Radix Salviae miltiorrhizae and Cortex Moutan compared to bioassay-
guided fractionation. Cryptotanshinone and dihydrotanshinone I were found using 
QCAR to be active for protecting cardiomyocytes against ischemia-induced injury 
(Cheng et al., 2006). Using a QCAR approach, Wang et al. managed to optimise a 
herbal medicine for decreasing plasma cholesterol levels, Qi-Xue-Bing-Zhi-Fang, 
by identifying and varying two active components in the herbal extract (Wang et 
al., 2006). In a separate report, Wang et al. also managed to identify a ginsenoside 
Rb1 to be cytotoxic from Panax ginseng extracts using a data mining approach 
and a causal discovery algorithm (Wang et al., 2008). Chau et al. developed a 
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partial least-squares (PLS) model to reveal the chromatographic regions of a 
herbal medicine most strongly related to its activity. It was stated that by inputting 
whole chromatographic profiles and total bioactivity, a quantitative pattern-
activity relationship approach can help to predict total activity from the 
chromatographic fingerprint and also to predict features in the fingerprint related 
to the activity (Chau et al., 2009). A QCAR model using the PLS method was also 
constructed  by Froufe et al. to predict the antioxidant activities of wild 
mushrooms (Froufe et al., 2009). 
 From the examples listed, metabolomics and MVDA seemed to be a 
potential tool for aiding drug discovery from medicinal plants. 
 
1.3.4 Techniques used in metabolomic studies 
 Figure 1.5 shows the general workflow of a metabolomic study. The 
workflow shows the relationship between analytical techniques such as LC-MS 
and GC-MS and using MVDA for the identification of marker metabolites. In the 
case of drug discovery from medicinal plants, the marker metabolites would be 
compounds that are bioactive.  
Good reviews have been written to describe the techniques used in 
metabolomics (Wang et al., 2005; Shyur and Yang, 2008). Metabolomic studies 
on plant extracts can be performed using techniques such as gas chromatography-
mass spectrometry (GC-MS) (Lisec et al., 2006; Ma et al., 2008), liquid 
chromatography-mass spectrometry (LC-MS) (Zhi et al., 2008), thin layer 
chromatography (TLC) (Roberts et al., 2008), Fourier transform infrared 
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spectroscopy (FT-IR) (Goodacre et al., 2007) and NMR (Lang et al., 2008; 
Mitova et al., 2008). After obtaining raw data from the above techniques, general 
data processing procedures include centroiding and deisotoping mass spectra to 
condense and reduce data, reduce variation in chromatograms, filtering off 
background signals, deciding on threshold windows of the mass (m/z) and 
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Thereafter, the data is being analysed by MVDA (Shyur and Yang, 2008). 
MVDA enables the analysis of data coupled with many variables (Sumner et al., 
2003). There are two major classes in MVDA—supervised and unsupervised 
MVDA. In the unsupervised MVDA, sample classification is not revealed in the 
analysis. However in supervised MVDA, this information is made known for 
model construction (Chen et al., 2007). Popular unsupervised methods include 
PCA, hierarchical clustering, K-means clustering and self-organizing maps, while 
supervised methods include partial least squares, orthogonal partial least squares, 
soft-independent modelling of class analogy, and partial least squares-
discriminant analysis (Sumner et al., 2003; Chen et al., 2007). One of the best 
known unsupervised methods of analysis is PCA (Ma et al., 2008). PCA is a well 
known technique for exploratory data analysis. As PCA can present data in low 
number of dimensions and also determine the least dimensions needed for 
replication of data (Andrews et al., 1996; Zhi et al., 2008), PCA allows data to be 
represented on a graph with different objectives. The representation on a graph 
enables data to be studied in a dimensional space for analysis of their proximity 
with other objects, hence facilitating classification and detection of unusual 




Hypothesis and Objectives 
 
2.1 Hypothesis 
The traditional uses of a medicinal plant may provide useful clues for drug 
discovery purposes. A. elliptica is traditionally used for treatment of chest pains 
(Burkill, 1966). Causes of chest pains include thromboembolism (Michota, 2005). 
Another reported traditional use of the herb is the treatment of parturition 
(childbirth) complications which is also related to problems in blood circulation. 
Hence it is hypothesised that A. elliptica possesses phytoconstituents with 
antiplatelet and/or anticoagulant activities that may be potential lead compounds 
for development of new drugs.   
In this project, the traditional bioassay guided fractionation is employed 
for isolation and identification of bioactive constituents. However, bioassay 
guided fractionation is a slow process. Metabolomics and MVDA have been 
proven to be useful tools for the discovery of biomarkers in animal tissues for 
diseases (e.g. cancer, metabolic syndromes and coronary diseases) and in plants, 
MVDA had recently been used for the identification of compounds having 
anticancer, antioxidant activities etc. It is hypothesised that MVDA can also be 
developed as a drug discovery platform for rapid identification of bioactive 




Adverse effects of current antiplatelet and anticoagulant drugs have been 
well documented. Currently used antiplatelet and anticoagulant drugs such as 
aspirin and warfarin have adverse effects including gastric mucosal erosions and 
excessive bleeding respectively. Given the limitations of the current treatments, 
the search for safer drugs is necessary. 
The overall objectives of this work are to investigate the potential antiplatelet 
and anticoagulant effects of A. elliptica and to isolate and identify the active 
compounds(s) responsible for the activities. Hence to achieve these objectives, the 
specific objectives are to 
1. Screen extracts of A. elliptica for antiplatelet and anticoagulant 
activities in vitro and in vivo.  
2. Identify and isolate the active compound(s) responsible for the 
antiplatelet and/or anticoagulant activity of the plant. 
3. Develop a platform involving MVDA to rapidly identify bioactive 
components from the plant extract without the need for bioassay-
guided fractionation. 
4. Study the pharmacokinetics of the isolated component(s) in rats. 
 
The successful development of metabolomics in natural product discovery 
would help in rapid identification of active compounds from medicinal plant 
extracts. The bioactive component, after being isolated, will be studied for its in 
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vivo effects and pharmacokinetic profile in rats. The information obtained will be 




Chemical analysis, antiplatelet and anticoagulation 
studies of A. elliptica extract  
3.1 Chemical analysis of A. elliptica extract 
3.1.1 Introduction 
It was previously discussed in Section 1.2.3.3 that A. elliptica is 
traditionally used for the treatment of various ailments such as parturition 
complications and chest pains which may be related to problems in blood 
circulation. Thus it is useful to know the chemical constituents of its extract. This 
chapter presents the work on the chemical analysis of A. elliptica extract and the 
screening for potential antiplatelet and anticoagulant activities. The information 
gained will be useful for the identification of bioactive components in the plant 
extract for the platelet aggregation and plasma coagulation assays to be 
performed.  
The chemical constituents in the stem, leaves and fruits of A. elliptica had 
been previously reviewed and discussed in Section 1.2.3.5. Chemical constituents 
found in A. elliptica include α-amyrin, β-amyrin, bauerenol, bergenin, 
isorhamnetin, quercetin, rapanone, syringic acid, 5-(Z-heptadec-4’-enyl)resorcinol 
and 5-pentadecylresorcinol. It had been reported that a mixture of α-amyrin and β-
amyrin were antiplatelet (Aragao et al., 2007).  In this study, α-amyrin and β-
amyrin were detected and found to be partly responsible for the antiplatelet 
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activity of the plant extract. Thus, it was of interest to develop a method to 
quantify, isolate and study the activities of both amyrins individually. 
Since both α- and β-amyrin are not easily ionised, the detection of the 
amyrins using mass spectrometry has to be optimised. Literature has shown that 
detection of α- and β-amyrin using LC-MS with electrospray ionisation (ESI) and 
atmospheric-pressure chemical ionisation mass spectrometry (APCI) gives a low 
sensitivity (Rhourri-Frih et al., 2009). LC-MS with atmospheric-pressure 
photoionisation (APPI) was more sensitive. Triterpenes are generally deemed to 
be non-volatile, so they are usually derivatised before analysing with GC-MS 
(Laurent et al., 2003; Regert et al., 2006; Coelho et al., 2007; Echard et al., 2007; 
Jacques et al., 2007; Lytovchenko et al., 2009; Rhourri-Frih et al., 2009; Scholz et 
al., 2009). However steps involving derivatisation are laborious when working 
with large number of samples, thus it would be useful to develop a sensitive 
analytical method without the need for derivatisation.  
 
3.1.2 Objectives 
In this study, the overall objectives are to develop chromatographic 
methods to analyse the components of the 70% v/v methanol A. elliptica leaf 
extract using HPLC and GC-MS. The specific objectives are to 
 
1. Optimise a HPLC method for the isolation of amyrins from the plant 
extract. 
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2. Develop, optimise and validate a GC-MS method to quantify the amount 
of amyrins in A. elliptica leaf extract. 
 
3.1.3 Materials and methods 
3.1.3.1 Plant material 
A. elliptica leaves were collected from Pasir Ris Park and identified by Mr 
Haji Samsuri bin Haji Ahmad from the Singapore Botanic Gardens. A voucher 
specimen of the plant (KHL0060/CJH/AE/29062006) is stored at the Department 
of Pharmacy, National University of Singapore.  
 
3.1.3.2 Reagents and standards 
Methanol was purchased from Tedia (Fairfield, OH). α-amyrin and β-
amyrin were obtained from Extrasynthase (Genay, France). Aspirin was obtained 
from Sigma Aldrich (USA). Methyltestosterone was obtained from the United 
States Pharmacopeia (Rockville, MD). 
 
3.1.3.3 Extraction and preparation of plant extracts  
The leaves of A. elliptica were freshly collected, washed and air dried 
before blending and refluxed for six hours with the appropriate solvents. Soxhlet 
extraction with either 70% v/v methanol or water was carried out separately. A 
total of 860 g of freshly collected leaves were extracted with 5.0 l of 70% v/v 
methanol. The extracts were evaporated to dryness using a rotary evaporator.  
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3.1.3.4 Fractionation of A. elliptica 70% v/v methanol extract 
Liquid-liquid fractionation was performed on 22.4 g of the A. elliptica 
70% v/v methanol extract by first suspending the extract in a total of 600 ml of 
water, and subsequently fractionating it sequentially with hexane, chloroform and 
butanol four to six times.  
In addition, 27.0 g of the dried 70% v/v methanol extract was fractionated 
using a preparative HPLC system. The dried extract was dissolved in 100 ml of 
HPLC grade methanol. After centrifuging at 14,000 rpm, the supernatant was 
removed using a pipette and fractionated using a preparative HPLC system 
(Agilent 1100 series, CA, USA) and a preparative Zorbax Eclipse XDB-C18 
column (250 mm x 21.2 mm I.D., particle size: 7 μm; Agilent, CA, USA) using 
methanol as the mobile phase. The injection volume was 2 ml, flow rate 20 ml 
min-1 and run time was 40 min. In total, 13 fractions were collected. All fractions 
were dried using a rotary evaporator. 
3.1.3.5 Analysis of the 70% v/v methanol extract using HPLC 
 An analytical HPLC system (Agilent 1100 series, CA, USA) and a 
Zorbax Eclipse XDB-C18 column (250 mm x 4.6 mm I.D., particle size: 5 μm; 
Agilent, CA, USA) was used. Separation of compounds was achieved using a 
binary gradient elution system consisting of water (A) and acetonitrile (B) at the 
following gradient: 0-30 min, 70-95% B; 30-40 min, 95-100% B; 40-100 min, 
100% B.  The injection volume was 5 µl, flow rate 1.5 ml min-1 and run time was 
100 min. The UV detection was set at 210 nm, while the DAD was scanned from 
190 to 400 nm. 
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3.1.3.6 Analysis of phytoconstituents in the 70% v/v methanol extract using 
GC-MS  
Analyses by GC-MS were carried out with a Shimadzu, gc2010 gas 
chromatograph coupled to a Shimadzu gp2010 mass spectrometer, a Shimadzu 
AOC-20i auto-injector and an AOC-20s auto-sampler. A DB-5 MS column of 
internal diameter 0.25 mm, length 30.0 m and film thickness 0.25 µm was used. 
The oven temperature was set at 60 °C and held for 5 min, increased to 200 °C at 
a rate of 7 °C/ min and held for 10 min. The temperature was finally increased to 
280 °C at a rate of 5 °C/ min and held for 30 min. The ion source and interface 
temperatures were kept at 200 °C and 180 °C respectively. Samples were injected 
under a splitless mode with split ratio -1.0. Each injection volume was 1 µl and an 
injection port dwell time of 0.3 s was set. The pressure of the Helium carrier gas 
was set at 100 kPa with a total flow of 50.0 ml min-1. The column flow was 1.61 
ml min-1 and the linear velocity was 46.3 cm s-1. Data recording was set from 5 to 
81 min for 50 to 900 m/z. 
Phytoconstituents were preliminarily identified by the Wiley Mass 
Spectral Library Registry 7 (NJ, USA). Identities of the α-amyrin and β-amyrin 
detected were confirmed by comparing the retention times and mass spectra of the 
signals with those of the standards. 
 
3.1.3.7 Isolation of β-amyrin using preparative and semi-preparative HPLC 
The 70% v/v methanol A. elliptica leaf extract (13.3 g) was dissolved in a 
total of 50 ml of HPLC grade methanol and fractionated by preparative HPLC as 
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described in Section 3.1.3.4. The fraction containing amyrins was collected and 
further purified by chromatography using a semi-preparative Zorbax SB-C18 
column (250 mm x 9.4 mm I.D., particle size: 5 μm; Agilent, CA, USA) using 
methanol as the mobile phase. The injection volume was 2 ml, flow rate 8 ml min-
1 and run time was 35 min. The UV detection for both preparative and semi-
preparative HPLC was set at 210 nm. Fractions containing β-amyrin was dried in 
vacuo. Melting points of the compound are uncorrected values and determined 
using a melting point apparatus (A Krüss Optronic, Germany). 
 
3.1.3.8 Sample preparation for amyrin quantification 
The 70% v/v methanol A. elliptica leaf extract was reconstituted in 
methanol to a concentration of 100 μg ml-1 for the GC-MS analysis. A 1 mg ml-1 
standard stock solution in methanol was prepared for both amyrins, and diluted to 
concentrations ranging from 0.5 ng ml-1 to 2 μg ml-1 for the GC-MS analysis. An 
internal standard, methyltestosterone, was spiked into all samples at a 
concentration of 1 μg ml-1 before analysis. All samples are centrifuged at 10, 000 
g for 10 min before the supernatants were used for analysis. 
 
3.1.3.9  GC-MS assay for amyrin quantification 
A Shimadzu (Kyoto, Japan) GC-MS system (gc2010 and qp2010 MS) was 
used for quantifying both α- and β-amyrins in A. elliptica 70% v/v methanol 
extract. Chromatographic separation was achieved with a DB5 column of film 
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thickness 0.25 μm, length 30.0 m and diameter 0.25 mm (Agilent Technologies, 
Santa Clara, CA). The initial oven temperature was 180 oC, and increased to 280 
oC at a rate of 50 oC min-1. This temperature was held for another 19 min. The 
helium flow rate was 1.6 ml min-1 and the interface and ion source temperature 
was 250 oC and 200 oC respectively. At the beginning of the assay development, 
the mass spectrometer was operated in the scan mode to obtain the mass spectra 
of α-amyrin, β-amyrin and methyltestosterone. After the identification of the 
major ions, the selected-ion monitoring (SIM) mode was applied, detecting m/z 
203, 218 and 426 for both α- and β-amyrins and m/z 43, 124 and 302 for the 
internal standard methyltestosterone. Quantification was done using the total ion 
chromatogram (TIC) of the quantifier ions, m/z 218 and 302 for the amyrins and 
methyltestosterone respectively.  
 
3.1.3.10 Method validation for GC-MS assay 
To assess linearity, the calibration curves were analysed using the linear 
least-squares regression.  The sensitivity of the GC-MS assay was represented by 
the LOD and LOQ, The LOD and LOQ were obtained by diluting the α- and β-
amyrin samples until the signal to noise ratio reached 3:1 and 10:1 respectively. 
The method was also validated for its specificity, precision and accuracy 
(recovery).  
For precision, repeatability and intermediate precision were determined. 
For repeatability, 8 concentrations of α- and β-amyrin standards were each 
assayed five times within a day. Intermediate precision assessed by determining 
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the RSD of the concentrations on different days. For inter-day variation, triplicate 
analyses of 8 concentrations of α- and β-amyrin standards were performed on three 
different days. 
Recoveries of α- and β-amyrin from the plant matrix were determined by 
spiking α- and β-amyrin standards at 3 different levels (0.5, 1.0, 1.5 μg ml-1) into 
the A. elliptica samples before extraction and subsequently determining the added 
amounts. 600 mg of A. elliptica leaves were extracted using Soxhlet extraction 
with 100 ml of 70% v/v methanol. Extraction was first carried out in triplicates on 
A. elliptica leaves with no added amyrins. The extraction was repeated by spiking 
the leaves with either 0.25 mg, 0.5 mg or 0.75 mg of both α- and β-amyrin 
standards. After extraction, the solvents were evaporated to dryness and the dried 
residues were reconstituted with 5 ml of HPLC grade methanol. Each of the 









3.1.4 Results and discussion 
3.1.4.1 Extraction and fractionation of A. elliptica 70% v/v methanol extract  
69.7 g of dried crude extract (8.1% w/w yield) was obtained from soxhlet 
extraction of 860 g of fresh A. elliptica leaves using 70% v/v methanol while 7.0 
g of dried crude extract  (8.5% w/w yield) was obtained from 82 g of fresh A. 
elliptica leaves when water was used as the extraction solvent. Of the 69.7 g of 
crude 70% v/v methanol extract, 22.4 g was used for liquid-liquid partitioning. 
The hexane, chloroform, butanol and water fractions obtained were 3.0 g, 1.5 g, 
2.6 g and 11.4 g respectively. From the 27.0g of 70% v/v methanol extract used 
for fractionation using preparative HPLC, a fraction weighing 127.8 mg 
containing α- and β-amyrin was obtained.  
  
3.1.4.2 Analysis A. elliptica crude extract using HPLC  
Analysis of the crude 70% v/v methanol extract was also performed using 
HPLC. Figure 3.1 shows the chromatograms of the crude 70% v/v methanol 








Figure 3.1 HPLC chromatograms of (A) 70% v/v methanol extract (0.5 mg 
ml-1), (B) α- amyrin standard (0.1 mg ml-1) and (C) β- amyrin standard (0.1 mg 
ml-1). 
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3.1.4.3 Identification of phytoconstituents in A. elliptica using GC-MS  
A GC-MS method was developed to analyse the A. elliptica extracts and 
fractions. A temperature of 280 oC was required to allow elution of all 
phytoconstituents in the extracts and fractions. As the phytoconstituents were co-
eluting at a steep temperature gradient, a gentle gradient of 5 to 7 oC/ min was 
used for the analysis.  
The gas chromatograms of the 70% v/v methanol extract are shown in 
Figure 3.2. An autolibrary search using the Wiley mass spectral library reveal that 
the compounds found in the 70% v/v methanol extract consisted mainly of fatty 
acids (palmitic acid, stearic acid), esters of fatty acids (methyl palmitate, methyl 
heptadecanoate, methyl linolenate), triterpenes (α- and β- amyrin), α-tocopherol 
and a resorcinol (5-pentadecylresorcinol). 
The gas chromatograms of the crude 70% v/v methanol extract, the hexane 
fraction, and those of α- and β- amyrin are shown in Figure 3.2. The retention 
times of β- amyrin and α- amyrin were 67.8 min and 79.0 min respectively, 
similar to those of the authentic standards. α- and β- amyrin were also 
differentiated by their MS (Figure 3.3). The intensity of the peak with m/z 203 in 
β- amyrin is approximately twice that of the intensity of the peak with m/z 203 in 



















Figure 3.2 Gas chromatograms of (A) 70% methanol extract of A. elliptica, 
(B) hexane fraction, (C) α-amyrin standard and (D) β-amyrin standard. 
 

































































Figure 3.3 Mass spectra of the standards (A) β- amyrin and (B) α- amyrin.   
 
3.1.4.4 Isolation of β- amyrin from A. elliptica  
β- amyrin was isolated first by fractionating the 70% v/v methanol extract 
through a preparative column. The HPLC chromatogram from preparative HPLC 
isolation is shown in Figure 3.4. As observed, α-amyrin is not well resolved from 
a neighbouring peak using this method of isolation, and thus not isolated. β-
amyrin was found to elute at 15.5 min. The fraction containing β-amyrin was 
concentrated and further purified using a semi-preparative column. The 
chromatogram of the β-amyrin fractionated by semi-preparative HPLC is shown 








Identification of the isolated β- amyrin from A. elliptica leaves was done 
by HPLC (Figure 3.6) as well as GC-MS (Figure 3.7). In total, 20.4 mg of β- 
amyrin was isolated from 13.3 g of dried 70% v/v methanol extract in the form of 
white crystals. The purity of the β- amyrin isolated was determined to be 96.1% 
by HPLC and 99.8% by GC-MS. Melting point of the crystals was determined to 
be 189.2 oC to 191.2 oC, comparable with those of the β-amyrin standards (187.0 
oC to 188.2 oC). The melting point of β-amyrin reported by Sowemimo et al. 
(1973) was 197 oC to 199 oC but agreed well with those with material and safety 




Figure 3.4 HPLC chromatogram of 70% v/v methanol leaf extract from 









Figure 3.5 HPLC chromatogram of 70% v/v methanol leaf extract from semi-





Figure 3.6 HPLC chromatograms of (A) isolated and purified β-amyrin and 








Figure 3.7 Gas chromatograms of (A) isolated and purified β-amyrin and (B) 
β-amyrin standard. 
 
3.1.4.5 GC-MS method for analysis of amyrins 
Various methods using HPLC, LC-MS and GC-MS had been developed 
for the detection or quantification of amyrins. The use of HPLC for the 
quantification of α-amyrin had been investigated. It was found that the LOD and 
LOQ were 0.4 μg ml-1 and 12 μg ml-1 respectively (Kumar et al., 2010). Although 
the method was determined to be precise, accurate and selective, the method is 
not sensitive enough at an LOD of 0.4 μg ml-1. Another method that is used for 
the analysis of amyrins involves the use of LC coupled with mass spectrometry. 
However, LC-ESI/MS is not preferred for the detection of neutral triterpenes with 
only one hydroxyl group in the structure as they are not easily ionised by ESI 






























(Rhourri-Frih et al., 2009). It was found that LC-APPI-MS was more sensitive 
than LC-ACPI-MS for the analysis of α- and β-amyrin. APPI is a relatively new 
ionisation method for LC-MS. Samples are evaporated by heating and a 
nebulising gas. The samples are then passed into the photoionisation region. An 
ionisable dopant in the region is vaporised, which then collides with the solvents 
and samples, producing analyte ions [M + H]+ or [M]●+ in the positive ion mode 
and [M - H]+ in the negative ion mode (Robb et al., 2000). The LOQ for α- and β-
amyrin in the SIM mode using LC-APCI-MS was 0.55 μg ml-1 and 0.56 μg ml-1 
respectively (Rhourri-Frih et al., 2009). LC-APPI-MS was 36 to 46 times more 
sensitive than LC-APCI-MS, with the LOQ for α- and β-amyrin in the SIM mode 
being 0.015 μg ml-1 and 0.012 μg ml-1 respectively (Rhourri-Frih et al., 2009). Gas 
chromatography-electron impact mass spectrometry (GC-EI/MS) has been 
popularly used for the analysis of triterpenes but silylation or derivatisation is 
required in the method to make the solutes volatile enough for analysis (Laurent 
et al., 2003; Regert et al., 2006; Coelho et al., 2007; Echard et al., 2007; Jacques 
et al., 2007; Lytovchenko et al., 2009; Rhourri-Frih et al., 2009; Scholz et al., 
2009). However steps involving derivatisation is laborious for large number of 
samples. A GC-MS method without the need for derivatisation of samples was 
reported for the quantification of β-amyrin (Kirby et al., 2008). The reported 
method required the GC oven temperature to be ramped up to 300 oC and the 
quantification was performed in SIM mode, detecting ions of m/z 203, 218 and 
426. 
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Initially, liquid chromatography-mass spectrometry (LC-MS) was 
attempted for assay development. However the sensitivity of the assay was low 
when APCI was used for analysis. The LOQ of β-amyrin was found to be about 
400 ng ml-1. This was agreeable to that reported in literature (Rhourri-Frih et al., 
2009). As the sensitivity of LC-MS was low, GC-MS was subsequently employed 
for the assay development. 
In order to select the ions for quantification, full scans of the mass spectra 
of α-amyrin, β-amyrin and methyltestosterone were first obtained. The mass 
spectra were shown in Figure 3.8. Ions with relatively high intensities were 
selected to monitor amyrins and methyltestosterone under SIM mode. 
Subsequently, ions with m/z 203, 218 and 426 were used for detecting both α- and 
β-amyrin while those with 43, 124 and 302 were used for detecting 
methyltestosterone. The mass spectra of both α- and β-amyrin were in agreement 
with those reported in literature (Gawronska-Grzywacz and Krzaczek, 2007; 
Boszormenyi et al., 2009). Ions with m/z 218 and 302 were chosen for 

















Figure 3.8 Scanning mode mass spectra of (A) α-amyrin, (B) β-amyrin and 
(C) methyltestosterone. 













































3.1.4.6 GC-MS method validation 
The LOD (S/N = 3) and LOQ (S/N = 10) for α-amyrin were found to be 
0.1 ng ml-1 and 1 ng ml-1 respectively. The LOD and LOQ for β-amyrin were 
found to be 0.1 ng ml-1 and 0.4 ng ml-1 respectively. The calibration curves for 
both α –amyrin and β-amyrin show good linearity over the concentration range 
0.5 ng ml-1 to 2 μg ml-1 with a correlation coefficient R2 > 0.995. The intra-day 
retention time variations (RSD) for α –amyrin and β-amyrin were 0.17 ± 0.04% (n 
= 5) and 0.23± 0.09% (n = 5) respectively. The inter-day retention time variations 
(RSD) for α –amyrin and β-amyrin were 0.28 ± 0.03% (n = 3) and 0.26 ± 0.05% 
(n = 3) respectively. The intra-day assay variations (RSD) for α –amyrin and β-
amyrin was 10.4 ± 0.17% (n = 5) and 9.6 ± 0.23% (n = 5) respectively. The inter-
day assay variations (RSD) for α –amyrin and β-amyrin were 12.1 ± 0.28% (n = 
3) and 9.1 ± 0.26% (n = 3) respectively. 
Specificity of the method is demonstrated. Specificity is defined as the 
ability to assess unequivocally the analyte in the presence of components which 
may be expected to be present. In this method, the GC-MS assay is validated for 
its ability to discriminate between compounds of closely related structures (α- and 
β-amyrin), and to ensure no interferences between the compounds studied. The 
GC-MS assay developed is able to discriminate between compounds of closely 
related structures (α- and β-amyrin), indicating good specificity (Figure 3.9). 










Figure 3.9 Gas chromatograms of (A) mixture of α-amyrin (peak 3; 2 ppm) 
and β-amyrin standards (peak 2; 2 ppm) and the internal standard, 
methyltestosterone (peak 1; 1ppm) spiked into HPLC grade methanol (B) A. 
elliptica 70 % methanol extract (100 ppm). Chromatograms are total ion 
chromatograms of selective ion monitoring (SIM) of α- and β-amyrin (m/z 203, 
218, 428) and methyltestosterone (m/z 43, 124, 302). 
 
Accuracy of the method was assessed by spiking known amyrin standards 
into the 70% v/v methanol A. elliptica leaf extract. To investigate the accuracy, 
recovery studies were done by spiking three different amounts of amyrin into the 
extract. The recoveries of the three concentration levels (0.5, 1.0, 1.5 μg ml-1) of 
spiked α-amyrin were 102.3 ± 7.7% (n=3), 100.2 ± 7.8% (n=3) and 106.9 ± 
13.0% (n=3) respectively. The recoveries of the three concentration levels (0.5, 
1.0, 1.5 μg ml-1) of spiked β -amyrin were 100.4 (n=2), 95.1 ± 17.5% (n=3) and 
117.8 ± 2.6% (n=3) respectively.  





















While Kirby et al. (2008) also developed a GC-MS method without 
requiring the β-amyrin samples to be derivatised, the method had not been 
validated. The method developed here is validated for both α- and β-amyrin. The 
time required for analysis is also shorter for this method (retention time of β-
amyrin = 15.2 min) compared to that of Kirby et al. (2008) (retention time of β-
amyrin = 18 min). Another advantage is that the GC oven temperature used in this 
assay (280 oC) is lower than that used by Kirby et al. (2008) (300 oC). The lower 
temperature used could be beneficial for preserving the integrity of GC columns. 
 
3.1.4.7 Quantification of α- and β-amyrins in the A. elliptica leaf extract and 
the fresh leaves 
 To quantify the amount of amyrins in the extract and leaves, three separate 
batches of leaves were individually extracted and analysed in triplicates. 
Calibration curves of α- and β-amyrin were generated. It was found that the 
concentrations of α- and β-amyrin were 0.6 ± 0.01% (w/w) and 1.0 ± 0.01% 
(w/w) of the dried A. elliptica leaf extract respectively. This translated to a 
concentration of 0.05 ± 0.001% (w/w) and 0.08 ± 0.001% (w/w) for α- and β-
amyrins in the fresh leaves. Thus it can be seen that α- and β-amyrin exist 






3.2 Antiplatelet and anticoagulation studies of A. elliptica extract  
3.2.1 Introduction 
Adverse effects of current antiplatelet and anticoagulant drugs have been 
well documented. Currently used antiplatelet and anticoagulant drugs such as 
aspirin and warfarin have adverse effects including gastric mucosal erosions and 
excessive bleeding. Given the limitations of the current treatments, the objective 
of part of the work is to discover lead compounds or novel antiplatelet and 
anticoagulant drugs from A. elliptica.  
In the previous section, A. elliptica extracts were chemically analysed and 
β-amyrin was isolated and quantified. In this section, the A. elliptica extract and 
isolated β-amyrin are studied for potential antiplatelet and anticoagulant activities. 
Currently, information on the traditional uses of the plant is very limited. While 
records are available for the disease symptoms the plant can treat, there is no 
information on the doses of the plant. It is understood that traditional records 
indicated that the leaves were boiled and drunk (Burkill, 1966), presumably with 
water. However in certain cases, whole leaves were eaten. In this study an organic 
solvent 70% v/v methanol was used, in the aim of extracting more compounds, 
compared to using either a non-polar or polar solvent. 
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3.2.2 Objectives 
The overall objectives of this section are to investigate the antiplatelet and 
anticoagulant activities of the A. elliptica extract, as well as its bioactive 
components in vitro. The specific objectives are to 
 
1. Investigate the antiplatelet activities of A. elliptica extracts and their 
bioactive components in vitro in rabbit blood by means of the impedance 
method using a whole blood aggregometer. 
2. Investigate the anticoagulant activities of A. elliptica extracts and their 
bioactive components in vitro in human blood by determining their effects 












3.2.3 Materials and methods 
3.2.3.1 Plant material 
A. elliptica leaves were collected and stored as described in Section 
3.1.3.1.  
 
3.2.3.2 Reagents and standards 
Methanol was purchased from Tedia (Fairfield, OH). Dimethyl sulfoxide 
(DMSO) was obtained from MP Biomedicals (Illkrich, France) while phosphate 
buffer saline (PBS, 8 g l-1 NaCl, 0.2 g l-1 KCl, 1.44 g l-1 Na2HPO4, 0.24 g l-1 
KH2PO4) bought from 1st Base (Singapore). Collagen (1 mg ml-1) was purchased 
from Chronolog (Havertown, PA). α-amyrin and β-amyrin were obtained from 
Extrasynthase (Genay, France). Aspirin was obtained from Sigma Aldrich (USA).  
 
3.2.3.3 Extraction and preparation of plant extracts  
The preparation of the 70% v/v methanol leaf extract of A. elliptica was as 
in Section 3.1.3.3. In addition, 82 g of leaves were extracted with 500 ml of 
distilled water. The extracts were evaporated to dryness using a rotary evaporator.  
 
3.2.3.4 Fractionation of A. elliptica crude extract 
Liquid-liquid fractionation was performed as described in Section 3.1.3.4.  
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3.2.3.5 Measurement of platelet aggregation 
Whole blood aggregation assay was carried out by the measurement of 
impedance using a whole blood aggregometer (Chronolog Corporation, 
Havertown, PA) as described by (Cardinal and Flower, 1980). Rabbit blood (Male 
New Zealand Whites, 2.5 ± 0.5 kg, anaesthetised with ketamine/xylazine mixture 
at 0.2 ml kg-1 body weight of each) from the central ear artery of the rabbits was 
collected into a citrated tube (Tapval, 4 ml blood collection tubes, 0.106 M citrate, 
Deltalab S.A., Barcelona, Spain). The animals were kept in accordance with the 
internationally accepted principles for laboratory animal use and care as found in 
the US guidelines (NIH publication #85-23, revised in 1985). 450 l of the blood 
prewarmed to 37 oC was then diluted with pre-warmed PBS (1:1) and allowed to 
equilibrate for two minutes. For the assay on plant extracts, 4.6 l of plant 
extracts in DMSO was added and the solution was allowed to equilibrate for two 
minutes. As for assays using the standards, 4.6 l of either α- or β-amyrin or a 
mixture of both in DMSO was used. 2 l of collagen was then added to initiate 
platelet aggregation. The test was allowed to run for 5 min. The final 
concentration of DMSO in the test solutions were kept constant at 0.5% v/v. All 
tests were carried out at least three times. Aspirin was used as a positive control to 
determine the extent of anti-platelet activity of the plant extracts and fractions. 
Inhibition of platelet aggregation (Z) is calculated as follows:  
 




where X is the impedance value for the control and Y is the impedance value of 
the sample. IC50 values were calculated using Graph Pad Prism version 3.03 
(GraphPad Software, Inc., CA, USA). 
 
3.2.3.6 Plasma coagulation assays 
The procedure for the plasma coagulation assays was modified from Lau 
(2006). Prothrombin time (PT) and activated partial thromboplastin time (aPTT) 
times were determined with a Sysmex CA-530 blood coagulation analyser 
(Sysmex Corporation, Kobe, Japan). The commercial lyophilised pooled human 
plasma (Ci-Trol level 1; Dade Behring, DE, USA) was reconstituted with 1 ml of 
distilled water and left to stand for at least 15 min. It was used within 8 h after 
reconstitution. To prepare the sample mixture, 2 l of plant extracts or standards 
dissolved in DMSO was added to 133 l of plasma for the measurement of the PT 
and aPTT. For the control, 2 l of DMSO was used instead. 
For measurement of PT, 50 l of the sample mixture was incubated for 
180 s. 100 L of PT reagent (Thromborel S; Dade Behring, DE, USA) was then 
added to the sample mixture. Time course of the test protocol was 120 s. If the 
blood coagulation was greatly inhibited, resulting in a PT time that was more than 
120 s, no coagulation would be detected. 
For measurement of aPTT, 50 l of sample mixture was incubated for 60 
s. 50 l of aPTT reagent (Actin FSL; Dade Behring, DE, USA) was then added to 
the sample mixture and further incubated for 180 s. Finally, 50 l of aqueous 
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CaCl2 was added. Time course of the test protocol was 190 s. If the blood 
coagulation was greatly inhibited, resulting in an aPTT that was more than 190 s, 
no coagulation would be detected. 
 
3.2.3.7 Statistical analysis 
All results are expressed as mean ± standard deviation. Statistical analyses 
of the groups and IC50 calculation were performed using ANOVA and the 
nonlinear regression function respectively on Graph Pad Prism version 3.03. 













3.2.4 Results and discussion 
3.2.4.1 Antiplatelet effects of A. elliptica extracts and fractions 
The antiplatelet activities of the A. elliptica water extract and 70% v/v 
methanol extract, as well as the fractions obtained by liquid-liquid partition are 
presented in Figure 3.10. At a concentration of 0.2 mg ml-1, all extracts and 
fractions showed between 18% to 35% inhibition of platelet aggregation induced 
by collagen, which were not significantly different from each other (p  > 0.05). 
Chemical analyses showed that the hexane fraction contained high concentrations 
of α- and β-amyrin. This implied that the amyrins could have contributed to the 
antiplatelet activity observed in the hexane fraction and 70% v/v methanol extract. 
On the other hand, the water fraction (obtained from liquid-liquid partitioning of 
the 70% v/v methanol extract) showed pro-aggregation activities. Further analysis 
of the components in the water fraction is required to understand why a pro-
aggregating effect was observed.  
Furthermore, the IC50 values for the inhibition of platelet aggregation by 
the 70% methanol extract of A. elliptica, the water extract of A. elliptica, and 
aspirin (positive control) were determined and presented in Table 3.1. While the 
70% v/v methanol extract showed a dose dependent increase in antiplatelet 
activity, the antiplatelet activity of the water extract decreased for concentrations 
above 40 µg ml-1. The 70% v/v methanol extract was about 10 times less active 













































Figure 3.10 Platelet aggregation inhibition by different A. elliptica extracts and 
fractions derived from the 70% v/v methanol extract at 0.2 mg ml-1. (n ≥ 3) 
 
  
Table 3.1 IC50 values of A. elliptica extracts for inhibition of collagen-
induced platelet aggregation. 
Sample IC50 values (μg ml-1) 
70% v/v methanol extract of A. elliptica 166.9 ± 46.7 
Water extract of  A. elliptica  18.4 ± 1.1 
Aspirin 16.5 ± 4.4 
 
n = 3. Values are reported as mean ± standard deviation. 
 
For concentrations of above 40 µg ml-1, the antiplatelet activity of the 
water extract decreased with increasing concentrations. This implied either the 
presence of both antiplatelet and proaggregating components in the water extract, 
or presence of a component with dual activities. Similar observations had been 
reported previously for a flavonoid, arcapillin, where antiplatelet activity was seen 
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at low concentrations but proaggregation activity was observed at high 
concentrations (Wu et al., 2001). According to published literature (Wee, 1992; 
HMRC and IMR, 2002; Jalil et al., 2004), the leaves are boiled and drunk by 
Malays for treatment of pain in the region of the heart. However, the dosage was 
not indicated and the exact liquid to prepare the decoction was not clearly 
specified. In general, the usual liquid used for decocting medicinal herbs is water. 
Jalil et al. (2004) previously reported a platelet activating factor inhibitor, 
5-(Z-heptadec-4’-enyl)resorcinol from the leaf extract of A. elliptica with an IC50 
value of 7.08 μM for the inhibition of PAF receptor binding on rabbit platelet 
using 3H-PAF as a ligand. Besides 5-(Z-heptadec-4´-enyl)resorcinol, other 
phytoconstituents identified in A. elliptica include 5-pentadecylresorcinol (Jalil et 
al., 2004), rapanone, β- amyrin (Chow et al., 1991), syringic acid, isorhamnetin 
and quercetin (Phadungkit and Luanratana, 2006). Bauerenol, α-amyrin and 
bergenin had also been reported in A. elliptica (Ahmad et al., 1977; Chow et al., 
1991; Kobayashi and de Mejia, 2005). Syringic acid was reported to have very 
weak antiplatelet activities on washed rabbit platelets induced by arachidonic acid 
and collagen (Yang et al., 2002). Numerous studies had been done on the 
antiplatelet activities of quercetin. Quercetin was found to inhibit PAF receptor 
binding on rabbit platelets with an IC50 value of 33.0 μM (Mazura et al., 2007). In 
addition, it was reported to inhibit platelet activation by ADP (Tzeng et al., 1991; 
Kobzar et al., 2005), collagen and arachidonic acid (Tzeng et al., 1991). Calcium 
mobilization in human platelets was inhibited by quercetin as well (Xiao et al., 
1995; Guerrero et al., 2007). In addition to collagen, ADP was also used to induce 
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platelet aggregation in the investigations here. However the results were 
inconclusive as very weak aggregation was observed with the control.  
To investigate if the amyrins detected were giving rise to the antiplatelet 
activity, the 70% v/v methanol was further fractionated by preparative HPLC into 
13 fractions as described in Section 3.1.3.4. Of the 13 fractions collected, the 
fraction containing both α- and β-amyrin showed the highest antiplatelet activity 
among the different fractions. A 35.6% platelet aggregation inhibition was 
observed when that highly active fraction was tested at a low concentration of 10 
μg ml-1. On the other hand, only 27.4% platelet aggregation inhibition was 
observed when 0.2 mg ml-1 of the 70% v/v methanol extract was tested (Figure 
3.10). This implied that the amyrins were responsible for the antiplatelet activity 
observed. 
 
3.2.4.2 Antiplatelet effects of α- and β- amyrin 
Following the identification of the two active components detected, α- and 
β- amyrin, their IC50 values were determined and compared to aspirin (positive 
control) in Table 3.2. 
Table 3.2 IC50 values of A. elliptica extract and bioactive components for 
inhibition of collagen-induced platelet aggregation. 
 
Sample IC50 values (μg ml-1) IC50 values (μM) 
70 % methanol extract of A. elliptica 166.9 ± 46.7 - 
α-amyrin    9.1 ± 1.0   21.3 ± 2.3  
β-amyrin 4.5 ± 0.6    10.5  ± 1.0   
Aspirin 11.3 ± 2.0 62.7 ± 11.1 
n = 3. Values are reported as mean ± standard deviation. 
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The pure components α-amyrin and β-amyrin gave IC50 values of 9.1 μg ml-1 
(21.3 μM) and 4.5 μg ml-1 (10.5 μM) respectively (Ching et al., 2010). They are at 
least 6 folds more active compared to aspirin (IC50 value 62.7 μM) and 3 times 
more active than the water extract of A. elliptica. In order to study any potential 
synergistic effect of the amyrins on inhibition of platelet aggregation, a mixture of 
amyrins (5 μg ml-1) in different ratios of the 2 amyrins were also used. The results 
showed no significant differences (p > 0.05) in platelet aggregation inhibition 
between the mixtures of amyrins (Table 3.3). 
 
Table 3.3 Percentage inhibition of platelet aggregation of amyrin standards  
Standards at 5 μg ml-1   
Percentage inhibition of platelet 
aggregation (%) 
α-amyrin 20.6 ± 6.21 
β-amyrin 49.0 ± 15.4 
7 parts of α-amyrin : 3 parts of β-amyrin 32.3 ± 10.0 
1 part of α-amyrin : 1 part of β-amyrin 29.8 ± 6.5 
3 parts of α-amyrin : 7 parts of β-amyrin 35.4 ± 14.5 
Values are reported as mean ± standard deviation. Activities of amyrin mixtures 
are not significantly different from each other (p > 0.05). n = 4-9. 
 
Both α- amyrin and β- amyrin have been reported to have diverse 
interesting biological activities, including anxiolytic, antidepressant (Aragao et 
al., 2006), antinociceptive (Otuki et al., 2005), liver-protective (Oliveira et al., 
2005) and gastroprotective (Oliveira et al., 2004) effects. Both the amyrins were 
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also separately found to exhibit anti-inflammatory activity (Akihisa et al., 1996). 
As both α- and β- amyrin are poorly soluble in water, this implied the possible 
presence of other bioactive components in the crude water extract with anti-
platelet activity.  
A mixture of α- and β- amyrin isolated from Protium heptaphyllum in a 
ratio of 2:1 respectively was shown to inhibit collagen induced platelet 
aggregation with an IC50 value of 90.0 μM (Aragao et al., 2007). The mixture was 
also found to inhibit platelet aggregation induced by ADP and arachidonic acid 
with IC50 values of 117.9 μM and 181.4 μM respectively. The current IC50 values 
for inhibition of collagen induced platelet aggregation at 5.3 μg ml-1 (12.4 μM) for 
α- amyrin and 3.6 μg ml-1 (8.4 μM) for β- amyrin are at least 7 fold smaller. α-
amyrin was also reported to inhibit PAF receptor with an IC50 value of 20.0 μM 
(Mazura et al., 2007). This is equivalent to an IC50 of 8.5 μg ml-1 using the 
molecular mass of α-amyrin of 426.72 g mol-1.  
 
3.2.4.3 Anticoagulant effects of A. elliptica extracts and fractions 
The effects of the A. elliptica extracts and fractions on the PT and aPTT of 
plasma coagulation are shown in Figure 3.11. The hexane fraction showed a slight 
but significant prolongation of the PT (p < 0.05), while the 70% v/v methanol 
extract (p < 0.01), the butanol fraction (p < 0.05), water extract and water fraction 
(p < 0.001) showed significant shortening of the PT. Both the crude water extract 
and the chloroform fraction showed no effects on the PT. Strong anticoagulant 
activities on aPTT were exhibited by both the crude extracts and the hexane and 
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chloroform fractions (p < 0.001). The butanol fraction and water fraction showed 
weaker effects in prolonging the aPTT (p < 0.01). 
At a concentration of 0.2 mg ml-1, the water extract showed only 
prolongation of the aPTT. However, the 70% v/v methanol extract exhibited both 
anticoagulant and procoagulant effects.  It was generally observed that the 
fractions extracted from more non-polar solvents (hexane and chloroform) 
exhibited anticoagulant effects on the aPTT. Plasma coagulation activities on the 
PT were shown on more polar fractions, the butanol and water fractions. This 
could imply that components with anticoagulant found in A. elliptica were of a 
more non-polar nature while those that caused increased coagulation were more 
polar. 
The phenomenon of plant extracts having both opposing activities on 
plasma coagulation had also been previously reported. Plasma coagulant activity 
was detected at high concentrations of the Jatropha curcas latex while 
anticoagulant activity was detected at low concentrations of the latex (Osoniyi 
and Onajobi, 2003). Two possible explanations were proposed to explain the 
phenomenon. The first was that the two different activities were induced by two 
separate components which may have acted optimally at different concentrations. 
The second possible explanation was that the same component had differing 
activities under different conditions (Osoniyi and Onajobi, 2003). For example, 
thrombin exhibits procoagulant activities when it cleaves fibrinogen to induce a 
fibrin clot. However it can also act as an anticoagulant when it activates protein C 
in the presence of the cofactor, thrombomodulin (Cantwell and Di Cera, 2000). In 
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this study, the anticoagulant effects on the aPTT (prolonging aPT) were seen in 
non-polar fractions while plasma coagulation activities on the PT (shortening PT) 
were obtained with the more polar fractions. The opposing activities on different 
pathways of plasma coagulation might imply the presence of different compounds 
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Figure 3.11 Plasma coagulation effects by different A. elliptica extracts and fractions at 0.2 mg ml-1; bergenin, quercetin, syringic 
acid at 0.1 mg ml-1; α- and β- amyrin at 0.01 mg ml-1.  (n ≥ 3. * p <0.05; ** p < 0.01; *** p < 0.001) 
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3.2.4.4 Anticoagulant effects of phytoconstituents found in A. elliptica  
In addition to α- and β- amyrin, phytoconstituents reported in A. elliptica 
in the literature include bergenin, quercetin and syringic acid (Chow et al., 1991; 
Phadungkit and Luanratana, 2006). Bergenin, quercetin and syringic acid 
standards were tested for effects on plasma coagulation at a concentration of 0.1 
mg ml-1 while the two amyrins were tested at 0.01 mg ml-1 due to their lower 
solubilities. All the compounds tested were found to have no significant effects on 
plasma coagulation (p > 0.05) (Figure 3.11). Although α- and β- amyrin were 
reported to exhibit antithrombin activity in vitro (Medeiros et al., 2002), no 
anticoagulant activity was exhibited by the compounds at 0.01 mg ml-1 in this 
study. The discrepancies may be due to the difference in concentration and the 
bioassay method used. The study by Mederios et al. showed that α- and β- amyrin 
at a concentration of 0.5 mg ml-1, were found to exhibit 39% and 78% 
antithrombin activity respectively. However this high concentration was not 
achieved in this study due to solubility problems. Moreover, Mederios et al. 
investigated only the antithrombin activity using a different experimental setup 
from that used in this study. Mederios et al. used a chromogenic reagent for 
detection of the antithrombin activity, while a light scattering method was used to 
determine the PT and aPTT in human plasma in this study. 
 
3.3 Conclusion 
In the first section of this chapter, HPLC and GC-MS methods have been 
successfully developed for the analysis of the 70% v/v methanol extract of A. 
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elliptica leaves. It was shown that α- and β-amyrin are major components in the 
plant extract. Short preparative and semi-preparative HPLC methods had also 
been developed to isolate β-amyrin from the leaf extract. α- amyrin co-eluted with 
other components and attempts to isolate it was not successful. A GC-MS method 
had been successfully developed for the analysis of α- and β-amyrins in the A. 
elliptica leaf extract. The method had been validated for its sensitivity, specificity, 
precision and accuracy. Unlike previous methods which require derivatisation 
(Laurent et al., 2003; Coelho et al., 2007; Echard et al., 2007), this method has 
been streamlined to exclude the derivatisation steps so that laborious steps are 
removed for future assays requiring large samples. This is also the first report of 
the quantification of both α- and β-amyrin in the leaves of A. elliptica. 
 In the second section of this chapter, the antiplatelet and anticoagulant 
activities of A. elliptica and its isolated component had been investigated in vitro. 
The 70% v/v methanol extract of A. elliptica was shown to have both antiplatelet 
and anticoagulant activities. β-amyrin was found to be one of the components 
responsible for the antiplatelet activity. This compound was isolated and purified. 
β-amyrin was found to be six times as active as aspirin in inhibiting platelet 
aggregation. A naturally occurring isomer of β-amyrin in the plant extract, α-
amyrin was also tested and found to have strong antiplatelet activities. While the 
70% v/v methanol extract of A. elliptica was shown to have anticoagulant 
activities, α- and β-amyrin were not found to be active. This showed that the 
anticoagulant properties of A. elliptica were attributed by other components and 




Multivariate data analysis method for discovery of 
bioactive components from A. elliptica 
  
4.1 Introduction 
The conventional method of identifying bioactive compounds from plant 
extracts usually involves bioassay-guided fractionation. The process of bioassay-
guided fractionation is tedious, involving repeated steps of fractionation and 
bioassays. Although the process may eventually yield bioactive components, 
much time is required. An added drawback is its difficulty to detect compounds 
which are in low concentrations. Chemoinformatics and Multivariate data analysis 
(MVDA) are used extensively in metabolomics which has applications in 
studying pathways of cardiovascular disease (Wheelock et al., 2009), discovery of 
biomarkers of various diseases such as diabetes mellitus (Li et al., 2009) and 
cancer (Kim et al., 2009), investigation of genotype-phenotype relationships, and 
optimising cell culture, metabolic engineering cell cultures (Oldiges et al., 2007), 
quality control of herbal medicines (Xie et al., 2008) etc. Metabolomics has also 
been developed for natural product research (Rochfort, 2005; Cheng et al., 2006; 
Wang et al., 2006; Wang et al., 2008; Chau et al., 2009; Froufe et al., 2009; Kim 
et al., 2010). It has been discussed in Section 1.3 about the different examples 
metabolomics can help in natural product drug discovery. In one example, the 
pharmacological action of a herb can be elucidated by comparing the metabolites 
of treated cells with a known drug. Metabolomics also enabled studies of 
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synergistic effects of complex herbal concoctions, and can help to predict active 
compounds from plant extracts. An additional advantage of metabolomics is the 
application of simple, sensitive and well established techniques for analysing 
samples. Rochfort (2005) had reviewed on the application of different analytical 
techniques such as Nuclear Magnetic Resonance (NMR) spectroscopy, mass 
spectrometry, gas and liquid chromatography, as well as a combination of the 
techniques in studying plant metabolites using metabolomics.  
As discussed in Section 1.3.3, there had been reports of successful 
application of different algorithms for the prediction of active components from 
natural products with different activities, such as cholesterol level reduction, 
cytotoxicity and antioxidant effects. This is the first report of using an MVDA 
method to investigate the antiplatelet and/or anticoagulant components of a plant 
extract. A. elliptica is used as the model plant in this case. In this chapter, the in 
vitro effects of plant extracts on platelet aggregation were correlated to the 
chemical constituents as determined by gas chromatography-mass spectrometry 
(GC-MS). The modeling used in this work is performed using easily available 
commercial software which can be applied simply to different extracts or 
bioactivities.  
In Chapter 3, an evaluation had been performed on the platelet aggregating 
and plasma coagulating activities of A. elliptica in vitro in rabbit blood and human 
plasma respectively. The results of the activity studies were correlated to the 
individual compounds in the extracts and fractions, and analysed using MVDA 
for prediction of potential active compounds in this chapter. The MVDA method 
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was further refined by increasing the number of different extracts studied, and 
also performing the platelet aggregating assay in human blood. In addition, a 
more comprehensive MVDA method was designed using more statistical tests for 
the prediction of active compounds. 
 
4.2 Objectives 
The overall objective of this work is to develop a platform method to rapidly 
identify bioactive compounds from crude plant extracts and their partially purified 
fractions using MVDA. The specific objectives are to 
 
1. Use existing data of biological activities (from Chapter 3) to explore the 
design of a platform MVDA method for rapid identification of compounds 
in plant extracts that are active, with minimal fractionation steps. 
2. Further development of the MVDA method using biological activities 
obtained from testing human blood. The MVDA method used will include 
additional modelling by Orthogonal Partial Least Squares (OPLS), Partial 
Least Squares projection of latent structures-Discriminant Analysis (PLS-
DA), Chi-Squared weighting, InfoGain weighting and also correlating the 
constituents of the plant extracts with bioactivity. 
3. Identify the antiplatelet and/or anticoagulation compounds present in the 
A. elliptica extract with the MVDA method developed. 
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4.3 Methods and Materials 
4.3.1 Plant material and chemicals  
A. elliptica leaves (716 g) were collected from Pasir Ris Park, Singapore, 
with permission from the National Parks Singapore. 
All extraction solvents used were of analytical grade. Methanol and 1-
butanol used were from Merck (Singapore). Ethanol and hexane were obtained 
from Fisher Scientific (UK). N-Methyl-N-(trimethylsilyl)trifluoroacetamide 
(MSTFA) reagent with 1% trimethylchlorosilane and methoxyamine 
hydrochloride (MOX reagent) were purchased from Thermo Scientific (USA). 
 
4.3.2 Extraction and preparation of plant extracts  
Extraction and preparation of plant extracts for the preliminary studies 
were described in Section 3.1.3.3. 
For further development of the MVDA method, freshly collected A. 
elliptica leaves were again washed with distilled water, air dried and blended. 
Soxhlet extractions of the leaves were performed by refluxing with the 
appropriate solvents for six hours to obtain three batches each of 70% v/v 
methanol extract, ethanol extract and water extract. In total, 179.7 g of leaves 
were extracted with 2100 ml of 70% v/v methanol, 101.9 g of leaves were 
extracted with 450 ml of 100% ethanol and 107.4 g of leaves were extracted with 
750 ml of distilled water. The quantity of leaves extracted for each batch is the 
same for the same extraction solvent used. For the purpose of compound isolation, 
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327 g of leaves were extracted with 70% v/v methanol. The extracts were dried 
using a rotary evaporator. The three batches of fresh leaves were collected from 
the same day. The extracts were evaporated to dryness in vacuo and reconstituted 
in dimethyl sulfoxide (DMSO) at a concentration of 40 mg ml-1 for testing in the 
platelet aggregation assay.  
 
4.3.3 Fractionation of A. elliptica extract 
For preliminary studies, fractionation of the A. elliptica 70% v/v methanol 
extract was described in Section 3.1.3.4. For further development of the MVDA 
method, liquid-liquid fractionation was carried out on three separate dried 70% 
v/v methanol extracts of A. elliptica leaves. The extracts were reconstituted in 150 
ml of distilled water and fractionated with 100 ml of hexane, butanol and distilled 
water sequentially to obtain three batches each of hexane fraction, butanol 
fraction and water fraction. All fractions were dried in vacuo and subsequently 
reconstituted in DMSO at a concentration of 40 mg ml-1. 
 
4.3.4 Derivatisation and development of GC-MS analysis of samples 
For the preliminary studies, 0.11 mg each of the A. elliptica 70% v/v 
methanol extracts, its hexane, chloroform, butanol and water fractions, were 
aliquoted into glass centrifuge tubes. The aliquoted extracts were dried using a 
nitrogen evaporator at 50 oC and derivatised. Derivatisation of the extracts was 
performed as described by Lisec et al., 2006. After drying, the extracts were 
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incubated with 40 μl of MOX reagent and shaken for 2 hours at 37 oC. 
Subsequently, 70 μl of MSTFA reagent was added to the mixture and shaken for 
30 min. The final solution was centrifuged at 2000 g for 20 min to obtain a clear 
solution and the supernatant was analyzed by GC-MS (Shimadzu, gc2010 and 
qp2010 MS, Japan). A DB-5MS column of film thickness 0.25 μm, length 30.0 m 
and diameter 0.25 mm was used. The oven temperature of the GC was held at 60 
oC for 5 min and increased to 200 oC in 7 min. The temperature was held for 10 
min and increased to 280 oC within 5 min. This temperature was held for another 
30 min. 
For further studies, fresh leaves were extracted in triplicate again. All 3 
batches of A. elliptica 70% v/v methanol extracts, its hexane, butanol and water 
fractions, the ethanol and water extracts, 0.11 mg each, were aliquoted into glass 
centrifuge tubes. The aliquotted extracts were dried using a nitrogen evaporator at 
50 oC and derivatised as above. 
The phytoconstituents were preliminarily identified using the Wiley Mass 
Spectral Library Registry 7 (NJ, USA). Analysis of all extracts or fractions was 
repeated twice, to obtain six gas chromatograms for each extract, fraction and 
blank (MOX and MSTFA only).  
 
4.3.5 GC-MS validation for MVDA 
The GC-MS method was validated for repeatability and intermediate 
precision. The intra-day and inter-day variations were assessed. To assess intra-
day variation, the first 70% v/v methanol extract was analysed three times within 
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a day, and the three different 70% v/v methanol extracts were analysed once each 
within a day. To assess inter-day variation, the first 70% v/v methanol extract was 
analysed once a day over three days. The relative standard deviations (RSDs) 
were calculated for the retention time and peak areas of 5 common compounds 
present in the samples. The compounds were chosen based on various retention 
times over the whole chromatogram. 
 
4.3.6 Measurement of platelet aggregation 
For preliminary studies, the platelet aggregation study of A. elliptica 
extracts on rabbit’s blood from Chapter 3 (Section 3.2.4.1) was employed for 
analysis using MVDA.  
For further development of the MVDA method, tests were performed on 
human blood using a fresh batch of extracts. Blood from three (one male and two 
female) normal healthy volunteers was drawn by a clinician according to an 
Institutional Review Board (IRB)-approved protocol by a clinician. Blood from 
the cubital vein was collected into citrated tubes (Tapval, 4 mL blood collection 
tubes, 0.106 M citrate, Deltalab S.A., Barcelona, Spain), and warmed to 37 ºC 
before usage. The whole blood aggregation assay was carried out with similar 
steps as described in Section 3.2.3.5. 
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4.3.7 Plasma coagulation assay 
 For preliminary studies, results of the plasma coagulation study of A. 
elliptica extracts reported in the previous chapter (Section 3.2.4.3) were employed 
for MVDA in this Chapter. For further studies, details of the plasma coagulation 
assays are as described in Section 3.2.3.6. 
 
4.3.8 Preliminary data processing  
As introduced earlier, a preliminary study of the data processing methods 
was first performed before the method was further developed. 
For the analysis of the chromatograms obtained, the Automated Mass 
Spectral Deconvolution and Identification System (AMDIS) version 2.65 
(National Institute of Standards and Technology, Gaithersburg, MD, USA) was 
used to convert the files into a format readable by GeneSpring MS version 1.2 
(Agilent, CA, USA). The data was normalised and the experiment parameter (the 
effect of the extracts on platelet aggregation or plasma coagulation) was 
associated with the different extract and fractions. The activities of the extract and 
fractions were determined by the platelet aggregation assay and plasma 
coagulation assay in Chapter 3. For the multivariate data analysis of the data, 
principle component analysis (PCA) was performed to check if the different 
extracts and fractions were distinguishable from each other, and also to observe 
the clustering trend of active and inactive extracts. To evaluate which are the 
compounds associated with the particular activity studied, GeneSpring MS was 
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used to filter compounds from the extracts with the desired activity with 
intensities at least 100 folds bigger than those without the activity.   
 
4.3.9 Data processing  
After the preliminary study, the GC-MS and bioassay data were analysed 
by different MVDA methods to identify potential antiplatelet compounds.  
 
4.3.9.1 Analysis using Mass Profiler Professional  
The chromatograms and data from all the extracts and fractions were first 
deconvoluted using AMDIS as described previously, then analysed using Mass 
Profiler Professional (Agilent, CA, USA). PCA and PLS-DA was used in the 
programme to observe the clustering of the different extracts and fractions. 
4.3.9.2 Analysis using OPLS, PLS-DA, Chi-squared weighting and InfoGain 
weighting 
SIMCA-P+ Version 12.0.1 (Umetrics, Sweden) was used to perform 
Orthogonal Partial Least Squares (OPLS) and Partial Least Squares projection of 
latent structures—Discriminant Analysis (PLS-DA) tests (Ma et al., 2008). The 
minimum number of non median values was set at 4, i.e. a particular compound 
must appear in a minimum of 4 out of 6 extract/fractions before it is considered in 
the analysis. This is to ensure that any potential contaminants that are present in 
only some of the extracts are excluded from the analysis. The spectrum was 
scaled using Pareto Variance (Ma et al., 2008). RapidMiner Version 4.5 (Rapid-I, 
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Germany) (Ibáñez et al., 2010) was used to perform Chi-Squared weighting and 
InfoGain weighting. For each test, contribution scores for biological activity were 
assigned to each compound. The top ten compounds with the highest contribution 
scores were listed as potential bioactive compounds. Based on the lists generated 
by the four tests, a consensus list that consisted of compounds identified as the top 
ten hits in at least three out of the four tests was created. This method is termed 
the consensus method in this study. 
 
4.3.9.3 Analysis by correlating compounds with bioactivity 
The second MVDA method was based on the assumption that the higher 
the concentration of the bioactive compound, the more biologically active is the 
extract or fraction. To identify bioactive compounds, a correlation was performed 
using Microsoft Excel on the concentrations and biological activities in the 
various extracts and fractions for each compound. The top ten compounds with 
the highest correlation coefficients were identified as potential bioactive 
compounds. This method is termed the correlation method in this study. 
For both methods stated above, noise or column bleeds, simple sugars, 
compounds that are not present in at least four out of the six samples, and 
compounds in inactive extracts and fractions were removed. The compounds were 
removed by deleting the data for these compounds and other information 
(concentration of the compound) from the combined compound list manually. 
This list was then used for analysis by the different methods 
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4.4 Results and discussion 
4.4.1 Preliminary development of the MVDA method 
The GC-MS data of the derivatised crude extract and fractions obtained 
(Figure 4.1) were directly analysed by GeneSpring MS. No prior identification of 
the metabolites was done.  
The results were as expected from a non-polar GC column. Non-polar 
compounds were eluted at longer retention times as can be seen from the non-
polar fractions (Figure 4.1A to C), while more polar compounds were eluted 
earlier (Figure 4.1D and E). It can be observed that similar compounds of the 70% 
v/v methanol extract from nonderivatised samples (Figure 3.2A) were eluted 
earlier in the derivatised samples (Figure 4.1A). This is due to the effect of the 
derivatisation, which increases the volatility of the compounds, causing them to 
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Figure 4.1 Typical gas chromatograms of derivatised (A) 70% v/v methanol 
extract, (B) hexane fraction, (C) chloroform fraction, (D) butanol fraction, (E) 
water fraction of A. elliptica 70% v/v methanol extract. 
 
 
4.4.1.1 PCA analysis of all extracts and fractions 
In this work, the chromatograms were first classified according to their 
identity, namely the 70% v/v methanol extract and the four different fractions, 
hexane, chloroform, butanol and water fraction. Figure 4.2 shows a PCA plot of 
the chromatograms of the different extracts. The clustering of the extract or 
fractions was based on the similarity of compounds present in the individual 
extract or fractions. Extract or fractions with closely similar compounds will 
cluster closer to each other. It can be seen that there was good separation of the 
different fractions, except the hexane (dark blue spots) and chloroform (yellow 
spots) fractions. This implied presence of similar compounds in the hexane and 
chloroform fractions. The water fraction (orange spots) and the 70% v/v methanol 
extract (purple spots) are clustered in separate groups, yet closely together. This 
shows that the majority of the compounds detected in the 70% v/v methanol 
extract by GC-MS consisted of polar compounds, as can also be seen from Figure 
4.1a and 4.1e.  















A PCA plot of the extract and fractions labelled by their different platelet 
aggregating activity is shown in Figure 4.3. The extract and fractions with 
antiplatelet activity was clearly separated from that with pro-aggregating activity. 
All extracts and fractions except the water fraction showed antiplatelet activity. 
However as the water fraction is closely clustered with the 70% v/v methanol 
extract which is antiplatelet, this implies the presence of strongly active non-polar 
compounds in the 70% v/v methanol extract which confer it its activity. Other 
non-polar fractions, i.e. the hexane, chloroform and butanol fractions showed 
antiplatelet activity (Figure 3.10).  
 
 
Figure 4.2 PCA analysis of chromatograms of the crude extracts and its four 
fractions. The PCA plot shows good separation of the 70% v/v methanol extract 
(●), the hexane fraction (●), chloroform fraction (●), butanol fraction (●), water 
fraction (●) and control (●) respectively. (n=6) 
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Figure 4.3 PCA analysis of chromatograms based on the extracts’ platelet 
aggregating activity. Yellow spots (●) represent antiplatelet activity and red spots 
(●) represent and pro-aggregating activity. Light blue spots (●) represent controls.  
 
A PCA plot of the extracts labelled by their plasma coagulation activity in 
affecting PT is shown in Figure 4.4. Procoagulation was seen for the crude 
extract, butanol and water fractions. The chloroform fraction showed no activity 
while the hexane fraction showed anticoagulant activity. This implied the 




Figure 4.4 PCA analysis of chromatograms based on the extract’s activity in 
affecting PT. Yellow (●) and red (●) spots represent anticoagulation and 
procoagulation respectively. Light blue spots (●) represent controls and extracts 
with no effect on PT. 
 
A PCA plot of the extract and fractions labelled by their anticoagulant 
activity in prolonging aPTT is shown in Figure 4.5. Strong anticoagulant activity 
was seen in the 70% v/v methanol extract, hexane fraction and chloroform 
fraction, while weak activity was observed in the butanol and water fractions. As 
before, the extract and fractions showing strong activity was clustered distinctly 
from those exhibiting weak activity. As the water fraction is closely clustered 
with the 70% v/v methanol extract, some compounds in the 70% v/v methanol 
extract existing in low concentrations could have contributed to the stronger 
activity. However because the 70% v/v methanol extract contained a wider variety 
of constituents, there may be synergistic effects by the different constituents, 
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Figure 4.5 PCA analysis of chromatograms based on the extracts’ 
anticoagulant activity in prolonging aPTT. Yellow (●) and red (●) spots represent 
strong (p <0.01 and p < 0.001) and weak (p < 0.05) activity respectively. Light 
blue spots (●) represent controls.  
 
4.4.1.2 Prediction of compounds with effects on platelet aggregation 
In total, 8636 masses (or referred to as a particular compound in the 
extract) were identified by GeneSpring MS. The activities studied and tagged with 
the chromatograms are “antiplatelet”, “proaggregating”, “anticoagulant” (against 
PT or aPTT) and “procoagulant” (against PT). By comparing the biggest fold 
changes of a certain mass from chromatograms with the activity to those that are 
inactive, the compounds with the highest concentrations in the chromatograms are 
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suspected to possess the particular activity. This allows a reduction in the number 
of compounds to be studied, but excludes those compounds that are highly active 
but in very low concentrations. Due to the large number of hits given by 
GeneSpring, only the top five hits with the largest fold changes and good MS 
spectral library matches (80% and above using the Wiley Mass Spectral Library) 
will be discussed. The putative compound identities discussed below were given 
only by the Wiley Mass Spectral Library, hence further confirmation studies 
would be needed. 
The top five hits for compounds predicted with antiplatelet activities are 
listed in Table 4.1. Of the compounds identified to have antiplatelet activity, α-
amyrin and β-amyrin were among the first five hits with biggest fold changes 
when comparing antiplatelet extracts against proaggregating extracts in the 
compound list after PCA analysis (Table 4.1). This output by the software is 
consistent with previous reports of the antiplatelet effects of α- and β -amyrin 










Table 4.1 List of putative compounds predicted with antiplatelet and 
anticoagulation (prolong aPTT) activities. 
 







α-amyrin Antiplatelet Antithrombin Aragao et al., 
2007; Ching et 
al., 2010; 
Medeiros et al., 
2002 
β-amyrin Antiplatelet Antithrombin Aragao et al., 
2007; Ching et 
al., 2010; 
Medeiros et al., 
2002 
tetradecanoic acid No effect Procoagulation Temme et al., 
1998; Tholstrup 
et al., 1994 
linoleic acid No effect No reports Li et al., 2006 
linolenic acid Proaggregation Procoagulation/No 
effect 
Hoak et al., 





Other filtered compounds with high match factors identified by the Wiley 
Mass Spectral Library include fatty acids such as tetradecanoic acid (myristic 
acid), 9,12-octadecadienoic acid (linoleic acid) and α-linolenic acid. Different 
forms of linoleic acids were reported to have differing effects on platelet 
aggregation. Li et al., 2006 reported that 10-trans, 12-cis-conjugated linoleic acid, 
9-trans, 11trans-conjugated linoleic acid and conjugated nonadecadienoic acid 
are antiplatelet. 9-cis, 11-trans-conjugated linoleic acid has moderate antiplatelet 
activity and linoleic acid and 9-cis, 11-cis-conjugated linoleic acid have no effect 
on platelet aggregation. Tetradecanoic acid was also reported to have no effects 
on whole blood aggregation (Temme et al., 1998). On the other hand, linolenic 
acid was reported to cause increased platelet aggregation as well as plasma 
coagulation (Hoak et al., 1967). While some compounds which are known to 
cause platelet aggregation were detected, it was possible that the presence of 
highly active compounds, α-amyrin and β-amyrin, could have contributed to the 
overall antiplatelet activity of the extracts. 
Compared to the list of predicted compounds with antiplatelet activity, the 
list of compounds with proaggregant activity are mostly carbohydrates such as 
galactonic acid, sucrose, α-D-galactoside and α-D-galactopyranose. 
Carbohydrates like sucrose is very polar and are found in the water fraction. As 
sugars are not heat stable, the numerous hits indicating presence of simple sugars 
could imply that they were fragmented from oligosaccharides or other 
compounds. Polysaccharides are well studied for their anticoagulant activities 
(Bray et al., 1989; Mourao, 2004; Fonseca et al., 2008). Heparin itself is a sulfated 
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glycosaminoglycan. Heparin-mimetics being synthesised are also 
oligosaccharides (Petitou et al., 1999; Herault et al., 2002). However, it had been 
reported that sugar moieties of pennogenin glycosides are important for inducing 
platelet aggregation (Fu et al., 2008). Another compound listed was nonadecanoic 
acid which did not have any reported effects on platelet aggregation. 
 
4.4.1.3 Prediction of compounds with effects on plasma coagulation 
Prediction of compounds with anticoagulant activity (active in prolonging 
PT) was performed by filtering the compounds with the first five hits with biggest 
fold changes when comparing extracts/fractions with anticoagulant activity 
against those with procoagulant activity. Compounds predicted to prolong PT are 
listed in Table 4.2. 
β- amyrin is among the compounds predicted to prolong PT. Although 
both α- and β- amyrin have been reported to exhibit antithrombin activity in vitro 
(Medeiros et al., 2002), there are no reports on the amyrins affecting plasma 
coagulation. However there are no reported effects of hexanedioic acid, 








Table 4.2 List of putative compounds with anticoagulation (prolong PT) 
activity. 
 







β-amyrin Antiplatelet No reports Ching et al., 2010
hexanedioic acid No reports No reports NIL 
methylethylketone No reports No reports NIL 
tetracosanoic acid No reports No reports NIL 
linolenic acid Proaggregation Procoagulation/No 
effect 
Hoak et al., 1967; 
Kelley et al., 
1993 
 
Compounds predicted by the software to shorten PT (procoagulation) 
consisted of maltose, α-D-galactoside, 2(3H)-furanone, citric acid and D-ribonic 
acid. As discussed in the previous section, polysaccharides are usually known to 
be anticoagulant. Such metabolites identified by the software could have been 
fragmented from a larger moiety, or exist in high concentrations, leading to 
masking of the presence of other active components. There are no reported 
activities related to plasma coagulation for 2(3H)-furanone, citric acid and D-
ribonic acid.  
Prediction of compounds with anticoagulant activity (active in prolonging 
aPTT) was performed by filtering the compounds with first five hits with biggest 
fold changes when comparing extracts/fractions with strong activity against those 
with weak activity (Table 4.1). As most of the extracts and fractions with 
anticoagulant activity overlap with those with antiplatelet activity, most of the 
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compounds identified that can prolong aPTT are similar to those detected with 
predicted antiplatelet effects (Table 4.1), including α- and β- amyrin.  
Other compounds listed were 9,12-octadecadienoic acid, α-linolenic acid 
and tetradecanoic acid. Studies of dietary α-linolenic acid on humans showed no 
effect on the bleeding time, prothrombin time and partial prothrombin time for the 
subjects involved (Kelley et al., 1993). However, studies have not been 
conclusive so far. While Chan et al., 1993 also showed that the ratio of dietary α -
linolenic acid to linoleic acid had no effect on bleeding time, Tohgi, 2004 
reported a reduction in plasmin α2-plasmin inhibitor complex level, plasminogen 
activator inhibitor-1 activity, and thrombin antithrombin III complex level in type 
2 diabetic patients when the ratio of dietary α -linolenic acid to linoleic acid is 
reduced. Tetradecanoic acid was reported to increase Factor VII coagulant 
activity (Tholstrup et al., 1994). 
The preliminary results show that metabolomics is a promising method to 
predict bioactive components with antiplatelet and/or anticoagulant activities. The 
antiplatelet activities of α- and β –amyrin that were predicted by GeneSpring MS 
agreed with experimental results as well as reports from literature. However the 
disadvantage of the current method of filtering for bioactive compounds is that 
too many hits are obtained. It is preferable to have not more than 10 hits per 
activity in order for more targeted screening. More investigations have to be done 
to optimise the filtering of compounds by GeneSpring MS or by other softwares. 
In addition, the compounds with smaller fold changes should be explored.  
 118
 With the results obtained from the optimization assay, some parameters 
were changed in the subsequent assay. Instead of only analyzing the A. elliptica 
70% v/v methanol extract, its hexane, chloroform, butanol and water fraction, 
additionally ethanol and water extracts were obtained and incorporated in the 
assay. The chloroform fraction however was removed. This was because the 
compounds in the chloroform and hexane fractions were largely similar as can be 
seen from their chromatograms (Figure 4.1 b and c). As the gas chromatograms of 
the fractions were complex and difficult to compare by visual inspection, MVDA 
was employed to analyse the chromatograms. The two fractions were found to be 
clustered with each other (Figure 4.2), implying that an extra fractionation step 
using chloroform was not essential. Moreover, the antiplatelet activities of the 
hexane and chloroform fractions were not significantly different from each other 
(Figure 3.10). As a result, it was decided that the chloroform fraction was to be 
removed from the subsequent assay. The water and ethanol extracts were added as 
these two solvents were commonly used in the preparation of traditional herbal 
concoctions. Thus it would be interesting to investigate the bioactive compounds 
in these two extracts as well. 
 
4.4.2 Further development of the MVDA method 
4.4.2.1 Validation of GC-MS method for MVDA study 
The GC-MS method for performing the MVDA was validated for its 
intermediate precision. The intra-day variation was assessed by determining the 
RSDs of the retention times and peak areas for five compounds. They were 0.01% 
 119
to 0.05% and 5.3% to 14.7% respectively. The inter-day variation was also 
assessed. The RSDs of the retention times and peak areas were 0.01% to 0.03% 
and 10.7% to 14.5% respectively. The method was deemed precise as the RSDs of 
retention times and peak areas were lower than 15% for five compounds 
(Pasikanti et al., 2008). 
 
4.4.2.2 GC-MS analysis of all extracts and fractions 
The gas chromatogram of the crude extract and fractions obtained are 
shown in Figure 4.6. Preliminary identification of the compounds present was 
carried out using the autolibrary search function of the Wiley Mass Spectral 
Library. From the chromatograms, a combined compound list, which included all 
the different compounds and their peak areas in all extracts, fractions and 
controls, were compiled. 855 different compounds were obtained. This compound 
list was later used for MVDA. The hexane fraction contained more compounds 
with longer retention times, followed by the butanol fraction and lastly, the water 
fraction. These compounds were the non-polar compounds that partitioned into 

































































































Figure 4.6 Typical gas chromatograms of (A) blank, (B) 70% v/v methanol 
extract, (C) ethanol extract, (D) water extract, (E) hexane fraction, (F) butanol 




















4.4.2.3 PCA and PLS-DA analysis of the extracts and fractions 
Analysis of the chromatograms was first performed using PCA and PLS-
DA on MPP. MPP is an upgraded version of GeneSpring MS, both programmes 
from Agilent Technologies. 
It can be seen from Figure 4.7 that the different extracts and fractions 
showed clear clustering from each other in both the PCA and PLS-DA plots. Only 
the 70% v/v methanol extract and its water fraction were clustered closely 
together. The close clustering of the 70% v/v methanol extract and its water 
fraction is also seen in the preliminary study in Figure 4.2. This implied that the 
majority of the compounds present in the 70% v/v methanol extract consisted of 
polar compounds which are also present in the water fraction. While the 70% v/v 
methanol extract and water fraction show close similarity in compounds, they 
show opposing platelet aggregating activities. At a concentration of 0.2 mg ml-1, 
the 70% v/v methanol extract showed antiplatelet activity. At the same 
concentration, the water fraction enhanced platelet aggregation. This implied that 
the antiplatelet activity is attributed to the non-polar compounds found in the 70% 
v/v methanol extract but not its water fraction. 
From Figure 4.7, it can also be seen that the 70% v/v methanol extract, the 
water extract, and the ethanol extract shows distinct clustering from each other. 
This implied that there are compounds that are unique to each of the extracts, thus 




















Figure 4.7 (A) PCA scatter plot (B) PLS-DA scatter plot of the 
chromatograms showing distinct clustering of the different extracts and fractions. 
●—blank (MSTFA); ●--70% v/v methanol extract; ●-- ethanol extract; ●--water 
extract; ●-- hexane fraction; ●--butanol fraction; ●-- water fraction. 
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4.4.2.4 Antiplatelet activities of A. elliptica crude extract and its fractions 
The percentage inhibition of platelet aggregation due to A. elliptica 



















































Figure 4.8 Percent inhibition of platelet aggregation by different A. elliptica 
extracts (0.2 mg ml-1) and fractions (0.2 mg ml-1), β-amyrin (10 µg ml-1) and 
aspirin (10 µg ml-1) compared to control; n = 6 except for aspirin where n = 3; * p 
< 0.001 
  
At 0.2 mg ml-1, the 70% v/v methanol extract, ethanol extract, hexane 
fraction and butanol fraction inhibited platelet aggregation significantly as 
compared to the control (p < 0.001). The percentage inhibitions ranged from 6% 
to 45%, but they did not differ significantly from one another (p > 0.05). Aspirin, 
a positive control, produced a significant platelet aggregation inhibition of 26% at 
10 µg ml-1 as compared to the control (p < 0.001). 
The water extract and water fraction showed opposing activities as 
compared to the other extracts and fractions. Platelet aggregation was 
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significantly enhanced at 0.2 mg ml-1 as compared to the control (p < 0.001). The 
proaggregating activity of the water fraction was consistent with that reported in 
Section 3.2.4.3. But the water extract showed antiplatelet activity instead in 
Section 3.2.4.3 at the same concentration. However, it was observed earlier that 
the water extract showed different activities at different concentrations. 
Antiplatelet activity was observed to decrease at increasing concentrations, and 
the compounds with antiplatelet activities in this batch of extract could be 
different as compared to previously. 
The various extracts and fractions had different effects on collagen-
induced platelet aggregation as they contained different compounds. The 70% v/v 
methanol extract, ethanol extract, hexane fraction and butanol fraction might 
contain antiplatelet compounds which were absent in the water extract and water 
fraction. This implied that the compounds responsible for the antiplatelet effects 
could be non-polar in nature. These non-polar compounds would correspond to 
peaks with longer retention times in the gas chromatograms (Figure 4.6).  
 
4.4.2.5 Effects of A. elliptica crude extract and its fractions on plasma 
coagulation 
The plasma coagulation assay provided information on the anticoagulant 
effects A. elliptica extracts, fractions and potential bioactive compounds. 
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4.4.2.5.1 Effects of extracts and fractions on PT 
The effects of A. elliptica extracts and fractions on PT as compared to the 
control are shown in Figure 4.9.  
 
 
Figure 4.9 Effects of A. elliptica extracts (0.2 mg ml-1), fractions (0.2 mg ml-
1) and heparin (1 µg ml-1 and 5 µg ml-1) on PT compared to control; n = 6 except 
heparin where n = 3; * p < 0.001 
 
All extracts and fractions shortened PT significantly at 0.2 mg ml-1 as 
compared to the control (p < 0.001) and they are comparable to that reported in 
Section 3.4.2.3. The PT of the extracts and fractions did not differ significantly 
from one another (p > 0.05). Heparin at 1 µg ml-1 did not affect PT significantly 
as compared to the control (p > 0.05). However, at a higher concentration of 5µg 
ml-1, heparin prolonged PT significantly and no coagulation was detected within 
120 s.  
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As the extracts and fractions shortened PT, compounds that are able to 
enhance the extrinsic pathway of plasma coagulation might be present. Since their 
effects did not differ significantly from one other, these procoagulant compounds 
might be present at comparable concentrations in all the extracts and fractions. 
Heparin did not prolong PT at 1 µg ml-1, but this is not unexpected as heparin 
prolongs aPTT rather than PT (Hirsh et al., 2001). However, it prolonged PT at 5 
µg ml-1 as high concentrations of heparin may affect PT (Fenyvesi et al., 2002). 
 
4.4.2.5.2 Effects of extracts and fractions on aPTT 
The effects of A. elliptica extracts and fractions on aPTT as compared to 
the control are shown in Figure 4.10.  
Other than the water fraction, all extracts and fractions were found to 
prolong aPTT significantly at 0.2 mg ml-1 as compared to the control (p < 0.001). 
These results are also comparable to those reported in Section 3.2.4.3. The aPTT 
ranged from 34.0 s to 41.8 s, and they did not differ significantly from one 
another (p > 0.05). Only the water fraction had no significant activity at 0.2 mg 
ml-1 as compared to the control (p > 0.05). Heparin, a positive control, prolonged 
aPTT significantly to 37.8 s at 1 µg ml-1 (p < 0.001). It resulted in no coagulation 




Figure 4.10 Effects of A. elliptica extracts (0.2 mg ml-1), fractions derived from 
the 70% v/v methanol extract (0.2 mg ml-1) and heparin (1 µg ml-1 and 5 µg ml-1) 
on aPTT compared to control; n = 6 except heparin where n = 3; * p < 0.001 
 
The extracts and fractions exhibited anticoagulant effects via the intrinsic 
pathway, implying that they contain anticoagulant compounds that prolonged 
aPTT. These anticoagulant compounds were likely to be in higher concentrations 
in all the extracts and fractions except the water fraction, which did not show 
significant prolongation of the aPTT.  
 
4.4.2.6 Prediction of potential antiplatelet compounds by MVDA 
The platelet aggregation assay showed that the 70% v/v methanol extract, 
ethanol extract, hexane fraction and butanol fraction were antiplatelet, while the 
water extract and water fraction enhanced platelet aggregation (Figure 4.8). 
Assuming that the compounds in the water extract and water fraction did not have 
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antiplatelet activity, the compounds from the water extract and water fraction 
were removed manually during data pre-processing. Noise, sugars and 
compounds that were not present in at least four out of the six samples were also 
removed. A consensus list shown in Table 4.3 was produced after performing the 
four tests using the two software: OPLS and PLS-DA using SIMCA-P+ and Chi-
Squared weighting and InfoGain weighting using RapidMiner. Seven compounds 
were identified in at least three out of the four tests. All the compound names 
were exact quotes from the Wiley Mass Spectral Library Registry 7. 
 
Table 4.3 Consensus list of potential antiplatelet compounds (compounds 
identified as the top ten hits in at least three of the four tests) 
 





No. of tests the 
compound 






1 β-amyrin trimethylsilyl ether BF, EE, HF, ME 4 98 
2 α-amyrin EE, HF, ME 4 98 
3 Silane, [[(3.beta.)-lanosta-8,24-dien-3-




4 9,14-Bis(4-cyanophenyl)benzo[b]triphenylene BF, EE, HF 4 97 
5 Phosphine, tris[4-(trimethylsilyl)phenyl]- 
(CAS)  
HF 4 99 
6 4'-tert-butyl-3,5-bis(4-tert-
butylphenyl)biphenyl-2,2'-diol 
BF, HF 3 84 
7 Arabinonic acid, 2,3,5-tris-O-(trimethylsilyl)-, 
.gamma.-lactone 
BF 3 98 
*BF, butanol fraction; EE, ethanol extract; HF, hexane fraction; ME, 70% v/v 
methanol extract 
 
Table 4.4 shows a list of top ten compounds with the highest correlation 
coefficients obtained using the correlation method. Since α-amyrin and β-amyrin 
which were known to be antiplatelet (Aragao et al., 2007; Ching et al., 2010) were 
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common in both results, the MVDA methods were effective in identifying them 
as antiplatelet. The consensus method could identify α-amyrin and β-amyrin in all 
the four tests. The correlation method also identified α-amyrin and β-amyrin as 
the fourth and tenth potential antiplatelet compounds respectively. Further 
investigations should be done to verify the activity of other compounds listed with 
potential antiplatelet activity. 
 
Table 4.4 Correlation list of potential antiplatelet compounds (top ten 
compounds with the highest correlation coefficients) 
 
No. Potential antiplatelet compound 
 
Extract/fraction 










(CAS) 1-monostearin-DITMS  
BF, EE, HF, ME, WE, 
WF 0.499 99 
2 Mercaptoacetic acid, 
bis(trimethylsilyl)-  








4 α-amyrin EE, HF, ME 0.364 98 
5 Bis-O-trimethylsilyl-palmitinic acid-
glycerin-(1)-monoester 
ME, WF 0.276 99 
6 Hexadecanoic acid, 2,3-
bis[(trimethylsilyl)oxy]propyl ester 
(CAS) 1-monopalmitin-DITMS  
BF, EE 
0.263 99 
7 2-Isopropoxy-Propanenitrile  EE, HF, ME 0.250 99 
8 Dodecanoic acid, trimethylsilyl ester 
(CAS) lauric acid-MONOTMS 
HF 
0.250 99 
9 Adenine, Bis-N-(trimethylsilyl)- ME,WE 0.248 91 
10 β-amyrin trimethylsilyl ether BF, EE, HF, ME 0.244 98 
*BF, butanol fraction; EE, ethanol extract; HF, hexane fraction; ME, 70% v/v 
methanol extract; WE, water extract; WF, water fraction 
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According to literature, 10 phytoconstituents have so far been reported in 
A. elliptica. They are α-amyrin (Ahmad et al., 1977), β-amyrin (Ahmad et al., 
1977; Chow et al., 1991), bauerenol (Ahmad et al., 1977; Chow et al., 1991), 
bergenin (Liu et al., 1993), isorhamnetin (Phadungkit and Luanratana, 2006), 
quercetin (Phadungkit and Luanratana, 2006), rapanone (Chow et al., 1991), 
syringic acid (Phadungkit and Luanratana, 2006), 5-(Z-heptadec-4’-
enyl)resorcinol (Jalil et al., 2004) and 5-pentadecylresorcinol (Jalil et al., 2004). 
Of these 10 compounds, 6 of them (α-amyrin (Aragao et al., 2007; Mazura et al., 
2007; Ching et al., 2010), β-amyrin (Aragao et al., 2007; Ching et al., 2010), 
quercetin (Tzeng et al., 1991; Kobzar et al., 2005; Mazura et al., 2007), syringic 
acid (Yang et al., 2002), 5-(Z-heptadec-4’-enyl)resorcinol (Jalil et al., 2004) and 
5-pentadecylresorcinol (Jalil et al., 2004) have been reported to have antiplatelet 
activities. As there are 2 positive predictions, this equates to a precision of 28.6% 
and 20% for the consensus method and correlation method respectively. The 
recall for both was 33% since 2 out of the 6 known antiplatelet compounds were 
detected in A. elliptica.  
In this study, four analytical methods were used to construct a consensus 
list of predicted bioactive compounds. The reason for using multiple methods is 
because in extracts and fractions with many different compounds, it is inevitable 
that an analytical method may wrongly identify some inactive compounds as 
bioactive. However, these errors are expected to be different for each analytical 
method because each uses a different algorithm. For example, OPLS and PLS-DA 
differs in the manner in which they treat classorthogonal variation (Bylesjö et al., 
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2006). This creates a slightly different list of potential bioactive compounds from 
both methods, even though both methods are extensions of the partial leastsquares 
(PLS) methodology. Thus, generating a consensus list of bioactive compounds 
from the lists of potential bioactive compounds produced by the four analytical 
methods should reduce the chance of identifying inactive compounds as bioactive. 
 
4.4.2.7 Prediction of anticoagulant compounds using MVDA 
The plasma coagulation assay showed that the various extracts and 
fractions shortened PT (Figure 4.9), and thus it was assumed there were no 
anticoagulant compounds that acted on the extrinsic pathway. On the other hand, 
all extracts and fractions, with the exception of the water fraction, prolonged 
aPTT significantly (Figure 4.10). Hence, anticoagulant compounds that acted on 
the intrinsic pathway could be present in the relevant extracts and fractions. For 
this test, only noise, sugars and compounds that were not present in at least four 
out of the six samples were removed during pre-processing. This gave a 
consensus list shown in Table 4.5. Six compounds were identified to have 
anticoagulant activity in at least three out of the four tests. A correlation list 








Table 4.5 Consensus list of potential anticoagulant compounds (compounds 
identified as the top ten hits in at least three of the four tests). 
 
No. Potential anticoagulant compound 
No. of tests the 
compound 
appeared as 





1 Octadecanoic acid,2,3-bis[(trimethylsilyl)oxy]propyl ester (CAS) 1-monostearin-DITMS 4 99 
2 Butanedioic acid, [(trimethylsilyl)oxy]-, bis(trimethylsilyl) ester (CAS) malic acid 3TMS 4 99 
3 Erythrose, )-methyloxim, tris-O-(trimethylsilyl)- 4 99 
4 Acetamide, 2,2,2-trifluoro-N-methyl-N-(trimethylsilyl)- (CAS)N-methyl-N-trimethylsilyl trifluoroacetamide 3 99 
5 
Xylonic acid, 2,3,5-tris-O-(trimethylsilyl)-, .gamma.-
lactone, D- (CAS) 2,3,5-tri-o-trimethylsilyl-xylono-1,4-
lactone 
3 97 
6 Tetronicacid, tetrakis-O-(trimethylsilyl)- 3 99 
 
Table 4.6 Correlation list of potential anticoagulant compounds (top ten 
compounds with the highest correlation coefficients). 
 





1 Tetradecanoic acid, trimethylsilyl ester (CAS) myristic acid-MONOTMS 0.661 90 
2 Octadecanoic acid,2,3-bis[(trimethylsilyl)oxy]propyl ester (CAS) 1-monostearin-DITMS 0.660 99 
3 Silane, [[(3.beta.)-lanosta-8,24-dien-3-yl]oxy]trimethyl- (CAS) lanosterol trimethylsilyl ether 0.648 94 
4 .alpha.-Phenyl-.beta.-trimethylsiloxystyrene  0.647 96 
5 ethyl 6-phenyl-2-(trifluoromethyl)-4-oxohex-5-enoate  0.628   
6 β-amyrin trimethylsilyl ether 0.610 98 
7 Phosphine, tris[4-(trimethylsilyl)phenyl]- (CAS) Phosphine, tris[p-(trimethylsilyl)phenyl]-  0.577 99 
8 6,6-dimethyl-2-[(trimethylsilyl)methyl]-4-oxo-2,3,4,5,6,7-hexahydrobenzofuran  0.540 98 
9 N,O-bis(acetyl)-S-[2-(4-ethenylphenyl)-2-hydroxyethyl]-L-cysteine-methyl ester  0.536 95 
10 2-Isopropoxy-Propanenitrile  0.499 96 
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Only octadecanoic acid,2,3-bis[(trimethylsilyl)oxy]propyl ester was 
common in both results. However, there were no reports on its anticoagulant 
effects. β-amyrin was identified by the correlation method to be anticoagulant 
although it was found not to be so in the plasma coagulation assay (Section 
3.4.12). This prediction could be a false positive. One possible reason for the false 
positive could be due to the effects of the extracts and fractions being not 
significantly different from one another (p > 0.05). The anticoagulant compounds 
in the various extracts and fractions might be present at comparable 
concentrations, rendering the anticoagulant compounds not reliably identified. For 
the correlation method to be useful, there should be significant differences in the 
activities between the extracts/fractions. No reports on the anticoagulant effects of 
other potential anticoagulant compounds as listed in Tables 4.3 and 4.4 can be 
found.  
 
4.4.2.8 Confirmation of antiplatelet activity of β-amyrin 
The isolation of β- amyrin was reported in Chapter 3. An independent 
platelet aggregation assay was repeated using the isolated β-amyrin at a 
concentration of 10 μg ml-1 and a 13.2% inhibition of platelet aggregation was 
obtained. At the same concentration, aspirin showed a 26.1% inhibition of platelet 
aggregation.  
The antiplatelet activity of the amyrins accounted in part for the activities 
seen in the 70% v/v methanol extract, the ethanol extract, the hexane and butanol 
fractions, but not in the water extract and water fraction. It can be seen from 
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Figure 4.6 that the amyrins are not present in both the chromatograms of the water 
extract and water fraction. 
 
4.4.2.9 Advantage of using MVDA for natural product drug discovery 
An advantage of using MVDA for discovery of bioactive compounds over 
bioassay-guided fractionation is the significant reduction in the number of 
repeated chromatography required. Jalil et al., 2004 reported a bioassay-guided 
fractionation method leading to the discovery of a potent platelet activating factor 
receptor antagonist. Repeated chromatography and bioassays were needed to 
obtain the pure compound. Using MVDA, 2 steps are required. After determining 
the activity of the fractions obtained by liquid—liquid partitioning, all samples are 
analyzed by GC-MS and MVDA, which can point out the putative bioactive 
compounds immediately. If the identities of the compounds are known, bioassays 
can be performed to confirm the activities. Otherwise, a targeted isolation and 
structural elucidation should be carried out prior to further bioassays.  
There is much potential for future developments using MVDA for natural 
product discovery using the current method, In this study, all compounds in the 
plants were assumed not to have any synergistic or antagonistic effects. In other 
words, the compounds were assumed to be acting independently and do not 
promote platelet aggregation. As plant extracts contain a myriad of components, 
further experiments can be done to include this parameter in the study. Further 
more, analysis using liquid chromatography can also be used to analyse 
compounds not detected by GC-MS.  
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4.5 Conclusion 
A rapid and simple method of identifying bioactive compounds from 
crude plant extracts and their partially purified fractions using MVDA has been 
developed and demonstrated. Successful prediction of α-amyrin and β-amyrin as 
potential antiplatelet agents in A. elliptica corroborated with independent bioassay 
results. While the amyrins have been successfully predicted, other hits should also 
be further evaluated to ensure the reliability of the method.Using MVDA to 
identify potential bioactive components may reduce time and cost of drug 
discovery and increase efficiency. GC-MS has been demonstrated to be useful in 
the current work for rapid identification of compounds with antiplatelet activity in 
A. elliptica. This simple method using easily available commercial software 
(SIMCA-P, RapidMiner and Microsoft Excel) can be optimised and applied to 





Antiplatelet, anticoagulation and pharmacokinetic studies 
of A. elliptica and its isolated bioactive component in rats 
 
5.1 Ex vivo and in vivo antiplatelet and anticoagulant activities of A. 
elliptica and β-amyrin in rats 
5.1.1 Introduction 
A. elliptica is a medicinal plant used traditionally by the Malays for 
conditions such as pains in the region of the heart, fever, diarrhoea and liver 
poisoning. The traditional uses and scientific studies of the plant have been 
reviewed in Section 1.3.2. It has been shown in Section 3.1.4.7 that α- and β-
amyrins are the major components in the A. elliptica plant extract. In Chapter 3, 
collagen-induced platelet aggregation and plasma coagulation assays performed in 
vitro also suggest that the amyrins could be partly responsible for the activities of 
the leaf extract (Ching et al., 2010). α- and β-amyrins are triterpenes found 
naturally occurring in a variety of plants (Xu et al., 2004). The biological 
activities of the amyrins, such as anxiolytic, antidepressant (Aragao et al., 2006), 
antinociceptive (Otuki et al., 2005), liver-protective (Oliveira et al., 2005), 
gastroprotective (Oliveira et al., 2004), antiplatelet (Aragao et al., 2007; Ching et 
al., 2010) and anti-inflammatory (Akihisa et al., 1996) have been reported. As the 
amyrins exhibit a wide range of biological activities, they could be promising lead 
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compounds for further pharmaceutical development. In addition, α- and β-amyrin 
can be commonly found in vegetables such as peas (Pisum sativum) (Morita et al., 
2000) and cabbages (Brassica oleracea) (Martelanc et al., 2007), thus there could 
be potential food-drug interaction when drugs are consumed together with such 
vegetables.  
Previous investigations of the antiplatelet activities of A. elliptica 
elucidated three components responsible for the activity. 5-(Z-heptadec-4’-
enyl)resorcinol was shown to inhibit platelet activating factor receptor binding on 
rabbit platelets (Jalil et al., 2004), while - and β-amyrin were shown to inhibit 
collagen-induced platelet aggregation in rabbits in vitro (Ching et al., 2010). Since 
only β-amyrin was successfully isolated and purified as described in Section 
3.1.4.4, the isolated β-amyrin will be studied in vivo in this chapter. In this study, 
platelet aggregation and plasma coagulation tests were performed using rats, and 
results from this study will be useful for future clinical studies of the compounds. 
 
5.1.2 Objectives 
The overall objective of the work in this section is to investigate the in 
vivo and ex vivo antiplatelet and anticoagulant activity of A. elliptica and its 
isolated component, β-amyrin. The specific objectives are to 
 
1. Investigate the effects of the A. elliptica 70% v/v methanol extract and its 
isolated component, β-amyrin on haemostasis using the rat model by the 
tail bleeding assay. 
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2. Investigate the antiplatelet and anticoagulation effects of the A. elliptica 
70% v/v methanol extract and its isolated component, β-amyrin using the 
rat model by a collagen-induced platelet aggregation test and a plasma 
coagulation test. 
 
5.1.3 Materials and Methods 
5.1.3.1 Plant material and extraction 
Leaves of A. elliptica were extracted using 70% v/v methanol by Soxhlet 
extraction as described in Section 3.1.3.3. The solvent was evaporated to dryness 
in vacuo and the dried extract was reconstituted in appropriate solvents for 
chemical analysis or bioassays.  
 
5.1.3.2 Chemical analysis of plant extract using HPLC and GC-MS 
The analysis of the leaf extract was carried out using both HPLC and GC-
MS. Details of the methods are as in Section 3.1.3.5 and 3.1.3.6 respectively.  
 
5.1.3.3 Isolation of β-amyrin 
β-amyrin was isolated from A. elliptica leaf extract as described in Section 
3.1.3.7. Briefly, the 70% v/v methanol extract (21.5 g) was reconstituted in HPLC 
grade methanol and fractionated using a preparative HPLC system and a 
preparative Zorbax Eclipse XDB-C18 column using methanol as the mobile 
phase. The fraction collected was further purified using a semi-preparative 
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column. Purity of the isolated β-amyrin was checked by analyzing the compound 
against its standard (Extrasynthese, Genay, France) using both HPLC and GC-
MS.    
 
5.1.3.4 Animals 
Male Sprague-Dawley rats (200–300 g) were purchased from the 
Laboratory Animal Centre (Singapore), and housed at the Animal Holding Unit of 
National University of Singapore. The experiments were carried out in 
accordance to internationally accepted guidelines on laboratory animal use (NIH 
publication No.85-23, revised in 1985) and the protocols were approved by the 
Institutional Animal Care and Use Committee (IACUC) of the National 
University of Singapore. The animals were maintained in an air-conditioned room 
at a temperature of 22 ± 1 oC and a humidity of 62 ± 2%, with unrestricted access 
to food and water. Three days of acclimatisation were allowed before any 
experimentation. 
 
5.1.3.5 In vivo tail-bleeding assay  
The rats were divided into four treatment groups (six rats per group) and 
orally administered with 0.5% CMC (vehicle control), aspirin (30 mg kg-1), leaf 
extract (300 mg kg-1) or β-amyrin isolated from the leaf extract (30 mg kg-1). 
They were anaesthetised intraperitoneally with a mixture of ketamine (75 mg kg-
1) and xylazine (10 mg kg-1) at 90 min after dosing. The tail-bleeding model was 
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based on previous methods with minor modifications (Beviglia et al, 1993; Lau et 
al., 2009). Briefly, the tail was pre-warmed for 5 min in phosphate buffered saline 
(PBS; 8 g 1-1 NaCl, 0.2 g 1-1 KCl, 1.44 g 1-1 Na2HPO4, 0.24 g 1-1 KH2PO4) at 37 
oC. The bleeding was induced by transection of the rat tail at 2 mm from the tip. 
The distal portion (3 cm) of the tail was immersed vertically into PBS at 37 oC. 
The time between the start of transaction to bleeding cessation was recorded as 
the bleeding time. Bleeding cessation was considered to be the time when the 
flow of blood stopped for at least 30 s. If the bleeding did not cease by 15 min, the 
experiment was ended with pressure being applied to the wound to stop the 
bleeding. 
 
5.1.3.6 Ex vivo platelet aggregation assays 
Blood (4 ml) from each rat was collected, intra-cardiacally at 110 min after 
dosing, directly into citrated bottles (Tapval, 4 ml blood collection tubes, 0.106 M 
citrate, Deltalab S.A., Barcelona, Spain). The whole blood aggregation assay was 
carried out by the measurement of impedance using a whole blood aggregometer 
(Chronolog Corporation, Havertown, PA) as described in Section 3.2.3.5. 
 
5.1.3.7 Ex vivo plasma coagulation assays 
The collected blood from the rats was centrifuged at 1500 g for 15 minutes 
to obtain clear plasma as the supernatant. For the prothrombin time (PT) test, 50 
µl of plasma was mixed with 100 µl of Thromborel S (Human placental 
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thromboplastin, Calcium added, DADE BEHRING, Marburg, Germany) and 
incubated for 180 s. The maximum time for detection of a clot formation was 
standardised at 120 s. For the aPTT determination, 50 µl of plasma was mixed 
with 50 µl of aPTT reagent (DADE, Actin FSL, activated PTT reagent, DADE 
BEHRING, Marburg, Germany) and incubated for 60 s. This was followed by an 
addition of 50 µl of calcium chloride (Calcium chloride solution, 0.025 M, DADE 
BEHRING, Marburg, Germany) and a further incubation of 240 s. The time for 
the plasma to clot was determined by the Automated Blood Coagulation Analyzer 
CA-500 Series (Sysmex, Kobe, Japan). The maximum time for detection of a clot 
formation was set at 190 s. All tests were carried out in triplicates. 
 
5.1.3.8 Statistical analysis 
The percentage inhibition of platelet aggregation, PT and aPTT are 
reported as means ± standard deviations of results obtained in triplicates. 
Analyses of significance of values compared with controls, where appropriate, 









5.1.4 Results and Discussion 
5.1.4.1 Isolation of β-amyrin 
From the soxhlet extraction, 42.9 g of dried leaf extract was obtained from 
517.5 g of fresh leaves. This equates to a yield of 8.3% w/w of the leaves. 21.5 g 
of dried leaf extract was reconstituted in 40 ml of methanol and used for the 
isolation of β-amyrin. The total amount of β-amyrin isolated and purified was 
96.8 mg. The isolated compound was a white powder. The identity of β-amyrin in 
the extract was verified by running the standard for comparison as well as by 
mass spectrometry and an autolibrary search using the Wiley mass spectral library 
in GC-MS. 
 
5.1.4.2 Tail bleeding assay 
The tail bleeding times of rats administered with either the vehicle, leaf 
extract, β-amyrin or aspirin are shown in Table 5.1. The doses of the drugs and 
extract were estimated from a previous study by Chua (2005). The rats treated 
with either the leaf extract or β-amyrin had longer bleeding times compared to the 
control rats. The results suggest that both β-amyrin and the leaf extract have 
antithrombotic effects as demonstrated by the prolonged bleeding times compared 






Table 5. 1 Tail-bleeding times after oral administration of test samples (n 
denotes the number of rats being analysed for each test sample). * p < 0.05; ** p 
< 0.01 compared with the control 
 
 Treatment (Dose) Dose (mg/ kg, oral) Bleeding time/ s 
No. of rats with bleeding 
times > 15 min 
Control (n=6) − 398 ± 54 0 
Leaf Extract (n=6) 300 741 ± 150** 2 
β-amyrin (n=6) 30 628 ± 200* 1 
Aspirin (n=5) 30 864 ± 81** 4 
 
The mean bleeding time of the rats treated with 300 mg kg-1 of leaf extract 
was not statistically different from that of rats dosed with 30 mg kg-1 (166.5 μmol 
kg-1) of aspirin. This shows that the leaf extract could affect haemostasis by 
prolonging bleeding. There are also no significant statistical differences between 
the bleeding times elicited by the same dosage of 30 mg kg-1 of either aspirin or β-
amyrin, implying the efficacy of β-amyrin to prolong bleeding. However, 30 mg 
kg-1 of β-amyrin is equivalent to 70.3 μmol kg-1, which is less than half that of the 
dosage of aspirin. The results could imply that β-amyrin is more efficacious at 
prolonging bleeding. The results were in agreement with in vitro results shown 
previously. In Section 3.2.4.2, it was reported that β-amyrin had an IC50 value for 
inhibiting collagen-induced platelet aggregation that is six times lower than 
aspirin when the effects were studied in vitro on rabbit’s blood (Ching et al., 
2010).  
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The tail-bleeding time assay is a model of haemostasis and affected by 
different factors such as platelet aggregation and plasma coagulation (Mackman, 
2004). Further ex vivo assays were performed to investigate the platelet 
aggregation and plasma coagulation effects of the leaf extract and β-amyrin.  
 
5.1.4.3 Ex vivo platelet aggregation assay 
The percentage inhibition of platelet aggregation of the different treatment 
































Figure 5.1 Ex vivo comparison of percentage inhibition of collagen-induced 
platelet aggregation after treatment with different test samples in SD rats. Error 
bars represent standard deviation and experiments on each animal were done in 
triplicates. Doses of test samples indicated in brackets; n denotes the number of 




Approximately 30 to 40% inhibition of collagen-induced platelet 
aggregation was observed in the two groups of rats treated with β-amyrin (30 mg 
kg-1 or 70.3 μmol kg-1) and the leaf extract (300 mg kg-1). Aspirin (30 mg kg-1 or 
166.5 μmol kg-1) resulted in greater inhibition of platelet aggregation (69%). 
While aspirin showed a greater inhibition, it has to be noted that on a molar basis, 
the rats were treated with a lower dose of β-amyrin (70.3 μmol kg-1) compared to 
aspirin (166.5 μmol kg-1). These results agree with the tail-bleeding time assay, 
which showed that β-amyrin was able to prolong bleeding at the studied dosage. 
The results also implied that β-amyrin is orally active, and could affect collagen-
induced platelet aggregation in vivo as well as in vitro (Aragao et al., 2007; Ching 
et al., 2010). Investigations of a α- and β-amyrin mixture in vitro showed that it is 
able to inhibit ADP-induced platelet aggregation but only weakly inhibit 
arachidonic acid-induced platelet aggregation (Aragao et al., 2007). It is known 
that ADP exerts its platelet activating effects via two receptors, the P2Y1 and 
P2Y12. Binding of ADP to P2Y1 causes changes in platelet shape and transient 
aggregation, while binding of ADP to P2Y12 induces signalling which results in 
platelet aggregation and eventually, growth and stabilisation of the thrombus 
(Dorsam and Kunapuli, 2004). P2Y12 also takes part in the amplification of 
platelet aggregation caused by other agonists such as thromboxane A2 (TXA2) 
and thrombin (Offermanns, 2006). The other important platelet agonist, collagen, 
mediates platelet adhesion under high shear stress by interacting indirectly with 
GPIb  via the von willebrand factor (Varga-Szabo et al., 2008). This interaction 
activates GPIIb/IIIa, which allows platelets to aggregate. At low shear stress 
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conditions, GPIa/IIa and GPVI on the platelet surface bind collagen (Varga-Szabo 
et al., 2008). GPVI has an important role in activating the platelet, which leads to 
a chain of events involving adhesion, aggregation and degranulation of the 
platelet (Varga-Szabo et al., 2008). Based on existing knowledge, further work 
should be done to elucidate the mechanism of α- and β-amyrin in inhibiting 
platelet aggregation involving these pathways and receptors. 
α- and β-amyrin mixtures had been studied for various activities in vivo 
and showed promising effects. The activities studied include analgesia (Aragao et 
al., 2007), anti-inflammatory (Aragao et al., 2007), anti- colitis (Vitor et al., 
2009), anxiolytic (Aragao et al., 2006), antidepressant (Aragao et al., 2006), 
antinociceptive (Holanda Pinto et al., 2008), antitubercular (Higuchi et al., 2008), 
gastroprotective (Oliveira et al., 2004), protection against liver injury (Oliveira et 
al., 2005) and scratching suppression (Oliveira et al., 2004). α- and β-amyrin have 
also been individually assessed for their anti-inflammatory in mice (Akihisa et al., 
1996). When α-amyrin was studied for its anti-inflammatory activity on mice, it 
was shown that while α-amyrin had no effect on the cyclooxygenase (COX)-1 and 
COX-2 activities in vitro, the compound was able to dose-dependently inhibit 12-
O-tetradecanoylphorbol-acetate -induced COX-2 expression in the mouse skin 
(Medeiros et al., 2007). Aspirin is known to act on COX by reducing the synthesis 
of TXA2 in platelets, thereby preventing aggregation. More investigations should 
be carried out to find out if the amyrins are able to act in a similar fashion. 
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5.1.4.4 Ex vivo plasma coagulation assay 
Figure 5.2 shows the PT and aPTT of rats after treatment with the vehicle, 
leaf extract, β-amyrin or the positive control, aspirin.  The results of the ex vivo 
plasma coagulation assay showed that the leaf extracts and β-amyrin did not 
exhibit any anticoagulant activities.  
On the contrary to our previous investigations which showed that the leaf 
extract prolonged the aPTT but not PT in vitro, the ex vivo studies here showed 
that the leaf extract did not prolong plasma coagulation at an oral dose of 300mg 
kg-1. Such an observation could be due to the active component being 
administered at too low a dosage, low bioavailability or poor absorption via the 
oral route, metabolic inactivation or simply inter-species variation in drug 
response in which the active compound in the leaf extract might only be effective 
in human blood. Similar to the results of in vitro plasma coagulation assay in 
Section 3.2.4.4, β-amyrin did not show anticoagulation effects in vivo. Although it 
was reported that β-amyrin possesses antithrombin activity in vitro when a 
chromogenic bioassay was performed (Medeiros et al., 2002), β-amyrin did not 
show any anticoagulant activity in this study as seen from the PT and aPTT 
obtained. These results imply that β-amyrin had increased the bleeding time of 









































Figure 5.2  (A) PT and (B) aPTT after treatment with different test samples in 
SD rats. Error bars represent standard deviation and experiments on each animal 
were done in triplicates. Doses of test samples are indicated in brackets; n denotes 
the number of rats in each treatment group. * p < 0.05 compared to control. 
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5.1.5 Conclusion 
This is the first report of A. elliptica leaf extract and its isolated 
component β-amyrin on haemostasis, platelet aggregation and plasma coagulation 
in vivo in rats. In summary, the results showed that the leaf extract of A. elliptica 
has antiplatelet effects, but not anticoagulant effects. It is shown from the assays 
that β-amyrin is one of the components in the leaf extract responsible for the 
antiplatelet effects. Both the extract and β-amyrin, when dosed orally to rats, 
could increase tail bleeding times and inhibit platelet aggregation. However as 
opposed to the in vitro studies conducted, the extract did not result in the 
prolongation of PT or aPTT. The lack of anticoagulant activity is probably due 
either to the concentration or inactivation of the active components by 
metabolism. Further work is required to elucidate the other active components in 
the leaf extract and the mechanisms of action of the isolated compound, β-amyrin. 
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5.2 Pharmacokinetic study of A. elliptica and its bioactive components, α-
amyrin and β-amyrin in rats 
5.2.1 Introduction 
Pharmacokinetics plays a vital role in drug discovery and development. In 
drug development, good in vitro activities might not translate to good in vivo 
activities if the drug does not have good bioavailability and suitable duration of 
action. According to a review by Lin and Lu (1997), many failures of drug 
candidates were due to unacceptable pharmacokinetic properties, for example too 
long or short half lives, poor absorption and extensive metabolism. It is thus 
important to understand the pharmacokinetics of the drug early in development so 
that a decision could be made to either exclude a compound from further 
screening or to optimise the pharmacokinetic properties of the compound. It is 
important to note that approximately 40% of failures of drug candidates in clinical 
development were due to unfavourable pharmacokinetics (Kennedy, 1997; 
Kubinyi, 2003; Prentis et al., 1988). From the high failure rate, it can be seen that 
pharmacokinetics play an important role in drug discovery. 
 In Chapter 3, it was shown that the 70% v/v methanol A. elliptica leaf 
extract and its isolated component, β-amyrin is antiplatelet in vivo. However to 
the best of our knowledge, the pharmacokinetic profiles of α- and β-amyrin have 
not been reported. In order for the compounds to be investigated as a drug, it 
would be useful to understand its absorption and clearance profiles, for estimation 
of the dosages and to further improve the pharmacokinetic properties of the 
compound.  
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The lack of a reliable analytical method could have hindered the 
pharmacokinetic studies of the amyrins. To facilitate further investigations of 
these compounds, this study aims to develop and validate a GC-MS method to 
quantify α- and β-amyrin in rat plasma. Since only β-amyrin was isolated and 
studied in vivo previously, the pharmacokinetic profile of β-amyrin was studied in 
this section. This is the first report on the pharmacokinetic profile of β-amyrin. 
The information obtained from this study will be useful for further investigations 
on the potential medicinal application of the amyrins.  
 
5.2.2 Objectives 
The overall objective of this section is to assess the pharmacokinetic 
profiles of α- and β-amyrin in Sprague-Dawley rats. The specific objectives are to 
  
1. Develop and validate a GC-MS method for the detection and 
quantification of α- and β-amyrin in rat plasma. 
2. Investigate the pharmacokinetics of α- and β-amyrin in the 70% v/v 








5.2.3 Materials and methods 
5.2.3.1 Reagents 
α- and β-amyrin (98.5%) were purchased from Extrasynthese (Genay 
Cedex, France) while the sodium salt of carboxymethyl cellulose (CMC) was 
purchased from Hopkin and Williams (Chadwell Heath, UK). HPLC grade 
methanol was obtained from Tedia Company (Fairfield, OH). Methyltestosterone 
was obtained from U.S Pharmacopeia (Rockville, MD). 
5.2.3.2 Preparation of plant extract 
The 70% v/v methanol extract was prepared as described in Section 
3.1.3.3. The plant extract was dried in vacuo before suspending in 0.5% (w/w) 
CMC. The concentrations of α- and β-amyrins in the plant extract were quantified 
using GC-MS. 
 
5.2.3.3 GC-MS method development for detection of the amyrins and 
internal standard methyltestosterone 
 A Shimadzu (Kyoto, Japan) GC-MS system (gc2010 and qp2010 MS) was 
used for quantifying both α- and β-amyrins in the rat plasma. Chromatographic 
separation was achieved with a DB5 column of film thickness 0.25 μm, length 
30.0 m and diameter 0.25 mm (Agilent Technologies, Santa Clara, CA). The 
initial oven temperature was 180 oC and increased to 280 oC at a rate of 50 oC 
min-1. This temperature was held for another 19 min. The helium flow rate was 
1.6 ml min-1. The interface and ion source temperatures were 250 oC and 200 oC 
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respectively. At the beginning of the assay development, the mass spectrometer 
was operated in the scan mode to obtain the mass spectra of α-amyrin, β-amyrin 
and methyltestosterone. After the identification of the major ions, the selected-ion 
monitoring (SIM) mode was applied, detecting ions with m/z 203, 218 and 426 
for both α- and β-amyrins and ions with m/z 43, 124 and 302 for the internal 
standard, methyltestosterone. Quantification was done using the total ion 
chromatogram (TIC) of the quantifier ions with m/z 218 and 302 for the amyrins 
and methyltestosterone respectively.  
  
5.2.3.4 Sample preparation 
Stock solutions of α- and β-amyrins and the internal standard, 
methyltestosterone were prepared in methanol and stored at 4 oC, away from light. 
The final concentrations of calibration standards for α- and β-amyrin were 1, 5, 
10, 50, 100, 500, 1000 and 2000 ng ml-1. To assess the accuracy of this assay, 
quality control samples (1, 200 and 1500 ng ml-1) were also prepared 
independently. All samples were prepared freshly by spiking 5 μl of appropriate 
concentrations of amyrin into 100 μl of pooled rat plasma. For the processing of 
plasma samples, 5 μl of internal standard, methyltestosterone (20 μg ml-1) was 
spiked into 100 μl of plasma in a clean 1.5 ml microcentrifuge tube. The samples 
were mixed well before 300 μl of ice cold methanol was added, vortexed for 1 
min and centrifuged at 10,000 g for 10 min. After the protein precipitation, the 
supernatant was transferred to a clean microcentrifuge tube and evaporated to 
dryness. The residue was reconstituted in 100 μl of methanol and centrifuged for 
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another 5 min at 10,000 g. 1 μl of the resulting supernatant was injected into the 
GC-MS. 
 
5.2.3.5 GC-MS assay validation for pharmacokinetic study 
 The assay was validated for its selectivity, sensitivity, linearity, precision, 
repeatability, accuracy and absolute recovery. The post preparative, freeze-thaw, 
short term and long term stability profiles of α- and β-amyrins were also assessed. 
 Selectivity was initially investigated by comparing the chromatograms of 
plasma pooled from 8 individual rats to the same pool of plasma spiked with α- 
and β-amyrin and the internal standard methyltestosterone. A confirmation was 
performed by the collecting pre-dosing samples from the 10 individual rats used 
in the pharmacokinetic study. The selectivity of the assay was determined by the 
chromatographic separation of the compounds between the pre-dosing and post-
dosing plasma samples. In the mass spectra obtained by SIM, the ratios of the 
detected ions of each compound were used as a secondary control for determining 
selectivity.   
 The sensitivity of the GC-MS assay was represented by the limit of 
detection (LOD) and limit of quantitation (LOQ), defined by comparing measured 
signals from samples with known concentrations of analyte with those of blank 
samples, and by establishing the minimum concentration at which the analyte can 
be reliably detected or quantified. A signal to noise ratio of 3 and 10 is used for 
estimating the LOD and LOQ respectively. 
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 The ratio of the peak area of the amyrins to methyltestosterone was 
defined as the analytical response. GraphPad Prism Version 3.03 (San Diego, CA) 
was used to assess the linearity of the calibration curve, where x was the 
concentration of amyrin and y was the analytical response. A weighting factor of 
1/x2 was applied in the linear regression (Lin and Ho, 2009; Lin et al., 2009). The 
calibration was executed on 5 consecutive days. For intra-day analysis, 5 replicate 
of samples were prepared; for inter-day assay, duplicate samples were prepared. 
Similarly, quality control (QC) samples (1, 200 and 1500 ng ml-1) were also 
prepared and analyzed. The intra- and inter-day relative standard deviation (RSD) 
at individual concentration was used as a precision / reproducibility indicator.   
 The absolute recovery (%) was calculated by comparing the peak areas of 
the quality control samples with the peak areas of plasma-free samples containing 
the same concentration of amyrins. The analytical recovery (%) was calculated by 
comparing the amounts of amyrin detected to that spiked into plasma. 
 The stability profiles of α- and β-amyrin solutions were obtained by 
storing the sample solutions of the standards at 24 oC for 7 days. Stability of the 
standards in plasma under different conditions was measured using the QC 
samples. Post preparative stability of the samples was assessed by re-measuring 
the processed samples after storage at 24 oC for 24 h. Freeze-thaw stability of the 
samples was evaluated by subjecting the samples to 3 freeze (-80 oC)-thaw (24 oC) 
cycles. Short term stability of the samples was investigated by storing the samples 
at 4 oC for 24 h and long term stability by storing the samples at -80 oC for 14 
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days. Stabilities of the above conditions were calculated by comparing the amount 
of amyrins left before and after storage. 
 
5.2.3.6 Pharmacokinetic study design 
This pharmacokinetic study was carried out following the “Guidelines on 
the Care and Use of Animals for Scientific Purposes” (National Advisory 
Committee for Laboratory Animal Research, Singapore, 2004). The study design 
and animal handling procedures of this study were reviewed and approved by the 
Institutional Animal Care and Use Committee of the National University of 
Singapore (NUS).  
Ten Sprague-Dawley rats (male, 300-320 g) were purchased from the 
Comparative Medicine Center of NUS. The rats were maintained in a specific 
pathogen free animal facility (24°C, 60% relative humidity) at the Comparative 
Medicine Center and kept on a 12-h light/dark cycle with free access to food and 
water. On the day before the pharmacokinetic study, a polyethylene tube (I.D. 
0.58 mm, O.D. 0.965 mm, Becton Dickinson, Sparks, MD 21152, USA) was 
implanted into the right jugular vein under isoflurane anaesthesia. This cannula 
was used for intravenous drug administration as well as for blood sampling. The 
rats were divided into three groups. Group 1 (n = 4) received single oral 
administration of 300 mg kg-1 crude plant extract through oral gavage (equivalent 
of 1.9 mg kg-1 and 3 mg kg-1 of α- and β-amyrin respectively); group 2 (n = 3) 
received single oral administration of β-amyrin standard (3 mg kg-1) suspended in 
0.5% (w/w) carboxymethyl cellulose sodium through oral gavage; group 3 (n=3) 
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received single intravenous administration of β-amyrin (1 mg kg-1) dissolved in 
ethanol  at a concentration of 5 mg ml-1, through a 30-sec infusion. Serial blood 
samples were collected before dosing and at 45, 90, 110, 180, 300, 480, 720 and 
1440 min after oral gavage and 5, 15, 30, 60, 90, 120, 180, 300, 480, 720, 1440 
min after intravenous administration. After the intravenous dosing or blood 
sampling, the cannula was flushed with 0.2 ml heparin-saline (10 I.U. ml-1). After 
centrifuging at 3,000 g (4 °C) for 10 min, the plasma was collected and stored at -
80 °C. The protocol of this pharmacokinetic study was modified from two 
previous reports (Lin and Ho, 2009; Lin et al., 2009).  
 
5.2.3.7 Pharmacokinetic analysis 
 The pharmacokinetic parameters in this study were calculated using the 
non-compartmental model with the software WinNonlin standard version 1.0 
(Scientific Consulting Inc., Apex, NC). For rats that received oral administration 
of the plant extract or β-amyrin standard (Groups 1 and 2), the plasma exposure 
(area under the plasma amyrin concentration versus time curve, AUC0→t) was 
calculated by the linear trapezoidal rule with the time point from 0 to the last time 
point (Lin and Ho, 2009; Lin et al., 2009).  The AUC0→t for rats that received the 
intravenous administration (Group 3) was calculated using the same rule, but with 
a logarithmic scale (Lin and Ho, 2009; Lin et al., 2009).  Clearance (Cl) values for 
the rats given intravenous administration (Group 3) was calculated using non-
compartmental methods (Cl = Dose / AUC0→t). The bioavailabilities (F) of β-
amyrin after oral administration in Groups 1 and 2 were calculated as follows:  
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F (%) = [AUC0→t (Groups 1 or 2)/ 3 mg kg-1]/ [AUC0→t (Group 3)/ 1 mg kg-1] × 
100% 
 Due to the presence of a secondary peak in the plasma β-amyrin 
concentration versus time curve in rats that received intravenous administration, 
the apparent volume of distribution (V) was calculated with the first 3 data points 
(up to 30 min) using one-compartmental first order elimination model as 
described in Das et al. (2008).  
 
5.2.3.8. Statistics 
 Statistical analyses were performed using GraphPad Prism Version 3.03. 
All experimental values were reported as mean ± standard deviation (SD). A two-
tailed t-test was used to compare the pharmacokinetic parameters between the 








5.2.4 Results and discussion 
5.2.4.1 GC-MS assay development and validation 
α-amyrin, β-amyrin and methyltestosterone were eluted only at high 
temperatures. The oven temperature of the GC-MS was thus held at 280 oC for 19 
min in order for complete elution of the 3 compounds. The selectivity of the assay 
is determined. Figure 5.3 shows the GC-MS chromatograms of a pre-dosing 
plasma sample, a blank plasma sample spiked with methyltestosterone and amyrin 
standards, as well as a plasma sample taken from a rat dosed with the plant 
extract. The internal standard, methyltestosterone, eluted at 5.9 min. No 
interfering peak was observed in the blank pooled plasma samples or in the pre-
dosing samples at these timings (Figure 5.3a). Although α- and β-amyrin are 
structural isomers, they were well separated and eluted at 17.2 min and 15.9 min 
respectively (Figure 5.3b). Moreover, no interfering peak was identified in the 








Figure 5.3 GC-MS chromatograms of (A) a pre-dosing plasma sample (B) a blank plasma sample spiked with 1 μg ml-1 
methyltestosterone (peak 1; 5.944 min) and 100 ng ml-1 each of β-amyrin (peak 2; 15.854 min) and α-amyrin (peak 3; 17.193 min) (C) 
methyltestosterone (peak 1; 5.937 min), β-amyrin (peak 2; 15.836 min) and α-amyrin (peak 3; 17.170 min) in a plasma sample taken from a 
rat 5 h after being dosed with 300 mg kg-1 of the plant extract. 
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The calibration curves for α- and β-amyrins were obtained by spiking the 
standards of the two amyrins into pooled rat plasma. Data for the linearity, LOD and 
LOQ is presented in Table 5.2. 
 
Table 5.2 Linearity, LOD and LOQ data of α-amyrin and β-amyrin standard 
calibration curves. 
 
Sample Linear range (ng mL-1) R2 value LOD (ng ml-1) LOQ (ng ml-1)
α-amyrin 1 – 2000 0.9963 – 0.9976 0.4 1.0 
β-amyrin 1 – 2000 0.9976 – 0.9990 0.4 1.0 
 
The intra-day and inter-day RSD were less than 12% and 9% respectively for both 
α- and β-amyrin (Table 1). Recoveries of the amyrins were good. The absolute 
recoveries of both amyrins were more than 70 % while the intra-day and inter-day 
analytical recoveries were greater than 95% (Table 5.3). Both α- and β-amyrins 
appeared to be stable at all tested storage conditions (Table 5.4). In summary, a 
reliable GC-MS method has been developed and validated to quantify α- and β-
amyrin in rat plasma.  
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Table 5.3 Absolute and analytical recoveries of α-amyrin and β-amyrin. 
    Spiked concentration (ng ml-1) of α-amyrin   
    1 RSD (%) 200 RSD (%) 1500 RSD (%) 
Absolute Recovery (%)  85.1 ± 9.34 9.82 72.7 ± 8.48 11.7 
70.7 ± 
3.13 4.43 
Intra-day Analytical Recovery 
(%) 95.3 ± 10.5 11.0 96.7 ± 11.6 12.0 
99.1 ± 
4.39 4.43 
Inter-day Analytical Recovery 
(%) 95.9 ± 5.70 5.94 95.1 ± 8.60 9.04 
98.1 ± 
4.82 4.91 
        
   Spiked concentration (ng ml-1) of β-amyrin  
  1 RSD (%) 200 RSD (%) 1500 RSD (%) 
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Table 5.4 Stability of α-amyrin and β-amyrin. 
Stability (% Remained)  Spiked concentration (ng ml-1) of α-amyrin   Spiked concentration (ng ml-1) of β-amyrin 
    1 200 1500  1 200 1500 
Stock solution stored at 24ºC for 
7 days 101 ± 8.5 104 ± 5.4 101.8 ± 7.7  99.4 ± 7.3 105 ± 13.5 97.0 ± 7.0 
Plasma samples stored at 4ºC for 
24 h 106 ± 5.3 93.9 ± 3.2 90.3 ± 11.2  97.3 ± 3.3 104 ± 9.7 89.7 ± 9.0 
Plasma samples stored at -80ºC 
for 14 days 107 ± 6.2 90.0 ± 4.3 94.4 ± 4.0  90.5 ± 9.5 92.2 ± 2.8 90.2 ± 5.6 
Plasma samples after 3 Freeze-
thaw cycles 101 ± 7.6 91.6 ± 6.4 98.0 ± 13.8  109 ± 11.2 110 ± 6.1 106 ± 9.1 
Post-preparative samples stored 
at 24ºC for 24 h 99.5 ± 8.8 107.8 ± 8.9 102 ± 6.3  101 ± 3.7 104 ± 8.9 101 ± 1.5 
Results are presented as mean ± SD
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5.2.4.2 Pharmacokinetic profiles of α- and β-amyrin 
 The pharmacokinetic profiles of amyrins were subsequently assessed in 
Sprague-Dawley rats using the validated GC-MS method. To our knowledge, this was 
the first attempt to measure amyrins in biological samples. Earl et al. (2002) 
previously reported that the majority of the amyrins in Shea oleine were excreted 
unchanged in rats and humans when administered orally, which implied that there was 
little or no metabolism of the amyrins after oral absorption. Figure 5.4 shows the 
pharmacokinetic profile of β-amyrin after a single intravenous or oral administration. 
When administered intravenously, plasma β-amyrin concentration declined rapidly 
over the first 30 min, but the concentration increased subsequently in the following 2 
h. The appearance of this secondary peak suggested the presence of enterohepatic 
recirculation. A moderate apparent volume of distribution was found (V = 1317 ± 253 
ml kg-1). The clearance of β-amyrin was extremely slow (Cl = 2.04 ± 0.24 ml min-1 
kg-1). Similarly, the terminal half-life of β-amyrin was found to be very long (t1/2 λz = 
610 ± 179 min).  










































































Figure 5.4 (A) Plasma concentration versus time profiles of amyrins in rats after 
receiving:  a single intravenous administration of 1 mg kg-1 β-amyrin standard (■) (n = 
3); a single oral dose of β-amyrin standard at 3 mg kg-1 (▲) (n = 3); a single oral dose 
of 300 mg kg-1 plant extract equivalent of 3 mg kg-1 of β-amyrin (▼) and 1.9 mg kg-1 
of α-amyrin (♦) (n = 4). (B) Plasma concentration versus time profiles of amyrins for 
the period 5 to 300 min. Data is presented as mean ± SD. 
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Table 5.5 Pharmacokinetic parameters of α-amyrin and β-amyrin in rats. 
 β-amyrin standard IV (Group 3) 
β-amyrin standard 
oral dose (Group 2) Plant extract oral dose (Group 1) 
Dose (mg kg-1) 
1 3 300 
(equivalent of 3 mg kg-1 
β-amyrin) 
300 
(equivalent of 1.9 mg kg-1 
α -amyrin) 
V (ml kg-1) 
 1317 ± 253    
AUC0→24h (min µg ml-1) 
 411 ± 61.9 10.6 ± 2.84 47.3 ± 4.46* 32.2 ± 2.3 
Cl (ml min-1 kg-1) 
 2.04 ± 0.24    
t1/2 λZ (h) 
 10.2 ± 3.0 10.3 ± 1.6 8.3 ± 2.3 9.2 ± 1.1 
MRT0→24h (h) 
 8.0 ± 0.4 8.5 ± 1.4 8.7 ± 0.4 9.2 ± 0.6 
Cmax (ng ml-1) 
  18.7 ± 8.4 75.0 ± 10.2* 46.8 ± 4.13 
tmax (h) 
 - 3 (n = 2) or 5 (n = 1) 3 (n = 3) or 5 (n = 1) 3 (n = 1) or 5 (n = 3) 
F (%) 
  0.86 ± 0.23 3.83 ± 0.36*  
Results are presented as mean ± SD 
n= 4 for Group 1 and n=3 for Group 2 and 3 




From Figure 5.4, it can be seen that after oral gavage, β-amyrin was absorbed 
gradually and the plasma concentration peaked at either 3 or 5 h post-dosing in both 
Group 1 and 2. When β-amyrin was administered in the crude plant extract, the 
maximal plasma concentration (Cmax) was about 3-fold higher than that acquired with 
the suspension of pure compound (75.0 ± 10.2 v.s. 18.7 ± 8.4, two-tailed t-test: p < 
0.001). Similarly, the bioavailability of β-amyrin administered with the plant extract 
matrix was about 3-fold higher than the pure compound (3.8 ± 0.36 v.s. 0.86 ± 0.23, 
two-tailed t-test: p < 0.001). Clearly, the plant extract matrix was able to enhance the 
absolute oral bioavailability of β-amyrin. Similar phenomena have also been observed 
in other studies. A report on resveratrol in humans showed that the bioavailability of 
the compound was 6-fold higher when administered in the form of red wine or grape 
juice, compared to that administered as tablets enriched with resveratrol (Ortuno et al., 
2010). Similarly, Mukinda et al. showed that luteolin derivatives in Artemisia afra 
extracts were more efficiently absorbed in Caco-2 cells compared to pure solutions of 
the compounds (Mukinda et al., 2010).  The mechanism for this observation was 
unclear, but it was hypothesized that some constituents in the plant extract matrix 
could have inhibited efflux transporters of the compounds, while enhancing 
metabolism in the intestinal cells so that they were more easily absorbed via 
basolateral transporters (Mukinda et al., 2010). Keung et al. (1996) found that the 
bioavailability of daidzin in the extract of Radix Puerariae was approximately 10 
times greater than the pure compound when administered intraperitoneally. This was 
attributed in part, to the plant extract enhancing the solubility of daidzin in aqueous 
environments. Moreover, rutin was also observed to have a better absorption in the 
form of a buckwheat tea preparation compared to the pure form (Graefe et al., 2001). 
It was hypothesized that the tea preparation contained co-factors in the plant extract 
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matrix that increased the solubility of rutin, as well as decreased the viscosity of the 
mucus layer of the intestines, leading to increased absorption. Similarly, it could be 
postulated that a higher oral bioavailability of β-amyrin in crude plant extract was due 
to the increased solubility and/or competition in metabolism. However, the exact 
mechanisms are to be elucidated in future study.  
Although the bioavailability of β-amyrin was increased by the plant extract 
matrix, it was still considered very low (3.77%). The low bioavailability observed is 
not surprising as the log P value of β-amyrin is 9.2, much higher than the 
recommended log P value of 5 for an orally active drug in the Lipinski’s rule of 5. 
Solubility-enhancing drug delivery system may be useful for the oral delivery of β-
amyrin. 
After reaching Cmax, the plasma β-amyrin concentration declined gradually, 
and still remained in the plasma (10.7 ± 2.3 ng ml-1 and 2.7 ± 0.2 ng ml-1 respectively 
for Group 1 and Group 2) 24 hrs after oral administration. Other than the AUC, Cmax 
and bioavailability, the t1/2λz and mean residence time (MRT) of β-amyrin in Group 1 
and 2 were not significantly different from each other. Similarly, the t1/2λz and MRT of 
β-amyrin in Group 3 were similar to those in Group 1 and 2. As the isomer of α-
amyrin exists naturally in the A. elliptica extract, it is of interest to investigate the 
pharmacokinetic profile of α-amyrin as well. The pharmacokinetic profile of α-amyrin 
was compared to that of β-amyrin in Fig. 5.4. From Table 5.5, it can be seen that α-
amyrin was absorbed to a similar extent as β-amyrin as the dose normalized AUC0→t 
and Cmax of both α- and β-amyrin were similar.   
 Although the pharmacokinetic profiles of both α- and β-amyrins have not 
been previously reported before, the pharmacokinetics of some other triterpenes has 
been investigated. For example, oleanolic acid, a compound belonging to the same 
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class (oleanane) as β-amyrin, possessed a very low oral bioavailability (0.7%). This 
was comparable to the oral bioavailability of β-amyrin reported here (0.86 ± 0.23%). 
The low oral bioavailability of oleanolic acid was attributed to its poor gastrointestinal 
absorption and hepatic first-pass metabolism. Studies of oleanolic acid conducted on 
Caco-2 cells suggested that the compound had low permeability and the absorption 
was mediated by passive diffusion (Jeong et al., 2007). Further investigations on the 
bio-membrane permeability and metabolic stability of α- and β-amyrin are warranted.  
 
5.2.4.3 Application of pharmacokinetic study to antiplatelet and anticoagulant 
activity of A. elliptica extract in rats  
In Section 5.1, blood sampling from the rats were taken at time points 
comparable to the pharmacokinetic study (tail bleeding as performed at 90 min and 
blood was collected intra-cardiacally at 110 min). In Sections 5.1.4.2 and 5.1.4.3, the 
results showed that rats treated with pure β-amyrin did not show longer tail bleeding 
times or stronger platelet aggregation inhibition compared to the group treated with 
leaf extract (Table 5.1).  
From this study, the bioavailability of β-amyrin is found to be low and is also 
affected by the matrix which the amyrin is in. The bioavailability of β-amyrin was 
3.83% when given in the form of the leaf extract, as compared to 0.86% when given 
as a suspension. β-amyrin concentration in rat plasma at time points 90 to 110 min 
was 20 to 40 ng ml-1 for rats dosed with 300 mg kg-1 of leaf extract and 10 to 14 ng 
ml-1 for rats dosed with 3 mg kg-1 of pure β-amyrin. In rats dosed with the leaf extract, 
there was also presence of 12 to 23 ng ml-1 of α-amyrin in the rat plasma. The rats in 
the ex vivo platelet aggregation assay were dosed with 30 mg kg-1 of pure β-amyrin or 
300mg kg-1 leaf extract, thus there should be comparatively a higher concentration of 
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amyrin in rats treated with pure β-amyrin than those dosed with the leaf extract. 
However the results of the tail bleeding assay and ex vivo platelet aggregation assay 
were comparable between the rats treated with pure β-amyrin and those dosed with 
the leaf extract. This implies the presence of other bioactive components in the leaf 
extract that could contribute to the bleeding times and antiplatelet activity observed. 
 For the in vitro plasma coagulation assay in Section 3.2.4.4, 0.01 mg ml-1 of β-
amyrin was used in the assay but prolongation of neither PT nor aPTT was observed. 
A higher concentration of amyrins would be attained in the blood of the rats in the ex 
vivo plasma coagulation assay, but no prolongation of the PT and aPTT was observed 




In this study, a reliable GC-MS method was developed and validated to 
quantify α- and β-amyrin in rat plasma. A preliminary pharmacokinetic study was 
subsequently carried out in Sprague-Dawley rats.  It was found that β-amyrin 
displayed an extremely slow clearance, a very long terminal half-life and low 
bioavailability in rats. As β-amyrin shows a wide range of biological activity, future 
investigations on the amyrins may be focused on their detailed pharmacokinetics, 






Medicinal plants have played an important role in the treatment of diseases 
since antiquity. Even in modern medicine, it has been reported that approximately 
50% of the drugs introduced since 1994 are either natural product or natural product-
derived compounds. From current research trends, natural products will continue to be 
an important source of lead compounds for new drugs. In the treatment of 
cardiovascular diseases caused by thromboembolism, there is a continual need for 
better drugs. Common adverse effects of current antiplatelet or anticoagulant drugs 
used to treat cardiovascular diseases include excessive bleeding and gastrointestinal 
toxicity. In view of the short comings of the current drugs, development of better 
drugs with fewer adverse effects is necessary.  
In Chapter 1, an overview of antiplatelet and anticoagulant drugs, medicinal 
plants and metabolomics is presented. In particular, the herb of interest, A. elliptica, 
traditionally used to treat diarrhoea, liver poisoning, fever, parturition complications 
and pain in the region of the heart etc., is reviewed. In this work, one of its traditional 
usage namely for “pain in the region of the heart” is interpreted as symptoms related 
to problems in blood circulation. This in turn is related to platelet aggregation and 
plasma coagulation. 
Chapter 2 states the hypothesis and objectives of this work. It is hypothesised 
that A. elliptica possesses phytoconstituents with antiplatelet and/or anticoagulant 
activities that may be potential lead compounds for development of new drugs. The 
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objective of the work is to investigate the potential antiplatelet and anticoagulant 
activities of A. elliptica and to identify and isolate the active compound(s) responsible 
for the activities. 
 In Chapter 3, it was successfully shown that the A. elliptica 70% v/v methanol 
extract has antiplatelet and anticoagulant activities in vitro on rabbit’s blood and 
human plasma respectively. β-amyrin was successfully isolated from the 70% v/v 
methanol extract of A. elliptica and found to have antiplatelet activity. The 70% v/v 
methanol extract had an IC50 value of 167μg ml-1 in inhibiting collagen-induced 
platelet aggregation, while β-amyrin had an IC50 value of 10.5 μM. Its structural 
isomer, α-amyrin, was also present in A. elliptica. Unfortunately, it was not 
successfully isolated. However, it was also active and the commercial standard gave 
an IC50 value of 21.3 μM.  The amyrins were also three to six times more potent than 
aspirin (IC50 = 62.7 μM) with regards to the antiplatelet activity. This is the first report 
of the antiplatelet activity of the individual amyrins.  
A GC-MS method was developed and validated to quantify the amount of 
amyrins in the plant extract. Derivatised GC-MS methods have been popularly used 
for the analysis of triterpenes but derivatisation is required in the method to make the 
solutes volatile for analysis. However the steps for derivatisation are laborious and 
inefficient when large numbers of samples are required for analysis. In Chapter 3, the 
GC-MS method was streamlined to remove the derivatisation step. The concentrations 
of α- and β-amyrins were subsequently quantified to be 0.6% w/w and 1.0 % w/w 
respectively of the dried A. elliptica leaf extract. These correspond to 0.05% w/w and 
0.08% w/w of α- and β-amyrin in the fresh leaves respectively. While the A. elliptica 
leaf extract showed anticoagulant activities, the isolated compound β-amyrin did not 
exhibit anticoagulant activities at the tested concentrations. Further work should 
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therefore include isolation of compounds responsible for the anticoagulant activity, 
and also other compounds that are antiplatelet in the leaf extract. 
The isolation of the active compound, β-amyrin was performed by a 
conventional fractionation method. It is widely recognised that the conventional 
method has several disadvantages as discussed in Section 1.3.3. Conventional 
methods of detecting bioactive compounds are slow and tedious, involving repeated 
steps of fractionation and bioassays. An added drawback is its difficulty to detect 
compounds in low concentrations. Hence in Chapter 4, a novel MVDA drug 
discovery method has been successfully developed for identifying potential 
antiplatelet compounds from medicinal plant extracts, without the need for bioassay-
guided fractionation. The modeling used in this work is performed using easily 
available commercial software. This MVDA method consists of two modeling. The 
first is named the consensus method, where Orthogonal Partial Least Squares (OPLS), 
Partial Least Squares projection of latent structures-Discriminant Analysis (PLS-DA), 
Chi-Squared weighting and InfoGain weighting were performed. The second is named 
the correlation method, where a correlation of the concentrations of constituents and 
biological activities in the various extracts and fractions for each compound was done. 
In total, 855 different compounds were detected by GC-MS analysis. Both the 
consensus and correlation methods identified α- and β-amyrin as potential antiplatelet 
compounds, among others. Successful prediction of α- and β-amyrin as potential 
antiplatelet agents in A. elliptica corroborated with independent bioassay results. The 
method may reduce time and cost of drug discovery and increase efficiency. This 
novel platform method can be applied to other plant extracts and biological activities, 
thus reducing time and cost of drug discovery. 
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 In vitro results from earlier chapters showed that the 70% v/v methanol extract 
of A. elliptica had antiplatelet and anticoagulation properties, and both α- and β-
amyrin were partly responsible for the antiplatelet activities. As β-amyrin was isolated 
successfully, further in vivo work on the extract and on pure β-amyrin was carried out. 
Thus in Chapter 5, an in vivo study in rats was performed to study the activities. In the 
study, rats were dosed orally either with 300 mg kg-1 of the 70% v/v methanol extract 
(equivalent of 1.8 mg kg-1 of α-amyrin and 3 mg kg-1 of β-amyrin), 30 mg kg-1 of 
isolated β-amyrin or 30 mg kg-1 of aspirin. After dosing, an in vivo tail-bleeding assay 
and ex vivo platelet aggregation and plasma coagulation assay were performed. 
Results of the tail-bleeding study showed that the bleeding times of rats dosed with 
the leaf extract were comparable to rats dosed with either 30 mg kg-1 of pure β-amyrin 
or aspirin. The ex vivo platelet aggregation assay done on the same rats showed that 
both the leaf extract and β-amyrin treated animals inhibited 30% of collagen-induced 
platelet aggregation. However anticoagulant effects were not seen in both groups of 
rats. This observation was different from that seen in in vitro plasma coagulation 
assays where 0.2 mg ml-1 of leaf extract was able to induce anticoagulation by 
increasing the aPTT in human plasma. Further investigations should be conducted to 
understand the reason behind, which could be either due to low concentrations of the 
active components, specie differences or metabolism and deactivation of the active 
compound when ingested in vivo. 
In Chapter 5, the pharmacokinetic profile of β-amyrin in rats was studied. Due 
to the large amounts of compounds needed, a commercial source of β-amyrin was 
used. Both α- and β-amyrins in the 70% v/v methanol extract of A. elliptica were 
monitored in the rats after oral administration. β-amyrin was found to have a very 
long terminal elimination half-life (t1/2 λz = 610 ± 179 min) and slow clearance (Cl = 
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2.04 ± 0.24 ml min-1 kg-1). The absolute oral bioavailability of β-amyrin in the plant 
extract was poor (3.83%) and was about 4-fold higher than that in the suspension of 
pure form (0.86%). When given in the plant extract, both α- and β-amyrin had a 
similar dose normalized Cmax. When these results were applied in the ex vivo platelet 
aggregation tests in Chapter 4, it was calculated that there should be comparatively a 
higher concentration of amyrin in rats treated with 30 mg kg-1 of pure isolated β-
amyrin than those dosed with 300 mg kg-1 the leaf extract. This implies the presence 
of other bioactive components in the leaf extract that could contribute to the bleeding 
times and antiplatelet activity observed since the 2 experimental groups have 
comparable activities. Thus it is worthwhile to investigate the effects of other hits 
identified in the MVDA method (Chapter 4) as well as to identify other unknown 
bioactive components in the active extracts and fractions (Chapter 3). Due to the poor 
solubility and low oral bioavailability, future research should focus on improving the 
solubility and bioavailability of the amyrins by exploring various formulations and 
appropriate drug delivery systems. A more extensive pharmacokinetic study should 
also be done by increasing the number of animals and monitoring the plasma 
concentrations over a longer period of time. 
 Since the amyrins have been identified to be active, more extensive studies of 
the toxicity of the amyrins are required for them to be further developed into drugs. 
As the amyrins were found to have antiplatelet effects, the exact mechanism of action 
could be elucidated. It was also reported that the amyrins have a wide range of 
pharmacological effects. The non-specificity, any adverse effects and potential for 
herb-drug interaction may pose a challenge in its further development and should be 
further evaluated. Clinical trials will be needed before the amyrins can be approved as 
new therapeutics. 
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In conclusion, the results presented in this thesis provide some scientific 
evidence for the traditional uses of A. elliptica. Further work is warranted to develop 
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